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ABSTRACT 
Mammalian sperm motility is a prerequisite for in vivo fertilization and alterations in this 
parameter are commonly observed in infertile males. However, we still do not have a complete 
understanding of the molecular mechanisms controlling it. The first aim of this study was to identify 
proteins involved in human sperm motility deficiency, by using TMT protein labeling and LC-MS/MS 
to compare proteins of sperm samples differing in motility (asthenozoospermic versus 
normozoospermic). LC-MS/MS resulted in the identification of 1157 proteins, of which 80 proteins 
were found differentially abundant between the two groups of samples. The differential proteins 
were analyzed by GO, cellular pathways and clustering analyses and resulted in the identification of 
core deregulated proteins and pathways associated with sperm motility dysfunction. These 
included proteins associated with energetic metabolism, protein folding/degradation, vesicle 
trafficking and the cytoskeleton.  Contrary to what is usually accepted, these outcomes support the 
hypothesis that several metabolic pathways (notably mitochondrial-related ones) contribute 
towards regulating sperm motility. Moreover, this work considerably contributes to the increase of 
the compiled list (185 proteins) of differentially expressed proteins in asthenozoospermic samples.  
Additionally, the second objective of this study was to contribute to the first 
comprehensive metabolomic characterization of human sperm cell extracts through the application 
of two untargeted metabolomics platforms based on proton nuclear magnetic resonance (1H-NMR) 
spectroscopy and gas chromatography coupled to mass spectrometry (GC-MS). Using these two 
complementary strategies we were able to identify a total of 69 metabolites, of which 42 were 
identified using NMR, 27 using GC-MS and 4 by both techniques. The identity of some of these 
metabolites was further confirmed by two-dimensional 1H-1H homonuclear correlation 
spectroscopy (COSY) and 1H-13C heteronuclear single-quantum correlation (HSQC) spectroscopy. 
Most of the metabolites identified are reported here for the first time as present in mature human 
sperm. The relationship between the metabolites identified and the previously reported sperm 
proteome was also explored. Interestingly, overrepresented pathways included not only the 
metabolism of carbohydrates, but also of lipids and lipoproteins. Of note, a large number of the 
metabolites identified belonged to the “amino acids, peptides and analogues” super class. The 
identification of this initial set of metabolites represents an important first step to further study 
their function in male gamete physiology and to explore potential reasons for dysfunction in future 
studies. We also demonstrate that the application of NMR and MS provides complementary results, 
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thus constituting a promising strategy towards the completion of the human sperm cell 
metabolome.  
 Furthermore, we have performed the first combined analysis of the human sperm 
identified metabolites and human sperm compiled proteome, using bioinformatic tools. This 
resulted in interesting outcomes, with metabolism as a most significant pathway, but also 
reinforcing the importance of fatty acids oxidation and lipids metabolism, among others. 
Alltogether, our study show the importance of performing an integrated analysis (proteomics and 
metabolomics) to biologicaly better understand human sperm cells. We have also preformed the 
preliminary comparison between the metabolic fingerprints of extracts of human sperm samples 
with different motility. As very preliminary outcomes, we observed a general lower concentration 
of the identified metabolites in asthenozoospermic samples when compared to normozoospermic 
ones.  
 In conclusion, our work aimed to contribute to better understand human sperm motility (at 
protein and metabolite level) and also to iniciate the analysis of human sperm metabolome. These 
will hopefully contribute to increase our knowledge about the molecular basis of male gametes and 
also to better understand human sperm (dys)function and male (in)fertility.  
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RESUMO 
 A mobilidade dos espermatozoides é um pré-requisito para a fertilização in vivo em 
mamíferos e alterações neste parâmetro são frequentemente observadas em machos inférteis. Em 
humanos esta patologia (percentagem de espermatozoides móveis reduzida) é definida como 
asthenozoospermia. Contudo, os mecanismos moleculares que controlam a mobilidade dos 
espermatozoides não estão completamente descodificados. Assim, o primeiro objectivo deste 
trabalho foi identificar proteínas envolvidas na mobilidade de espermatozoides humanos através 
de proteómica diferencial utilizando amostras normozoospérmicas e astenozospérmicas. As 
proteínas das diferentes amostras foram marcadas com marcadores isobáricos (TMT) e 
posteriormente identificadas e quantificadas por cromatografia líquida e espectrometria de massa 
em tandem (LC-MS/MS). Esta estratégia resultou na identificação de 1157 proteínas, das quais 80 
estavam presentes em quantidades significativamente diferentes em espermatozoides menos 
móveis. As proteínas diferenciais foram analisadas relativamente à sua ontologia génica (GO), 
função biológica e participação em vias celulares. Esta análise resultou na identificação de uma 
série de proteínas e vias desreguladas, associadas à disfunção da mobilidade espermática. Entre 
elas incluem-se proteínas associadas ao metabolismo energético, à conformação e degradação de 
proteínas, transporte de vesículas e citoesqueleto. Ao contrário do que é normalmente aceite, 
estes resultados vêem suportar a hipótese de que várias vias metabólicas (entre elas as 
mitocondriais) contribuem para a regulação da mobilidade dos espermatozoides. Este trabalho 
também contribuiu consideravelmente para o enriquecimento da lista de proteínas (somando um 
total de 185) que estão descritas como diferencialmente expressas em amostras 
astenozospérmicas.  
 O segundo objectivo do presente estudo foi contribuir para a primeira caracterização 
metabólica de extractos de espermatozoides humanos através da utilização de duas técnicas 
frequentemente utilizadas para identificação não direcionada de metabolitos: espectroscopia de 
ressonância magnética nuclear de protão (1H-RMN) e cromatografia gasosa acoplada a 
espectrometria de massa (GC-MS). Usando estas duas estratégias complementares identificámos 
um total de 69 metabolitos endógenos, dos quais 42 por RMN, 27 por GC-MS e 4 identificados por 
ambas técnicas. A identificação de alguns destes metabolitos foi ainda confirmada através de 
espectroscopia de duas dimensões: correlação homonuclear 1H-1H (COSY) e correlação 
heteronuclear 1H-13C (HSQC). Curiosamente, grande parte dos metabolitos descritos pertence à 
superclasse de “aminoácidos, péptidos e análogos”. Uma vez mais, através de análise 
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bioinformática das vias biológicas em que os metabolitos descritos estão envolvidos, volta a 
destacar-se o metabolismos de lípidos e a beta-oxidação de ácidos gordos. A identificação deste 
primeiro conjunto de metabolitos constitui assim um primeiro passo para futuros estudos 
metabolómicos, no sentido do melhor conhecimento dos gametas masculinos a nível molecular e 
fisiológico, e também da caracterização de diversas patologias. Neste trabalho mostrou-se também 
a importância do uso de técnicas complementares que poderão constituir ferramentas valiosas na 
descrição e compreensão do metaboloma humano. 
 Foi ainda explorada a relação entre a lista de metabolitos descritos com as proteínas 
descritas na compilação do proteoma de espermatozoides humanos, usando ferramentas 
bioinformáticas. Esta análise revelou a importância de vias não só como metabolismo de hidratos 
de carbono, mas também o metabolismo de lípidos e lipoproteinas, entre outros, constituindo 
assim a primeira análise integrada de proteínas e metabolitos de espermatozoides humanos. Por 
ultimo, neste trabalho efetuámos a primeira comparação preliminar entre a quantidade de 
metabolitos identificados em extractos de amostras com diferentes mobilidades. Os resultados 
sugerem a presença em menor quantidade de quase todos os metabolitos em extractos de 
espermatozoides menos móveis, abrindo assim caminho a novos trabalhos futuros para 
caracterização metabólica da mobilidade de espermatozoides humanos.  
 Em conclusão, o nosso trabalho teve como principal objectivo contribuir para o melhor 
entendimento da mobilidade de espermatozoides humanos (a nível proteico e metabólico) e 
simultaneamente dar o primeiro passo na análise do metaboloma de espermatozoides humanos, 
contribuindo desta forma para um aumento do conhecimento sobre a base molecular dos gametas 
masculinos e a (dis)função dos mesmos associada à (in)fertilidade. 
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CHAPTER I. INTRODUCTION 
1.1. The mammalian sperm cell 
1.1.1 Spermatogenesis  
 The mammalian spermatozoon is the end product of a differentiation process called 
spermatogenesis which consists of successive mitotic (spermatogoniogenesis), meiotic and post-
meiotic (spermiogenesis) phases within the seminiferous tubules of the testis (Fig. 1.1; (de Kretser 
et al., 1998). This process is highly controlled by hormonal regulation via the hypothalamic-pituitary 
axis (Holdcraft and Braun, 2004) and locally by the Leydig cells, responsible for the production of 
testosterone and oestradiol-17β (through a process called steroidogenesis; (Holstein et al., 2003)). 
 
Figure 1.1 – Spermatogenesis. 
Spermatogenesis is the differentiation process that culminates in the production of haploid sperm. It can be 
divided in three major phases. The spermatogoniogenesis is characterized by spermatogonial mitotic 
proliferation and formation of primary spermatocytes that then enter meiosis, a long phase characterized by 
changes in the chromatin. After two cell divisions, round spermatids are formed, which in turn undergo a final 
morphological differentiation step (spermiogenesis) that results in the production of spermatozoa. These, 
due to their unique shape and features, are able to leave the testis in the spermiation process.  
(Reproduced from Amaral 2009) 
 During the first stage of spermatogenesis (the mitotic phase, or spermatogoniogenesis), 
germ line stem cells undergo a series of divisions to expand the spermatogonial population. Diploid 
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spermatogonial stem cells start to differentiate and undergo the second stage of the 
spermatogenesis, the meiotic phase, which begins with the last cell cycle S phase and culminates in 
two cell divisions without DNA replication, producing haploid spermatids. In the last phase, called 
spermiogenesis, spermatids undergo complex morphological modifications that give rise to sperm 
(de Kretser et al., 1998). During this postmeiotic phase, the majority of the cellular components are 
reorganized and remodelled. Some of these remarkable alterations are: 1) the compaction of the 
nucleus; 2) the massive reduction of the cytoplasm, ending with the elimination of the majority of 
the typical somatic cell organelles, within residual bodies, which are phagocyted by Sertoli cells; 3) 
the Golgi apparatus undergoes conformational changes that result in the formation of a large 
secretory vesicle on the sperm head, the acrosome; 4) the formation of a highly specialized 
flagellum; 5) the rearrangement of the remaining mitochondria in elongated tubular structures, 
packed helically around the anterior portion of the flagellum (Otani et al., 1988; Eddy, 2006; 
Ramalho-Santos et al., 2009). All these events culminate in the formation of functional, 
hydrodynamic and highly differentiated cells, that are capable of crossing the female reproductive 
tract, reach and fertilize an oocyte, and undergo profound nuclear reorganization events essential 
for syngamy and early embryogenesis, and thus to begin the process that gives rise to the next 
generation. 
 
1.1.2 Mammalian sperm: a highly specialized cell 
 The mammalian sperm cell is composed of two main regions, the head and the flagellum, 
joined by the connecting piece (Fig. 1.2).  
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Figure 1.2 – Mammalian sperm cell structure.  
The mammalian sperm cells are divided in two main parts, head and flagellum. The flagellum is divided in 
four regions: the connecting piece (which attaches the head to the flagellum); the middle piece (where 
mitochondria are localized); the principal piece; and the end piece. (Adapted from (Eddy, 2006)). 
 
 
1.1.2.1 The Sperm Head 
 The head of the sperm cell contains the acrosome, the haploid nucleus, cytoskeleton 
structures and a small amount of cytoplasm.  
 The acrosome is a unique sperm organelle that originates from the Golgi complex, and 
which covers the anterior part of the nucleus and contains multiple hydrolytic enzymes necessary 
for the sperm to penetrate through the oocyte vestments and achieve fertilization, in an event 
called acrosome reaction (Holstein et al., 2003).  
 The main part of the sperm head is occupied by the nucleus where the sperm chromatin is 
highly condensed. This high level of compaction, a unique feature of the sperm nucleus, is due to 
the successive replacement of most histones (85-95%, depending on the species) firstly by nuclear 
transition proteins, and finally by protamines (the major nuclear proteins associated with 
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mammalian sperm DNA in its mature form), during the last stages of spermiogenesis (Fig. 1.3; 
(Oliva and Castillo, 2011; Castillo et al., 2014b). These relatively small (27-65 amino acids) and 
highly basic proteins, extremely rich in arginine and cysteine, are grouped in two families in human 
sperm: Protamine type 1 (P1; protamine 1) and Protamine type 2 (P2; including protamines 2, 3 and 
4) (Oliva and Dixon, 1991; Oliva and Castillo, 2011). Interestingly, both protamine families are 
essential for male fertility, and the alteration either of the amount of protamine content (Cho et al., 
2001, 2003) or of the relation between P1 and P2 (ratio P1/P2; (Oliva, 2006), can disrupt the 
stability of sperm DNA triggering DNA damage and male infertility. Some studies suggest that a 
higher prevalence of P2 may cause an increment of DNA damage susceptibility, since P2 contains 
fewer cysteine residues than P1 and consequently less disulphide cross-links (Corzett et al., 2002). 
Moreover, altered levels of P2 expression were described in infertile patients (Carrell and Liu, 2001; 
Oliva, 2006; Torregrosa et al., 2006). In conclusion the high level of DNA packaging contributes not 
only to the hydrodynamic shape of the sperm cell, but also to protect the DNA from oxidative stress 
and external aggressions, thus contributing to the integrity of the paternal genome. Furthermore, 
this highly compaction of the nucleus is one of the reasons whereby sperm cells are believed to be 
transcriptionally and translationally silent, at least for nuclear encoded genes (Miller et al., 2010; 
Baker, 2011; Amaral and Ramalho-Santos, 2013). 
 
Figure 1.3  – Chromatin changes during spermiogenesis.  
A chromatin model of the mammalian nucleohistone to nucleoprotamine transition is shown (Adapted from 
(Oliva and Castillo, 2011) ). 
 Concerning the 5-15% of DNA that remains packed by histones in the final conformation of 
the human sperm chromatin (Gatewood et al., 1987; Bench et al., 1996), and which remains less 
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tightly compacted than the remaining DNA, many studies have suggested that these clusters might 
be part of a sequence-specific component of the genome which is programmed for expression in 
early stages of embryonic development, by remaining less tightly compacted (Gatewood et al., 
1987; Hammoud et al., 2009; Castillo et al., 2014b). However, this subject is somehow controversial 
(Carone et al., 2014; Samans et al., 2014) and further studies will be needed to investigate the real 
role of these histones and DNA regions. 
 In addition to the inherited genetic information encoded in the DNA sequence, a growing 
body of evidence is suggesting that mammalian sperm may contain epigenetic information that 
might be crucial to the embryo (Carrell and Hammoud, 2010; Carone and Rando, 2012; Rando, 
2012; Castillo et al., 2014b; Hughes, 2014). This epigenetic information could be constituted among 
other markers by DNA methylation, modifications of histones, presence of chromatin-associated 
proteins and RNAs, chromatin structure and chromosome territories in the nucleus that may 
actively contribute to the regulation of the expression of some genes during development (Mercer 
and Mattick, 2013; Rivera and Ren, 2013; Brunner et al., 2014).  
 
1.1.2.2 The Sperm Flagellum 
 The flagellum (tail) is the largest part of the mammalian spermatozoon and is responsible 
for its movement. Structurally, it is divided in four distinct and well-defined segments: 1) the 
connecting piece (neck), 2) the middle piece, 3) the principal piece and 4) the end piece (Fig. 1.4; 
(Fawcett, 1975)). 
 The connecting piece (or neck region) is the short, most proximal portion of the flagellum 
that attaches it to the sperm head and contains the sperm centriole (responsible for organizing the 
aster that brings together the male and female pronuclei after fertilization in most mammals) 
(Navara et al., 1994; Sutovsky et al., 1996; Terada et al., 2000). The axoneme extends throughout 
the length of all four subdivisions of the flagellum, and contains the typical cilium conformation: 
nine outer microtubule doublets of the axoneme (OMDA) and a central pair (CP) of microtubules 
(9+2) (Fawcett, 1975). In addition, inner and outer dynein arms project from each of OMDA, 
whereas nine radial spokes (RS), one for each OMDA, project inwards the central pair in a helical 
fashion, being responsible for transmitting regulatory signals to the dynein arms (Fawcett, 1975; 
Porter and Sale, 2000) and also for regulating the size and shape of axonemal bending through 
calcium-dependent process (Wargo and Smith, 2003). The motor protein dyneins bind tubulin and 
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are responsible for converting the chemical energy derived from ATP hydrolysis into mechanical 
force and thus for propelling the flagellum movement (Lin et al., 2014).  
 
 
 
Figure 1.4  – Schematic representation of the ultrastructure of the human sperm.  
Sperm flagella are structurally divided into four areas: the connecting piece (or neck region), middle piece, 
principal piece, and end piece. The schematic cross-section of the middle piece shows the plasma membrane 
(PM) and mitochondrial sheath (MS) surrounding the nine outer dense fibres (ODFs). Within the ODFs are the 
axoneme components: the nine outer microtubule doublets of the axoneme (OMDA) with associated dynein 
arms (DA) and radial spokes (RS) and the central pair (CP) of singlet microtubule. The schematic cross-section 
of the principal piece shows the PM surrounding seven ODFs, because two ODFs are replaced by the two 
longitudinal columns (LC) of the fibrous sheath. The two columns are connected by transverse ribs (TR) and 
the axonemal components are unchanged. (Adapted from (Holstein et al., 2003; Turner, 2003) ) 
 
 The middle piece comprises approximately one-quarter to one-third of the length of the 
flagellum, and is characterized by the presence of the mitochondrial sheath (MS). It is also 
constituted by nine outer dense fibers (ODFs) that extend into the principal piece and surround 
each of the nine outer axonemal microtubule doublets (Fig. 1.4). The annulus marks the end of the 
middle piece and the start of the principal piece where two ODFs are replaced by two longitudinal 
columns of the fibrous sheath (FS), a unique structure that is restricted to the principal piece. The 
last portion of the sperm flagellum is the end-piece, a short terminal section containing only the 
axoneme surrounded by the plasma membrane. These features make the sperm a highly 
specialized and physically well-compartmentalized cell. It is also important to note that although 
axonemes are highly conserved in all ciliated and flagellated eukaryotic cells, the MS, ODFs and FS 
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are accessory structures that are exclusive to the mammalian sperm flagellum (Fawcett, 1975; 
Turner, 2003).  
 
Outer dense fibres (ODF) 
 The role of the ODFs has been proposed as merely structural, providing support for and 
passive elasticity to the long sperm tail (Fawcett, 1975). In fact, in the last few decades, some 
authors have isolated and characterized several ODF proteins in different species, including humans 
(Gastmann et al., 1993; Morales et al., 1994; Hoyer-Fender et al., 1995; Schalles et al., 1998; Zarsky 
et al., 2003; Eddy, 2006), and the majority of them are keratin-like intermediate proteins 
(Kierszenbaum et al., 1996; Tres and Kierszenbaum, 1996; Kierszenbaum, 2002). In addition, some 
of the genes encoding ODF proteins were successfully cloned of (Brohmann et al., 1997; Shao et al., 
1997; Petersen et al., 1999; O’Bryan et al., 2001; Yang et al., 2012) and the outcomes reinforce the 
hypothesis of the structural function of the ODFs. However, due to the lack of available ODF-
defective sperm models, the true role of ODFs in sperm motility is not completely clear, remaining 
largely speculative.  
 
Mitochondrial sheath (MS) 
 Sperm mitochondria are located exclusively in the MS of the middle piece. During 
spermatogenesis, germ cell mitochondria change their conformation, converting the orthodox 
forms in more condensed and metabolically more efficient ones (Ramalho-Santos et al., 2009). 
These are rearranged in elongated tubular structures (Ho and Wey, 2007) that are packed helically 
around the anterior portion of the sperm flagellum. At the end of this process, mature mammalian 
sperm possess 22-75 mitochondria arranged end-to-end in the middle piece (Otani et al., 1988). 
The sub-mitochondrial reticulum, a complex of filaments, seems to be the structure that sustains 
mitochondria and anchor them to the MS (Olson and Winfrey, 1990). This structure seems to 
depend on the expression of kinesin light chain 3 (KLC3), a protein that may bind both ODF1 and a 
mitochondrial outer membrane porin, creating a connection between them, and whose mutation 
has been proven to affect middle piece formation and sperm quality (Zhang et al., 2012b; Lehti et 
al., 2013). Moreover, the sperm mitochondria are encapsulated inside a keratinous structure 
formed by disulphide bonds between cysteine- and proline-rich selenoproteins (Calvin et al., 1981; 
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Ursini et al., 1999). This structure seems not only to confer mechanical stability, but also to be 
responsible for some distinctive properties of sperm mitochondria, namely the resistance to hypo-
osmotic stress, and the unfeasibility of completely isolating these organelles (Ramalho-Santos et 
al., 2009; Amaral et al., 2013b). The fact that some mitochondria are evolutionarily retained in a 
very specialized sperm region, unlike what happens in few non-mammalian animal species living in 
habitats with very low oxygen levels and which lack sperm mitochondria (Balsamo et al., 2007), 
suggests that these organelles have a crucial role in mammalian sperm function.  
 As in other cells sperm mitochondria produce ATP by aerobic respiration trough oxidative 
phosphorylation (OXPHOS; (Ramalho-Santos et al., 2009; Amaral et al., 2013b)). Although these 
organelles might have similar roles to those in somatic cells, sperm mitochondria have several 
unique proteins or protein isoforms (testis- or sperm-specific), such as cytochrome C (Goldberg et 
al., 1977; Hess et al., 1993) and subunit VIb of the cytochrome c oxidase 2 (COXVIb-2) (Hüttemann 
et al., 2003) among others (Blanco and Zinkham, 1963; Burgos et al., 1995; Travis et al., 1998), 
which functionally differentiate sperm mitochondria from the somatic counterparts. Any alteration 
in the sperm mitochondria that compromises their normal functionality may potentially affect male 
gamete function, including motility, highlighting the importance of these organelles in male 
reproduction (Piomboni et al., 2012; Amaral et al., 2013b). However, their physiological significance 
is still unclear and needs more investigation. 
Fibrous sheath 
 The FS consists of two longitudinal columns (LCs) connected by closely arrayed 
circumferential ribs, which surround the axoneme and the ODF. This highly resistant structure, 
which includes many proteins cross-linked by disulphide bonds, provides mechanical support and 
modulates flagellar bending, thus defining the shape of the flagellar beat (Fawcett, 1975; Olson et 
al., 1976). It also serves as a scaffold for proteins with indispensable roles in sperm motility, such as 
different signalling pathways and metabolism related proteins, namely glycolytic enzymes (Fig. 1.4) 
(Turner, 2006; Eddy, 2007). Some of the fibrous sheath proteins are cAMP-dependent protein 
kinase (PKA) anchoring proteins (AKAP), which are probably exclusive of spermatogenic cells (Eddy, 
2007). The most abundant AKAP protein, and also one of the major structural component of the 
fibrous sheath, is AKAP4 (Carrera et al., 1994; Fulcher et al., 1995a). This protein has been proven 
through gene targeting disruption to be involved in triggering of progressive sperm motility in mice, 
and consequently in fertility (Brown et al., 2003).  
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 There are also many testis-specific isozymes or proteins associated with enzymatic activity 
in the FS including multiple glycolytic enzymes (Krisfalusi et al., 2006) – namely Hexokinase 1-S (HK-
S; (Mori et al., 1993, 1998; Travis et al., 1998; Nakamura et al., 2010)), Glyceraldehyde 3-phosphate 
dehydrogenase-S (GAPDH-S; (Fenderson et al., 1988; Welch et al., 1992; Miki et al., 2004)), Enolase 
4 (ENO4; (Nakamura et al., 2013)), Triosephosphate isomerase 1 (TPI1; (Ijiri et al., 2013) –, a 
glutathione-S transferase (GSTM5; (Fulcher et al., 1995b)), two thioredoxins – sperm tioredoxin-1 
and 2 (SPTRX-1 and SPTRX-2; (Yu et al., 2002; Miranda-Vizuete et al., 2003)) –, and a pyruvate 
dehydrogenase E1 subunit (PDHB; (Fujinoki et al., 2004)).  
 Moreover, as scaffold for components involved in signal transduction and signalling 
pathways, the fibrous sheath contains for example some proteins of the Rho-GTPase signalling 
pathway, such as ropporin (Fujita et al., 2000). Ropporin is a spermatogenic cell-specific protein 
that binds rhophilin (Nakamura et al., 1999), which in turn interacts with Rho GTPase, important 
regulators of cellular processes associated with cell movement and adhesion and also with sperm 
motility (Fujita et al., 2000; Fiedler et al., 2013). 
 
1.1.3 Specific mammalian sperm features: maturation, capacitation and acrosome reaction 
 The human testes produce approximately 1000 spermatozoa per second (Amann and 
Howards, 1980). All these sperm cells, after released from seminiferous tubules, are transferred to 
the epididymis, where they finish their maturation process, which includes the acquisition of 
various proteins, probably in part through a structure called epididymosome (Frenette et al., 2010). 
Although at this point sperm cells are considered mature, they are still immotile and unable to 
fertilize the oocyte, as the sperm plasma membrane remains ‘biologically frozen’ until sperm leave 
the male’s body and begin the ‘defrosting’ process. This consists on a series of poorly understood 
maturation steps known as capacitation, which occurs in the female reproductive tract, and is 
mandatory for spermatozoa to become fertilization-competent (Chang, 1951; Abou-haila and 
Tulsiani, 2009; Okabe, 2013). This fertilizing competence acquisition includes molecular, physical 
and biochemical events such as an increase in plasma membrane permeability and fluidity due to 
cholesterol efflux, influx of ions (specially Ca2+ and bicarbonate (HCO3-)) that activate signalling 
cascades, internal pH rise and activation of protein kinases that promote protein phosphorylation, 
typically on tyrosine residues (Visconti and Kopf, 1998; Abou-haila and Tulsiani, 2009; Okabe, 
2013). The capacitation process seems to be reversible, so that sperm cells can adapt their 
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fertilizing ability to the external conditions (Fraser, 2010). This process also leads to profound 
structural and functional changes in the male gamete, namely in motility pattern (hyperactivation), 
preparing it for acrosome reaction and egg fertilization (Okabe, 2013).  
The acrosome reaction, a Ca2+-dependent exocytotic event, consists on the release of the 
hydrolytic enzymes contained in the acrosome, such as acrosin, which facilitate sperm penetration 
through the oocyte zona pellucida (Ramalho-Santos et al., 2007). Interestingly, progesterone, 
released by the cumulus cells, is one of the factors that triggers this reaction by the direct 
activation of a cation channel named CatSper, thus promoting Ca2+ influx apparently without the 
involvement of any metabotropic receptor (Lishko et al., 2011; Strünker et al., 2011). Another 
important factor seems to be membranar lipids, which are apparently involved in the modulation of 
calcium flux trough other calcium channels and participate in the regulation of acrosome exocytosis 
and fertilization (Cohen et al., 2014).  
After the penetration of the first oocyte vestments, specific molecules involved in the 
sperm-oocyte recognition are exposed and promote the interaction between the male and female 
gametes. For instance, the Izumo-Juno interaction (Inoue et al., 2005; Bianchi et al., 2014; 
Wassarman, 2014), seems to increase cell membrane fluidity and to facilitate fusion-related events, 
contributing to the fertilization of the oocyte (Primakoff and Myles, 2002; Okabe, 2013).  
 
1.1.4 Mammalian sperm motility  
 Although sperm motility is one of the most important features of these special cells, being 
absolutely crucial to accomplish their main goal, i.e., reach and fertilize an oocyte, the molecular 
mechanisms behind sperm motility and its activation and regulation are not fully understood 
(Turner, 2006; Inaba, 2011). These cells acquire the capacity to move forward during epididymal 
maturation, but do not become motile until released from the epididymis (Vadnais et al., 2013). 
 Mammalian sperm display two types of physiological motility:  1) activated progressive 
motility (typical from freshly ejaculated sperm) and 2) hyperactivated motility (characteristic from 
most sperm recovered from the site of fertilization) (Katz and Vanagimachi, 1980; Suárez and 
Osman, 1987; Turner, 2006). The first type of motility is characterized by strenuous and relatively 
symmetrical flagellar motion that results in a rapid forward movement. The second one starts after 
a period of time in the female reproductive tract or after in vitro incubation in appropriate medium, 
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and is characterized by asymmetrical flagellar bends, high amplitude and whip-like beating of the 
flagellum and a circular swimming trajectory. The hyperactivation of motility occurs during the 
process of capacitation, however it is not clear if this is a consequence of capacitation or a parallel 
independent event (Suarez, 2008). 
 The driving force for the flagellar motility is the result of the sliding of outer doublet 
microtubules by axonemal dyneins through a mechanochemical cycle of ATP hydrolysis (Satir, 1968; 
Summers and Gibbons, 1971). During this process, the dynein arms of the axoneme became 
phosphorylated and the dynein ATPase are activated, driving the hydrolysis of ATP and converting it 
into mechanical force (Tash, 1989). The dynein arms then transiently interact with their adjacent 
microtubular doublets and generate a power stroke, thus causing the microtubules to slide past 
one another (Satir, 1968; Summers and Gibbons, 1971; Brokaw, 1972) resulting in a bend 
movement along the flagellum. Calmodulin-dependent protein phosphatase calcineurin is one of 
the enzymes responsible for the reversion of this process through dynein dephosphorylation (Tash 
et al., 1988).  
It is important to note that dynein produces a unidirectional force (Sale and Satir, 1977). 
Thus, the generation of a normal axonemal bend requires that phosphorylation/ dephosphorylation 
events and concomitant activation/inactivation of the dynein arms, occur in an asynchronous 
manner along the length of the axoneme (Fig. 1.5) (Wargo and Smith, 2003). Each dynein arm 
interacts with its adjacent doublet, generates a stroke to force that doublet to bend and releases 
the doublet, so that the axoneme can return to its starting position and bend again in the opposite 
direction.  
 
Figure 1.5  – A possible model for the oscillatory mechanism of flagellar bending.  
Dyneins on two sides on the plane of the central pair (CP) apparatus (red and pink) are regulated by signals of 
the radial spokes (RS)/CP apparatus (blue), resulting in the formation of a planar wave. The axonemes are 
fixed at the basal body near the sperm head. The base or tip of the flagellum points toward the minus or plus 
end of doublet microtubules, respectively. Dyneins are minus-ended motors (red and pink arrows), sliding 
adjacent microtubules to the plus end (black and grey arrows). The bending provides feedback and switches 
active dyneins, resulting in the sliding of opposite microtubules across the bend. (Reproduced from (Inaba, 
2011))   
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1.1.4.1 Molecular mechanisms behind motility: cAMP and Ca2
+ signalling 
 The large majority of cellular and biochemical processes start as a response to extrinsic 
stimuli that trigger a specific receptor to initiate a signal transduction cascade. This typical pathway 
for stimulus-induced activation of a cellular process involves changes in conformation, 
phosphorylation, and/or localization of proteins, which results in the turn on/off of cellular 
processes. Sperm motility seems not to be an exception. Albeit some of the key factors involved in 
the initiation and regulation of sperm progressive motility are well known (including calcium ions 
(Ca2
+), bicarbonate (HCO3
-) and cyclic adenosine monophosphate (cAMP)), there are probably many 
others that remain to be identified (Eddy, 2006; Turner, 2006).  
 While the exact process by which sperm motility is initiated remains unclear, there are two 
major hypotheses: one suggests that it occurs as a result of the release of the sperm cells from the 
influence of an inhibitor factor, such as specific glycoproteins, present in the epididymal fluid 
(Usselman and Cone, 1983; Carr and Acott, 1984); the other one proposes that it happens by the 
activation of receptors located in the surface of the sperm cell (e.g. olfactory and GABA receptors), 
which could trigger a signalling response culminating in the activation of the motility (Calogero et 
al., 1996; Fukuda et al., 2004; Spehr et al., 2004; McKnight et al., 2014).  
 More recently, different strategies have been applied to study sperm motility, from diverse 
points of view. These include, for instance, the use of patch-clamp and mathematical modeling to 
decipher flagellar calcium signalling (Kirichok and Lishko, 2011; Olson et al., 2011), the use of 
imaging and fluid mechanics simulation of sperm swimming to reveal the influence of media 
viscosity in sperm motility (Kirkman-Brown and Smith, 2011),the use of protein-protein interaction 
detection tools to study the role of specific proteins in sperm movement (Fardilha et al., 2011), 
among others (Publicover and Barratt, 2011). 
 Inside the cell, the previously mentioned factors (Ca2
+, HCO3
- and cAMP), seem to play 
important roles in signalling pathways that have also been assumed to be involved in mammalian 
sperm motility regulation: cAMP/protein kinase A (PKA) pathway and calcium signalling (Tash and 
Means, 1982; Tash and Bracho, 1994; Ho et al., 2002; Turner, 2006). In addition, there are other 
signalling cascades less well characterised in mature sperm that may likely play roles in sperm 
motility, such as heterotrimeric and small G-protein-mediated pathways and pH changes (Fig. 1.6) 
(Nakamura et al., 1999; Fujita et al., 2000; Mannowetz et al., 2012; Nishigaki et al., 2014). 
Furthermore, data from knockout mouse models have made clear that several proteins are 
required for proper sperm flagellum functioning (Escalier, 2006; Inaba, 2011).   
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 Cyclic adenosine monophosphate (cAMP) 
 Cyclic adenosine monophosphate (cAMP) is a key second messenger in the regulation of 
sperm motility and the cAMP-dependent phosphorylation of flagellar proteins through the 
activation of PKA, is at least partially responsible for the initiation and maintenance of activated 
sperm motility in mammals (Tash and Means, 1982, 1983; Tash and Bracho, 1994). Upon 
ejaculation, an increase in intracellular cAMP levels occurs due to the activation of the sperm 
soluble adenylyl cyclase (sACY; responsible for the conversion of ATP into cAMP) by the action of 
bicarbonate, which is present in higher concentration in the seminal plasma and female 
reproductive tract than in the epididymal fluid (Okamura et al., 1985; Chen et al., 2000). This results 
in the activation of PKA that phosphorylates downstream proteins in serine/threonine residues 
(e.g. axonemal dynein) triggering a cascade of protein phosphorylation events and activation of 
tyrosine kinases, which culminates mainly in the phosphorylation of several proteins in tyrosine 
residues (Tash, 1989; Leclerc et al., 1996; Si and Okuno, 1999; Nolan et al., 2004). This mechanism 
is probably balanced by the action of phosphatases, specifically serine/threonine and tyrosine 
phosphatases, and the resulting net amount of protein phosphorylation seems to be correlated 
with sperm motility status (Tash and Bracho, 1994; Smith et al., 1996; Vijayaraghavan et al., 1996).  
 It has also been shown that male mice deficient for sperm sACY (Esposito et al., 2004; Hess 
et al., 2005) and PKA (Nolan et al., 2004) are infertile and have impaired sperm motility. 
Nevertheless, it is important to note that PKA and sACY do not seem to be required for the 
initiation of sperm motility, but rather for progressive motility improvement, by increasing the 
frequency of tail beating (Wennemuth et al., 2003; Nolan et al., 2004).  
 Furthermore, cAMP may also activate other signalling pathways in sperm by directly 
influencing the activity of some gated ion channels and/or cAMP-mediated guanine nucleotide 
exchange factors (Burton et al., 1999; Ren et al., 2001).  
 
 Calcium  
 Calcium is known to regulate both activated and hyperactivated motility in sperm cells 
(Suárez and Osman, 1987; Ho et al., 2002). It is also known that an increase in intracellular calcium 
happens during capacitation (Baldi et al., 1991), characterized by an extensive tyrosine 
phosphorylation of sperm proteins (Visconti and Kopf, 1998). Hence, besides the HCO3
-, sACY is also 
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activated by Ca2
+ (Jaiswal and Conti, 2003), and the presence of Ca2
+ in the extracellular medium is 
required for sACY-dependent increase in the frequency of flagellar beat triggered by bicarbonate 
(Carlson et al., 2007). Curiously, one of the facts that makes sACY so distinct from the 
transmembrane one, is its uniqueness activation by both bicarbonate and calcium (Chen et al., 
2000; Esposito et al., 2004; Hess et al., 2005).  
 Nevertheless, some data suggest that there are other calcium pathways independent from 
PKA that are also involved in mammalian sperm motility, namely via downstream action of the 
calmodulin (CaM). Some studies have reported that the inhibition of CaM decreases sperm motility 
(Si and Olds-Clarke, 2000). However, calcium/CaM cannot compensate the loss of sACY function, 
highlighting the importance of both pathways (Turner, 2006). The downstream target of CaM is 
calmudulin kinase (CaMK), with specific isoforms in the mammalian sperm flagellum, the inhibition 
of which also results in sperm motility reduction (Fig. 1.6) (Ignotz and Suarez, 2005; Marín-Briggiler 
et al., 2005). 
 Another evidence that highlights the importance of calcium and calcium-regulated events 
in sperm is the presence of numerous membrane channels that permit and control the passage of 
extracellular calcium, namely CatSper, and possibly control sperm movement (Lishko et al., 2012). 
In a recent study, Tamburrino and colleagues report that CatSper channel expression and function 
is associated with progressive motility in human sperm and may also be involved in the 
pathogenesis of asthenozoospermia (Tamburrino et al., 2014). These observations were also 
strengthened by other recent published work in which the authors found that only sperm with 
intact CatSper domains, able to organize in a time-dependent manner followed by a specific protein 
tyrosine phosphorylation pattern, could successfully migrate (Chung et al., 2014). Thus, 
bicarbonate, besides activating sACY resulting in an increase in cAMP and PKA activity (Chen et al., 
2000) also raises intracellular pH, which activates CatSper channels (Kirichok et al., 2006). 
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Figure 1.6 – Schematic representation of the signalling pathways known or believed to be involved in the 
regulation of mammalian sperm motility.  
Abbreviations: Ca – calcium; CaM – calmudulin; CaMK – calmudulin kinase; HCO3 – bicarbonate; sAC – 
soluble adenilate ciclase; ATP – adenosine triphosphate; cAMP – cyclic adenosine monophosphate; PK-A – 
protein kinase A; AKAP – cAMP-dependent protein kinase (PKA) anchoring proteins; FS – fibrous sheath 
(Reproduced from Turner, 2006). 
 
1.1.4.2 Motility fuel: the so-called energy debate 
 The male gamete is a cell with very high energy demands: besides the obvious need of ATP 
to propel the cell forward, energy is required to achieve capacitation and perform the acrosome 
reaction, as well as for ordinary homeostasis (du Plessis et al., 2014; Ferramosca and Zara, 2014). 
Indeed, when compared to other cell types (even with those known to need high levels of energy, 
such as skeletal muscle or heart cells), the rate of sperm ATP production is massive (Ruiz-Pesini et 
al., 2007). Moreover, sperm motility is not only one of the most energetically expensive 
phenomena in sperm activity, but it also has the particular requirement of large amounts of ATP 
locally, along the tail, where the dynein proteins transduce the chemical energy of ATP hydrolysis 
into mechanical force. 
 As mentioned before, sperm cells have a mitochondrial sheath located in the midpiece, 
where the oxidative processes may take place, whereas glycolytic enzymes are mainly located in 
the principal piece of the tail, connected to the fibrous sheath (Eddy et al., 2003; Miki et al., 2004; 
Ford, 2006). This denotes a subcellular compartmentalization of the two main metabolic pathways 
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involved in energy production: glycolysis and oxidative phosphorylation (OXPHOS) (Mukai and 
Travis, 2012). The origin of the large amounts of ATP needed by sperm, especially to fuel motility, 
has been discussed for decades by scientists in the so-called “sperm energy debate” (Ford, 2006; 
Ruiz-Pesini et al., 2007; Storey, 2008; Ramalho-Santos et al., 2009; Amaral et al., 2014a; du Plessis 
et al., 2014).  
 On one hand, and when compared to glycolysis, mitochondrial respiration results in a more 
efficient ATP synthesis. On the other hand, and since mitochondria are confined to the midpiece, 
this compartmentalization may limit the diffusion of OXPHOS-derived ATP along the tail. This fact, 
together with the lack of information about the existence and importance of ATP shuttles along the 
tail of mammalian sperm (Ford, 2006) and the massive presence of glycolytic enzymes along the 
fibrous sheath of principal piece, led some scientists to suggest that glycolysis would be the main 
source of sperm ATP, even in aerobic conditions, as it happens in tumour cells and in fast axonemal 
transport (Zala et al., 2013; Pereira et al., 2014). 
 The relevance of glycolysis in ATP production in sperm was mainly shown by using gene 
targeting to knockout (KO) some of the glycolytic enzymes, and that resulted in male infertility or 
subfertility (Miki et al., 2004; Odet et al., 2008, 2011; Danshina et al., 2010) due to impairment of 
sperm motility and low ATP levels. Furthermore, glycolysis in mouse sperm seems to also 
contribute to a pH-dependent flagellar beat frequency regulation (Mannowetz et al., 2012).  
 In human sperm, the presence of glycolyzable substracts promotes sperm motility and ATP 
content maintenance, which declines rapidly in its absence, even in the presence of oxidizable 
substrates (Peterson and Freund, 1970; Bone et al., 2000; Williams and Ford, 2001). Moreover, 
human sperm seem to convert exogenous labelled pyruvate into lactate, with no trace of oxidation 
in the tricarboxylic acid cycle (TCA), which indicates the prevalence of glycolysis (Hereng et al., 
2011).  
 However, and despite the fact that KO mice for the testicular isoform of cytochrome c, an 
essential protein for mitochondrial respiration, were fertile, their sperm were less motile and 
contained lower levels of ATP than controls (Narisawa et al., 2002). It has also been shown that the 
incubation of human sperm with different mitochondrial electron transport chain (ETC) inhibitors in 
media containing glucose resulted in a rapid reduction of sperm motility (Ruiz-Pesini et al., 2000; St 
John et al., 2005). Moreover, the occurrence of a mitochondrial DNA (mtDNA) point mutation that 
affects the activity of ETC complex I is linked to low-motility sperm that can be rescued through 
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succinate (subtract for ETC complex II) supplementation (Folgerø et al., 1993). Additionally, 
functional mitochondria seem to correlate with a better fertilization potential of human sperm 
(Ruiz-Pesini et al., 1998; Espinoza et al., 2009; Sousa et al., 2011). 
 Interestingly, the results of experiments using mouse epididymal sperm seem to imply that 
both glycolysis and OXPHOS are able to sustain sperm motility, although with a glycolysis in a 
predominant role (Mukai and Okuno, 2004). In fact, glycolysis and OXPHOS are not isolated and 
independent metabolic pathways inside the sperm; and similarly to what occurs in somatic cells, 
glycolysis may be a preparative pathway that continuously supplies carbon units to mitochondria, 
where complete oxidation occurs (Mukai and Travis, 2012). Moreover, despite the controversial 
results of different studies that has fuelled this debate during all these decades, one thing seems to 
became clear: we have to be very careful concerning the interpretation and generalization of data, 
because there are species-specific discrepancies (Ford, 2006; Ramalho-Santos et al., 2009), even 
when different mouse strains are used, i.e., the severity of phenotypes seems to be different (Odet 
et al., 2013). It is also important to keep in mind that the majority of studies to functionally address 
this question and study sperm motility and ATP levels was performed in a classical way, in vitro, 
incubating sperm in media supplemented with different substrates, in the presence or absence of 
inhibitors; and these conditions, as well as, times of incubation, temperatures and substrates and 
inhibitor concentrations, vary from study to study. One thing is now clear, sperm energy 
metabolism seems to be very versatile, easily adaptable to the exogenous substrates available, and 
the energy pathway used may vary among species, also depending on the substrate composition of 
oviductal fluids (Ford, 2006; Ruiz-Pesini et al., 2007; Ramalho-Santos et al., 2009).  
 Recently, the publication of the human sperm tail proteome by Amaral and co-workers, 
added some more players to the energy debate. These data suggest that other carbohydrate 
pathways might operate in human sperm, including those involved in galactose and glycogen 
metabolism (Amaral et al., 2013a). Also the compilation and analysis of the most complete human 
sperm proteome suggests that human sperm have functional Pentose Phosphate Pathway (PPP) 
(Amaral et al., 2014a), which seems to be important for mouse sperm fertility (Urner and Sakkas, 
1999, 2005). Remarkably, 24% of the sperm metabolic human sperm tail proteome includes 
proteins involved in both catabolic and anabolic lipid metabolism (such as fatty acid oxidation, 
carnitine shuttle, acycarnitine transport, ketone body catabolism, glycerol degradation, and 
phospholipid and triglyceride biosynthesis) and the inhibition of fatty acid oxidation with etomoxir, 
in the absence of exogenous substrates, severely affects sperm motility (Amaral et al., 2013a). 
These results were in accordance with previous studies that report the importance of beta-
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oxidation of free fatty acids to sperm function (Lenzi et al.; Jeulin and Lewin, 1996). Additionally, it 
was also reported that motility can be supported by ketone bodies in mouse sperm, suggesting that 
the loss of sperm function by a defect in the glycolytic pathway could be improved by the 
supplementation of ketone bodies as an energy source, using enzymes such as the testicular 
isoform of succinyl CoA transferase (SCOT-t), as a bypass enzyme for energy supplementation 
external to glycolysis (Tanaka et al., 2004b). Glycogen is also a possible endogenous source of 
energy in mammalian sperm. It was shown that dog sperm is capable not only to use endogenous 
glycogen as an energy source, but also to synthesize new glycogen in the presence of exogenous 
glucose (Ballester et al., 2000; Palomo et al., 2003). In dog sperm, glycogen is also important in the 
achievement of capacitation in medium without glucose (Albarracín et al., 2004). These could 
contribute for the long-term maintenance of human sperm motility in the absence of exogenous 
substrates (Amaral et al., 2011). However this hypothesis needs further investigation.  
 Taken together, these cumulative reports seem to demonstrate that in the few days that 
mammalian sperm can spend in the female reproductive tract, they might be able to utilize both 
glycolysis and OXPHOS, and also other metabolic pathways to produce ATP for different purposes 
(Ramalho-Santos et al., 2009; Amaral et al., 2013a, 2014a). The balance between all the metabolic 
pathways may vary between species, according to the substrates available during sperm’s travel 
(Ford, 2006; Ruiz-Pesini et al., 2007). All these evidences highlight the urgent need to design and 
perform more molecular studies in order to better understand sperm physiology and their 
molecular basis. 
 
1.1.5 Male infertility 
 Infertility, commonly defined as the inability to conceive after at least 1 year of regular and 
unprotected intercourse, affects 10-15% of the population and it is estimated that approximately 
40% is due to male etiology and poor sperm quality (Schulte et al., 2010; Dada et al., 2011; Hwang 
et al., 2011). Nowadays, male infertility diagnosis relies on the microscopic assessment of standard 
semen parameters, mainly sperm concentration, motility and morphology, in the native sample 
based on the World Health Organization (WHO) guidelines and reference values ((WHO, 2010); 
Table I). Based on that, a sperm sample is considered normal (normozoospermic) if it contains ≥15 
millions of spermatozoa per ml of semen, ≥32% of sperm with progressive motility and ≥4% of 
morphologically normal forms (WHO, 2010). If one of these parameters is below the reference 
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value, the sample is considered abnormal and dubbed oligozoospermic, asthenozoospermic or 
teratozoospermic, (low values of concentration, motility and morphology, respectively) (WHO, 
2010). 
 
Table 1.1 – Reference values for the evaluation of human sperm quality (WHO, 2010).  
Parameter Reference value (WHO, 2010) 
Ejaculate volume ≥ 1.5 ml 
Ejaculate pH ≥ 7.2 
Total sperm number ≥ 39 million sperm/ejaculate 
Sperm concentration ≥ 15 million sperm/ml ejaculate 
Sperm progressive motility ≥ 32 % total motile sperm 
Sperm morphology* ≥ 4 % normal forms 
Sperm vitality ≥ 58 % live sperm 
 *According to the strict criteria (Kruger et al., 1986). 
 
1.2 Human sperm proteomics  
 By definition, proteomics is the systematic analysis of all the proteins in a cell, tissue or 
organism, under a particular set of conditions and in a specific moment (Domon and Aebersold, 
2006; Cox and Mann, 2007). Proteins are vital parts of living organisms, with important structural 
functions and they are the main components of the physiological metabolic pathways of cells. 
Moreover, the role of the proteomics field, coupled to the constant improvement of the systems 
used to its study, namely mass spectrometry (MS) techniques, and the generation of enormous 
databases with peptides and proteins information, as well as the development of bioinformatics 
tools, are making possible to perform meta-analysis using large volume of data. Altogether, these 
have been leading scientists to better know and characterize cells, tissues and organisms, and also 
diseases or specific pathways, at the molecular level. Although the high-throughput proteomics is a 
recent field, during the last decades the number of proteomic studies increased abruptly and the 
refinement and improvement of the techniques used to identify and characterize large number of 
proteins occurs at high velocity, probably due to the large number of researchers that uses 
proteomics in different subjects and areas to a wide range of purposes (Ahrens et al., 2010). 
 The human sperm cell proteomics field is a good example of this evolution. Few decades 
ago no more than 100 different proteins had been described in the human male gametes. 
Nowadays, and thanks to the proteomics technological advances and study-designed 
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improvements, thousands of proteins have been described as part of human sperm. The most 
complete catalogue of human sperm proteins, which compiled the outputs of 30 proteomic studies, 
resulted in a list of 6198 different proteins (Amaral et al., 2014a). In this elegant work the authors 
have considered the literature until 2012, and have selected the studies that accomplish some 
confidence requirements for the identification of proteins by liquid chromatography coupled to 
tandem mass spectrometry (LC-MS/MS), as a false discovery rate (FDR) < 5% and two peptides per 
protein or a FDR < 1% (Amaral et al., 2014a). Currently, this catalogue is certainly bigger, with more 
proteins that were not previously described in human sperm. For example, two recently published 
works, conducted by Azpiazu et al. (2014) and Castillo et al (2014), that performed proteomics in 
human sperm added “new” proteins to this list (Azpiazu et al., 2014; Castillo et al., 2014a). This 
compilation work had also huge importance, since it turned possible and performed large-scale 
bioinformatics analysis, using bioinformatics platforms in order to understand which metabolic 
pathways are likely active in human sperm (Amaral et al., 2014a). 
 In fact, human sperm is a very suitable cell for proteomic studies since it is an accessible cell 
that can be easily purified and analysed (Oliva et al., 2008, 2009; Amaral et al., 2014a). Moreover, 
as mentioned before, sperm cells are believed to be transcriptionally and translationally silent, at 
least from nuclear encoded genes (Miller et al., 2010; Baker, 2011; Amaral and Ramalho-Santos, 
2013). This means that, at the end of the differentiation and maturation processes, the sperm cells 
have to contain all the proteins they need to be functional and accomplish their final objective, 
reach and fertilize an oocyte. The question is: are all proteins present in sperm cells functional 
proteins (either for sperm or for the oocyte and first steps of embryonic development) or are they 
mere leftovers of the spermiogenesis? Probably this question will be more easily answered after 
the complete characterization of the human sperm proteome. Then, will be easier to know if all the 
players of a specific pathway are present, which will allow researcher to focus on specific 
protein/pathway functionality, studying not only if these pathways are active but also their 
importance in sperm function. Therefore, during the last decades, many studies have been focused 
on the description of the human sperm proteome, starting mainly with whole cell proteomic 
analyses (Johnston et al., 2005; Martínez-Heredia et al., 2006; Baker et al., 2007; de Mateo et al., 
2007; Li et al., 2007; Wang et al., 2013). Furthermore, the proteomic analysis of subcellular 
fractions of sperm cell (i.e. samples enriched in heads, tails or nucleus) was also a strategy that has 
been contributing to the identification of “new” sperm proteins, as it enriches the samples in 
minority proteins (proteins present in low amount in the cell), allowing their identification and 
improving the throughput (de Mateo et al., 2011; Amaral et al., 2013a; Baker et al., 2013; Castillo et 
al., 2014a, 2014b). 
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 Considering sperm proteomics approaches, the first critical step is to ensure the purity of 
the samples, as the ejaculate has more than sperm cells (i.e. leucocytes, epithelial cells also known 
as round cells), and minor contaminations could lead to false positive results. For that, a normal 
procedure in human sperm proteomic studies is to select sperm cells, either by swim-up 
techniques, density gradient centrifugation or magnetic cell sorting (Fig. 1.7). After protein 
extraction, normally there are two technical strategies used in human sperm proteomic studies. 
The first one uses the initial protein separation (by one- or two-dimensional polyacrylamide gel 
electrophoresis (1D-PAGE, 2D-PAGE), followed by protein excision from the gel and digestion with 
enzymes (usually trypsin) into peptides. The second one performs the direct digestion of sperm 
proteins into peptides, with no previous separation. The peptides are further injected into mass 
spectrometer or separated using one- or two-dimensional liquid chromatography (1D-LC, 2D-LC) or 
isoelectric focusing (IEF) and then analysed by mass spectrometry (either by matrix-assisted laser 
desorption/ionization (MALDI)-MS or MS/MS) and identified using software to by search a 
peptide/protein databases (Fig 1.7) (Amaral et al., 2014a). 
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Figure 1.7 – Human sperm protemics strategies. 
Thi inicial step in any sperm proteomics study consists on the isolation of sperm cells (from both the seminal 
plasma and other cells coexisting in semen). Sperm proteins are then extracted from either the whole cell or 
from specific subcellular compartments (in this case subcellular fractionation is performed beforehand). Once 
proteins are extracted, there are two technical options: (1) proteins are separated either by 1- or 2-
dimensional polyacrylamide gel electrophoresis (1D-PAGE, 2D-PAGE), excised from the gels and digested 
(usually with trypsin) to generate peptides; 1D-acidic-PAGE may be used to resolve sperm nuclear proteins 
(mainly protamines: P1, P2), which cannot be resolved in a conventional SDS-PAGE; (2) proteins are diggested 
without previous separation. Finally, peptides are analysed by mass spectroscopy (either MALDI-MS or 
MS/MS) and identified by searching a protein database. In order to improve the throughput, peptides can 
first be separated by 1- or 2-dimensional liquid chromatography (1D-LC or 2D-LC) or by isoelectric focusing 
(IEF). (Reproduced from Amaral et al., 2014). 
 
 The previous separation of the proteins (1D-PAGE) and peptides (1D- or 2D-LC, IEF) 
noticeably increases the quality of the obtained results, since it reduces the complexity of the 
mixture of proteins. It is also important to note that the initial analyses of sperm proteins were 
normally carried out using 2D-PAGE and MALDI-time of flight (TOF) MS and the number of 
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identified proteins were around 100 proteins (de Mateo et al., 2007; Li et al., 2007; Martínez-
Heredia et al., 2008). Nowadays, and using LC-MS/MS, the recently published results, include the 
identification of thousands of human sperm proteins, confirming the higher efficiency and 
throughput of this methods (Baker et al., 2007, 2013; Amaral et al., 2013a; Wang et al., 2013).  
 
1.2.1 Comparative human sperm proteomics 
 As stated before, all the technological improvements and the creation of a catalogue of 
proteins present in human sperm cell (Amaral et al., 2014a), has been leading us to an increase of 
knowledge about the human male gametes gene products, that would be trivial to understand the 
molecular basis of their (dys)function and physiology and to address some (in)fertility questions, 
allowing the more confident search for novel putative biomarkers.  
 Therefore, the comparative and functional sperm proteomics has assumed an important 
role in the identification of differentially abundant proteins between distinct quality sperm or 
pathological conditions. In this field the most commonly used proteomic approach combined the 
2D-PAGE, with in-gel protein digestion and the identification of the peptides by MS (Fig. 1.7) 
(Holland and Ohlendieck, 2014).  
 Hitherto the comparative sperm proteomics has been applied to compare different quality 
samples, such as sperm samples from patients with failed fertilization versus fertilization after in 
vitro fertilization (IVF) (Pixton et al., 2004; Frapsauce et al., 2009; Azpiazu et al., 2014) or after 
artificial insemination (Xu et al., 2012), teratozoospermic versus normozoospermic sperm samples 
(Liao et al., 2009), diabetic patients sperm samples with non-diabetic obese patients and healthy 
donors (Paasch et al., 2010; Liu et al., 2014), or asthenozoospermic versus normozoospermic 
samples (Zhao et al., 2007; Martínez-Heredia et al., 2008; Chan et al., 2009; Siva et al., 2010; Parte 
et al., 2012; Amaral et al., 2014b). It has also been used to perform functional proteomics and 
compare, for example, capacitated versus non-capacitated sperm (Ficarro et al., 2003; Secciani et 
al., 2009). Therefore, this is an important area of research, and currently there are many other 
proteomics strategies with larger high-throughput capacity that can be more applied to study 
human sperm differential proteomes (Amaral et al., 2014b; Azpiazu et al., 2014).  
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1.2.1.1 Comparative human sperm proteomics focused on sperm motility 
Asthenozoospermia is one of the main seminal pathologies underlying male infertility, with 
a prevalence of up to 81 % (Thonneau et al., 1991; Curi et al., 2003). Moreover the concentration of 
progressively motile sperm seems to be the most predictive sperm parameter of both natural and 
assisted pregnancy outcomes (Tomlinson et al., 2013). However and despite its importance, we still 
do not have a comprehensive model of the myriad of molecular mechanisms controlling sperm 
motility.  
Thus, being proteomic technologies really efficient tools to help reveal molecular 
regulatory mechanisms, sperm motility is not an exception (Oliva et al., 2008, 2009). In fact, as 
mentioned above, various groups have used mass spectrometry approaches to compare the 
proteome of sperm from asthenozoospermic individuals with that of normozoospermic controls 
(Zhao et al., 2007; Martínez-Heredia et al., 2008; Chan et al., 2009; Siva et al., 2010; Parte et al., 
2012).  
In 2007 Zhao and co-workers compared the proteomic profile of sperm from 8 
asthenozoospermic patients and 8 normozoospermic fertile donors by 2D electrophoresis and 
MALDI-TOF, which resulted in the identification of 10 differentially expressed proteins (Zhao et al., 
2007). One year later Martinez-Heredia and colleagues used a similar approach with larger number 
of samples (20 asthenozoospermic patients and 10 fertile controls) and identified 17 differentially 
expressed proteins (7 proteins less-abundant and 10 proteins more-abundant in 
asthenozoospermic samples). In 2010, seven more proteins were identified as differentially 
expressed in asthenozoospermic samples, using similar approach to compare proteins from 17 
asthenozoospermic with 20 normozoospermic samples (Siva et al., 2010).  
Taking into account the important role of protein phosphorylation on sperm physiology, 
namely on motility, some studies have focused on performing differential phosphoproteomics to 
compare asthenozoospermic samples with normozoospermic ones, either by using conventional 2D 
electrophoresis (Chan et al., 2009) or by performing immobilized metal affinity chromatography 
(IMAC) (Parte et al., 2012) before MS analysis. The first study resulted in 12 differentially 
phosphorylated proteins after comparing 20 asthenozoospermic patients with 20 fertile controls 
(Chan et al., 2009). The comparative human sperm phosphoproteome of 4 severe 
asthenozoospermic patients with 4 normozoospermic samples resulted in 68 phosphoproteins up- 
and down-regulated in asthenozoospermic samples (Parte et al., 2012). 
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Merging the outcomes obtained in the aforementioned references, Amaral and co-workers 
have recently described that so far 109 specific proteins have been detected at altered levels in 
sperm samples with low motility (Amaral et al., 2014a). Worth mentioning, most of the differential 
proteins belong to the cytoskeleton or have metabolic functions. However, and although these 
outcomes are pertinent, it should be stressed that these studies relied on the use of relatively low-
sensitive proteomic techniques, when compared to more recent approaches. Moreover, in some of 
the studies the protein identification criteria were not indicated and therefore the possibility of 
false-positive identifications cannot be excluded. 
Higher throughput techniques, with greater detection power, are currently available. 
Indeed, the use of liquid chromatography tandem mass spectrometry (LC-MS/MS) in descriptive 
proteomic studies has revealed that the human sperm proteome is much more complex than 
previously anticipated (Baker et al., 2007, 2013; de Mateo et al., 2011, 2013; Amaral et al., 2013a, 
2014a; Wang et al., 2013; Castillo et al., 2014b). The field of quantitative proteomics is also in 
constant progress, and the use of isobaric labelling strategies (such as isobaric tandem mass tags; 
TMTs) have been applied to study proteome alterations in distinct somatic cells (Thompson et al., 
2003; Dayon et al., 2010; Sinclair and Timms, 2011; Raso et al., 2012; Everley et al., 2013).  
The TMT reagents are isobaric chemical tags that enable simultaneous identification and 
quantitation of proteins in different samples using MS/MS.  (Thompson et al., 2003; Sinclair and 
Timms, 2011). The tags are composed of a primary amine reactive group and an isotopic reporter 
group linked by an isotopic balancer group for the normalization of the total mass of the tags. 
Shortly, the amine-reactive (NHS)-ester-activated compounds covalently attach, with high 
efficiency, to the peptide amino terminus and free amino termini of lysine residues of peptides and 
proteins, labeling all the proteins (or peptides) in a sample. Furthermore, as the tags are 
isotopomers (share identical structure and mass) and they use C and N isotopes instead of H 
isotopes, these permits the coelution of the labelled peptides during LC separation and co-isolation 
during MS/MS analysis, resulting in fewer missing peptide identifications among samples. During 
MS/MS analysis each isobaric tag is also fragmented, producing a unique reporter ion mass that is 
used for sample identification and quantitation. Thus, the protein quantitation is accomplished by 
the comparison of the six reporter ions relative intensities in the MS/MS spectra (Thompson et al., 
2003). 
Recently, by using 2-plex TMT protein labelling and LC-MS/MS, Azpiazu and colleagues 
were able to efficiently identified several sperm proteins that are likely to be required for normal 
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embryo development (Azpiazu et al., 2014). Nowadays, the 6-plex TMTs have simpler structure and 
smaller mass, comparing to the first generation of 2-plex TMTs, with the clear objective to promote 
enhanced cleavage of the reporter groups. In this way, the reporter groups are released in a 
“pseudo-quiet region” of the MS/MS spectra, allowing high-quantification performance and the 
best tracking of more individual samples (Dayon et al., 2010).  
 
1.3 Reproductive metabolomics 
In recent years, the concept of biological fingerprint has emerged and comprehensive 
“omics” approaches (transcriptomics, proteomics, and metabolomics) have become a new but 
simultaneously an increasingly used way of addressing life complexity. Metabolomics is defined as 
the study of small, low molecular weight molecules and reflect downstream events of gene 
expression, thus it is considered to be closer to the actual phenotype than either proteomics or 
genomics (Kuile and Westerhoff, 2001; Nicholson and Lindon, 2008; Patti et al., 2012; Kovac et al., 
2013). In fact, comprehensive “omic” approaches have substantially allowed very detailed 
characterizations of the complex molecular composition of distinct cells, tissues and organisms 
(Smith et al., 2014).  
The identification of the metabolites and proteins as main determinants of the expression 
of the genomes and transcriptomes as also influenced by environmental cues, represents a first 
step to understand the normal composition and physiology of cells and tissues and their 
dysfunction associated to pathological states (Jodar et al., 2012; Wishart et al., 2013; Castillo et al., 
2014a, 2014b). In the case of the human spermatozoon, as mentioned before over 6000 proteins 
have been identified using mass spectrometry (MS), representing about 80% of the estimated 
proteome of this cell (Oliva et al., 2008, 2009; Amaral et al., 2013a, 2014a; Baker et al., 2013; 
Azpiazu et al., 2014). However, and in contrast to the substantial proportion of proteins identified, 
so far a relatively small number of around 20 metabolites have been identified in sperm cells of 
different model species (Oliva et al., 1982; Patel et al., 1999; Dreanno et al., 2000; Jones and Bubb, 
2000; Marin et al., 2003; Hung et al., 2009; Lin et al., 2009). This smaller number of metabolites is 
in part due to the fact that the number of metabolites in cells is much lower than that of proteins 
(Kouskoumvekaki and Panagiotou, 2011; Wishart et al., 2013). But it is also due to the fact that the 
full potential of current “omic” techniques has not yet been fully applied to the study of the sperm 
metabolome (Kovac et al., 2013).  
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The most widely used technique for metabolomic purposes has been nuclear magnetic 
resonance (NMR), mainly for historical reasons (Nicholson et al., 2002; Courant et al., 2013). 
However, more recently, MS-based methods have also proved to be extremely useful in 
metabolites identification and to have some advantages over NMR in terms of sensitivity 
(Theodoridis et al., 2008; Alexandre-Gouabau et al., 2011; Courant et al., 2013). Nevertheless, and 
in order to obtain broad metabolomic descriptions, both approaches (NMR and MS) seem to 
complement each other (Fancy et al., 2006; Patti et al., 2012; Zhang et al., 2012a).  
Metabolomic studies have been performed in sperm cells from different species, such as 
goat (Patel et al., 1998, 1999), boar (Jones and Bubb, 2000; Marin et al., 2003), turbot (Dreanno et 
al., 2000) and rhesus macaque (Hung et al., 2009; Lin et al., 2009). Rat testicular tissue (Griffin et 
al., 2000) and human seminal plasma have also been subjected to metabolomic analyses 
(Hamamah et al., 1993; Gupta et al., 2011a, 2011b, 2013). However, there are no published reports 
on the application of these two metabolomics techniques (NMR and MS) to the study of human 
sperm metabolites. Nevertheless, the characterization of the normal sperm metabolome would 
therefore represent an important first step towards a better understanding of the function of this 
cell and its dysfunction associated to male infertility or subfertility. As it happens with human 
sperm proteomics, it would be important to perform comparative metabolomics to better 
understand human sperm (dys)function and physiology. This, coupled to the use of systems biology 
and the bioinformatics tools available, will certainly be an excellent and valuable way to 
characterize human sperm cells and associated pathologies, and consequently will promote the 
discovery of new (in)fertility biomarkers. 
 
1.4 Objectives 
The first objective of this work was to define the roots for human sperm motility 
deficiencies at the protein level, by using high throughput TMT protein labelling and LC-MS/MS 
protein identification and quantification. For that we have compared the proteome of sperm 
samples differing in motility, asthenozoospermic versus normozoospermic samples (sub-chapter 
3.1). We have also compared our results with previous studies performed by others using less 
efficient proteomic approaches, in order to better understand human sperm motility (sub-chapter 
3.1.5). 
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Another objective of this work was to identify and report, for the first time and through 
two complementary untargeted metabolomics approaches (NMR and MS), the initial catalogue of 
the human sperm cell endogenous metabolites (sub-chapter 3.2). We also aimed to explore the 
relationship between the identified metabolites and the previously reported human sperm 
proteome (sub-chapter 3.3).  
The last objective was to compare for the first time, the metabolomics fingerprints of 
extracts from human sperm with different progressive motility, asthenozoospermic versus 
normozoospermic samples  (sub-chaper 3.4).  
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CHAPTER II. MATERIALS AND METHODS 
2.1 Chemicals 
 All reagents were supplied from Sigma Chemical Company (St. Louis, MO, USA) unless 
stated otherwise. 
 
2.2 Biological Material 
 Human semen samples were obtained from patients undergoing routine semen analysis at 
the Fertility Clinic (Clinic Hospital, Barcelona, Spain). All patients signed informed consent forms 
and all human material was used in accordance with the appropriate ethical and Internal Review 
Board guidelines. Semen samples were collected by masturbation into specific sterile containers 
after 3-5 days of sexual abstinence. Routine seminal analyses were performed according to the 
World Health Organization guidelines (WHO, 2010).  
 
2.3 Differential Proteomics 
2.3.1 Preparation and selection of sperm samples 
All semen samples were washed using Ham’s F-10 nutrient mixture (Life Technologies™, 
Paisley, UK) supplemented with 0.6 % (w/v) bovine serum albumin (BSA) and 26 mM bicarbonate 
(NaHCO3) at 37 °C. Thenceforth, a density gradient centrifugation was performed for each sample, 
using 80 % (v/v) and 40 % Percoll™ (GE Healthcare, Sweden) for 30 min at 400 g, at room 
temperature, following the WHO recommendations (WHO, 2010). The purity of all sperm samples 
was checked using phase contrast microscopy. Sperm motility and vitality (assessed using 0.5 % 
(w/v) Eosin Y) of all sperm samples were determined, according to the WHO recommendations 
(WHO, 2010).  
Only samples containing solely sperm cells after processing (i.e., without contaminating 
cells) were used for proteomic analyses. The selection of the sperm samples (5 asthenozoospermic 
and 5 normozoospermic) was further based on the outcomes of sperm motility and vitality. The 
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rationale was to compare groups of samples differing in progressive motility, but having similar % 
of live sperm. In the end and as expected, the asthenozoospermic group had a significantly lower 
motility (but similar vitality) compared to the normozoospermic group. Additional analysis were 
performed to compare the protamine 1 to protamine 2 (P1/P2) ratio, ensuring there were no 
differences between the P1/P2 ratio of the two groups of samples selected for the comparative 
proteomic analyses, with the objective to focus as much as possible in the motility parameter, 
excluding possible other factors. In order to corroborate our results, another strategy was applied 
using of normozoospermic samples fractionated into two fractions (higher and lower motility 
sperm) by swim-up technique (WHO, 2010), but these results are not part of this dissertation 
(Amaral et al., 2014b). 
 
2.3.2 Protein solubilization 
Sperm cells were washed with PBS and protein solubilization was independently performed 
for each sample, as described previously (Amaral et al., 2013a; de Mateo et al., 2013; Azpiazu et al., 
2014). Briefly, samples were incubated in Lysis Buffer [7 M urea, 2 M thiurea, 1% (w/v) 3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), 1% (w/v) N-
octilglucopyranoside, 18 mM dithiothreitol (DTT) and 2.4 mM phenylmethylsulfonyl fluoride 
(PMSF)] for 1 h at 4 °C, with constant shaking. Protein concentrations were determined using the 
Quick Start Bradford Protein Assay (BioRad, Hercules, CA, USA) following the manufacturer’s 
instructions. 
 
2.3.3 Protein labeling with isobaric tags (TMT 6-Plex) 
In addition to the 5 asthenozoospermic samples (A1 to A5) and the 5 normozoospermic 
samples (N1 to N5), internal controls (CT) were also included for normalization purposes. These 
controls consisted on a mixture of equal amounts of all the samples. 
For labeling, Tandem Mass Tag (TMT) six-Plex™ Isotopic Label Reagent Set (Thermo 
Scientific, Rockford, IL, USA) was used. Twenty five μg of each sperm sample/internal control were 
precipitated with 80% (v/v) cold acetone and separately labeled according to the manufacturer’s 
recommendations. Succinctly, proteins were incubated in 45 mM triethylammonium hydrogen 
carbonate buffer (TEAB) with 0.1% (v/v) sodium dodecyl sulfate (SDS), reduced in 9.5 mM tris (2-
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carboxyethyl) phosphine (TCEP) for 1 h at 55 °C and alkylated with 17 mM iodoacetamide for 30 
min, at room temperature, in the dark. Protein TMT labelling was used instead of TMT peptide 
labelling because we already had this approach set up in our unit. Also a pilot labelling experiment 
performed with TMT0 resulted in a sufficient number of peptide identifications to be able to reach 
our goals. TMT label reagents (0.8 mg each) were equilibrated to room temperature, dissolved in 
24 μL anhydrous DMSO and added to the reduced and alkylated proteins (Fig. 2.1). After 1 h, the 
reaction was quenched with 8 μL of 0.5% hydroxylamine for 15 min, under shaking. Labelled 
samples were then mixed in equal amounts in such a way that two pools of samples were obtained 
for each of the experiments (each consisting of 5 different samples plus the respective internal 
control; Fig. 2.1). After pooling, proteins were precipitated as described previously. 
 
Figure 2.1  – Overall strategy used for the identification of proteomic alterations in sperm with low 
motility.  
Comparative analysis was performed using asthenozoospermic (A1 to A5) versus normozoospermic (N1 to 
N5) samples. After 80%-40% Percoll purification, routine sperm quality was assessed (sperm viability, motility 
and purity) and based on the results 5 astheno and 5 normozoospermic samples were selected, considering 
statistical significant differences on motility (P value < 0.01) and no differences on the percentage of live 
sperm (P value > 0.05; bars graph: blue – normozoospermic and red – asthenozoospermic samples). The 
soluble proteins were extracted, digested, reduced, alkylated and labeled with TMT-6plex (126, 127, 128, 
129, 130, 131) isobaric tags. Equal amounts of the different samples plus an internal control (CT) were then 
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combined as shown in the dotted boxes and run on SDS-PAGE. Each dotted box represents the independent 
multiplexed pools processed. Pools resulting from the astenozoospermic versus normozoospermic 
comparative analysis were run in a gel (2 lanes). Each lane was then excised into very small fragments, which 
were digested with trypsin. Tryptic peptides were further separated by LC and proteins were identified and 
quantified through MS/MS.  
 
2.3.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Precipitated proteins were dissolved in Laemmli buffer (60 mM Tris-HCl pH 6.8, 2.2% (w/v) 
SDS, 5% (v/v) glycerol, 0.1 M DTT) and incubated for 10 min at 90 °C. After cooling, a total of 50 μg 
of labelled proteins were separated by SDS-PAGE (12 % acrylamide gel with a 3.9 % acrylamide 
stacking gel). The gels were fixed with 50 % methanol 10 % acetic acid and stained with EZBlue™ 
Gel staining reagent for 5 min (until a protein smear was slightly visible). 
 
2.3.5 Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS) 
 Gel lanes (Fig 2.1) were carefully cut into very small pieces (≈1 mm3) that were then 
processed for mass spectrometry analysis (Amaral et al., 2013a; Azpiazu et al., 2014). Gel slices 
were digested overnight with 100 to 150 ng trypsin (Promega, Madison, WI, USA) at 37 °C. Tryptic 
peptides were separated by means of nano liquid chromatography using a Proxeon EASY-nLC 
(Thermo Fisher Scientific, Waltham, MA, USA) with a flow rate of 400 nL/min, an EASY C18 trap 
column (5 μm, 120 Å, 100 μm inner diameter × 2 cm in length), and an EASY C18 analytical column 
(3 μm, 120 Å, 75 μm inner diameter x 10 cm in length). The following linear gradient, using Solvent 
B (97 % ACN, 0.1 % formic acid) and Solvent A (3 % ACN, 0.1 % formic acid), was employed: 5 % – 30 
% buffer B (90 min). MS/MS analysis was performed using an LTQ Orbitrap Velos (Thermo Fisher 
Scientific) with a nanoelectrospray ion source with precursor ion selection in the Orbitrap at 30000 
of resolution, selecting the 15 most intense precursor ions in positive ion mode. MS/MS data 
acquisition was completed using Xcalibur 2.1 (Thermo Fisher Scientific). For identification of TMT 
labelled peptides, higher energy collisional dissociation (HCD) with 40 % fixed collision energy (CE) 
was the fragmentation method used. 
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2.3.6 Protein identification and quantification  
Data were processed using Proteome Discoverer 1.4.1.14 (Thermo Fisher Scientific). For 
database searching, raw mass spectrometry files were submitted to the in-house Homo sapiens 
UniProtKB/Swiss-Prot database (released February 2014; 20240 protein entries) using SEQUEST 
version 28.0 (Thermo Fisher Scientific). The Percolator search node, a machine-learning supplement 
to the SEQUEST search algorithm that increases the sensitivity and specificity of peptide 
identifications, was also used (Käll et al., 2007). Searches were performed using the following 
settings: 4 maximum miss cleavage for trypsin; TMT-labelled lysine (+229.163 Da) and methionine 
oxidation (+15.995 Da) as dynamic modifications; cysteine carbamidomethylation (+57.021 Da) as 
static modification; 25 ppm precursor mass tolerance; 20 mmu fragment mass tolerance; 20 ppm 
peak integration tolerance; and most confident centroid peak integration method. The criteria used 
to accept identification included a minimum of 2 peptides matched per protein, with a false 
discovery rate (FDR) of 1 %. 
Quantitative analysis of the TMT experiments was performed simultaneously to protein 
identification using Proteome Discoverer software. Reporter ion quantification of HCD MS2 spectra 
was enabled and TMT-6 plex was set as quantification method. The quantification values were 
extracted from the reporter ions intensities (in; where n represents the reporter ions ranging from 
m/z 126.1 to m/z 131.1) and were corrected according to the isotopic purities of the reporter ions 
provided by the manufacturer. The reporter ions variability before normalization are indicated in 
supplementary table S3. Of note, over 90% of reporter ions had less than 20 % variability. In order 
to determine the relative abundance of each reporter, a normalization of the reporter intensities by 
the sum of all the reporter intensities was made (e.g., i126/i126+i127+i128+i129+i130+i131). Quantification 
values were rejected whenever any quantification channel was missing. For protein quantification 
purposes, only unique peptides were considered and protein ratios were normalized to protein 
median. Normalized values for each protein were exported to Microsoft Excel (v14.0.0) and only 
those proteins with quantification values for all the samples (i.e., 10 samples and 2 internal 
controls) were considered for further analysis. Seeing that 2 lanes of the gel were used the values 
of each sample were further normalized by the respective internal control sample. In order to settle 
if any of the quantified proteins was differentially expressed between the two groups 
(asthenozoospermic versus normozoospermic), statistical analysis was performed (see below) and a 
final list of differential expressed proteins was generated for each experiment. Additionally, and in 
order to validate the results obtained, the MS spectra of all differential proteins detected were 
manually checked.    
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2.3.7 Differential protein annotation and bioinformatics analyses 
Proteins identified in different amounts in each of the two experiments were classified 
according to subcellular localization and biological function(s) using the information available at the 
UniProt Knowledgebase (UniProtKB/Swiss-Prot) website (http://www.uniprot.org). The lists of 
differential proteins were also analyzed using the bioinformatics tool DAVID v6.7 (Database for 
Annotation, Visualization and Integrated Discovery; http://david.abcc.ncifcrf.gov/) in order to 
identify both overrepresented Gene Ontology Biological Process terms and putative active 
biological pathways (Huang et al., 2009a, 2009b). The significance of gene-enrichment analysis was 
expressed by an EASE Score, corresponding to a modified Fisher Exact P value (P values < 0.05 were 
considered significant).  
 
2.3.8 Clustering analysis 
Hierarchical clustering analysis of the quantitative data of the differential proteins was 
performed using PermutMatrix softwarev.1.9.3 (http://www.lirmm.fr/~caraux/PermutMatrix/), a 
software originally developed for gene expression analysis (Caraux and Pinloche, 2005), but that 
has also been validated for proteomics (Meunier et al., 2007). The protein intensity values of each 
sample/subpopulation were logarithmized and exported into PermutMatrix. Hierarchical clustering 
analysis was performed using the Pearson correlation and Ward’s minimum variance methods for 
data distance and aggregation (Meunier et al., 2007). Dendograms with samples on the x axis and 
protein name on the y axis were obtained.  
 
2.3.9 Determination of protamine 1 (P1)/protamine 2 (P2) ratio 
 In order to monitor the protamination status of the individual sperm samples as a way to 
assess overall sperm chromatin packing and protection, the P1/P2 ratio was also determined. 
Towards this goal, the insoluble fractions of the ten samples (5 astheno and 5 normozoospermic 
samples) were processed as described previously (Castillo et al., 2011). Basically, extracted 
protamines, along with external standards of known protamine concentrations, were run on acid-
urea polyacrylamide gels (acid-urea PAGE). Band intensities were quantified using Quantity One 
software (Bio-Rad Laboratories, Hercules, CA, USA) and used to determine the amounts of P1 and 
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P2 in each of the samples. Quantification calculations were based on a regression curve 
constructed with the protamine standards.  
 
2.3.10 Western blotting 
 The expression of two differential proteins, Tektin 1 (TEKT1) and WD repeat-containing 
protein 16 (WDR16) was determined in independent astheno and normozoospermic samples 
through western bloting. Fifteen μg of extracted proteins were run on SDS-PAGE, as described 
above, and transferred on ice to nytrocelulose membranes (NYTRAN Plus, Shcleicher & Schuell 
BioScience GmbH, Dassel, Germany) in transferring buffer (25 mM tris, 0.2 M glycine and 15% (v/v) 
methanol), for 1 h 15 min at 100 mA. Membranes were washed in Tris-buffered saline with 0.1% 
(v/v) Tween 20 (TBST) for 15 min and blocked in TBST with 5% (w/v) skim milk (Nestlé, Vevey, 
Switzerland) for 1 h at room temperature. For immunostaining, rabbit anti-TEKT1 (ab182777; 
Abcam, Cambridge, UK) and rabbit anti-WDR16 (ab170937; Abcam, Cambridge, UK) antibodies 
(diluted 1:1000 in TBST) were used. Membranes were incubated with primary antibodies for 1 h at 
room temperature and then washed thrice with TBST (10 min each). The secondary antibody 
(AmershamTM ECLTM Anti-Rabbit IgG, Horseadish Peroxidase-linked whole antibody; GE Healthcare 
Life Science, Buckinghamhire, UK) was applied to the membranes diluted 1:2500 in blocking 
solution for 1h at room temperature. For detection, the WesternBrightTM ECL Western Blotting 
Detection Kit (Advansta, Menlo Park, CA, USA), and a LAS-3000 imaging system (Fujifilm, Tokyo, 
Japan) were used. Band intensities were quantified using Quantity One software (Bio-Rad 
Laboratories, Hercules, CA, USA) and the ratio between band intensities of the two groups 
(asthenozoospermic to normozoospermic – Ast/Nor) was calculated. 
 
2.3.11 Statistical analyses 
 Statistical analysis was carried out using SPSS for Mac OS (version 20.0, Chicago, IL, USA). 
All variables were checked for normal distribution using the one-sample Kolmogorov-Smirnov test 
and for variance homogeneity using Levene’s test. Comparison between groups (i.e., 
asthenozoospermic versus normozoospermic samples) was performed using Student’s T-test in all 
the comparisons: 1) differential proteomic intensities results; 2) P1/P2 ratio between the two 
groups of sperm samples. P values < 0.05 were considered significant.   
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2.4 Metabolomics  
2.4.1 Biological material 
 Semen samples collection followed the same criteria described above (subchapter 2.2). In 
this study a total of 15 samples with a normal sperm count, normal sperm morphology and free 
from other contaminating cells (after processing) were used: 9 for proton nuclear magnetic 
resonance (1H-NMR) analysis and 6 for Gas Chromatography (GC) Time of Flight (TOF) / Mass 
Spectrometry (MS) analysis. For 1H-NMR 3 pools of samples were made (each one with 150 million 
sperm): 2 normozoospermic (n=2 in one pool and n=3 in the other pool) and 1 asthenozoospermic 
pool (n=4). For the GC-TOF/MS analysis 6 individual samples were used (each one with 15 million 
sperm): 3 normozoospermic and 3 asthenozoospermic samples. These samples were processed and 
classified following the WHO criteria (WHO, 2010). 
 
2.4.2 Sperm samples preparation and purification 
All semen samples were washed and purified following the same criteria methods 
previously described (subchapter 2.3.1). The purity of all sperm samples was checked using phase 
contrast microscopy and only samples with no detectable contamination with non-sperm cells after 
processing were used for metabolomics analyses. 
Sperm cells were then washed three times with cold PBS and, depending on the 
metabolomics technique used, cells were frozen with liquid nitrogen and stored at -80 °C for 
further metabolite extraction (for GC-TOF/MS analysis) or metabolites were directly extracted and 
lyophilized (for 1H-NMR), Fig. 2.2). 
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Figure 2.2  – Overall untargeted metabolomics strategy used for the identification of metabolites in human 
sperm.  
After purification the sperm samples were washed and the metabolites extracted with methanol/water (H2O) 
at a ratio of 2:1 (v/v) for NMR spectroscopy analysis and at a ratio of 8:1 (v/v) for GC-TOF/MS analysis.  
 
2.4.3 Sperm sample selection and metabolite extraction for 1H-NMR 
 Only samples containing solely sperm cells after percoll selection (i.e., without 
contaminating cells) were used for metabolomic analyses. Due to the relatively low sensitivity of 
NMR, a high amount of cells (150 million) were needed to extract enough metabolites for each 1H-
NMR spectroscopy experiment. Three different pools of samples with identical phenotypes were 
prepared: 2 normozoospermic pools (one with n=2 and another with n=3) and 1 
asthenozoospermic pool (n=4). The extracts of the first normozoospermic pool (n=2) ware used to 
set the NMR spectrometer parameters and acquire the first 1H-NMR spectra. The extracts of the 
other normozoospermic pool were used to perform the 1D and 2D NMR experiments for the 
identification of human sperm metabolites. 
 Simultaneously to the identification of human sperm endogenous metabolites, and in order 
to further explore, as a preliminary assay, if the human sperm signatures changed between 
different sperm sample quality, two pools of samples with 150 million sperm each one were used 
for 1H-NMR analysis based on different motilities: one with 4 asthenozoospermic samples and the 
other one with 3 normozoospermic samples (percentage of motile sperm mean±SEM = 30.17±4.58 
and 69.67±1.86, respectively). The third normozoospermic pool was used to setup the NMR 
machine and also to acquire 1D spectra for analysis (percentage of motile sperm 59.00±8.49). 
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 Extraction of low molecular weight metabolites was performed following a previously 
published procedure (Lin et al., 2007). Briefly, metabolites were extracted by re-suspending sperm 
pellets and precipitating proteins with 1 mL of cold methanol/water (2:1 v/v) solvent. After 
vortexing (15 sec, 3x with 15 sec incubation on ice in between each vortex), the samples were 
centrifuged at 12,000 g for 10 min at 4 °C. The supernatants (900 μL) were lyophilized and stored at 
– 80 °C.  
 
2.4.4 NMR analyses 
 Lyophilized extracts of 150 million sperm were resuspended in 700 μL of deuterium oxide 
(D2O, 99% D) containing 0.28 μg/μL of 3-(Trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP; 
98 atom % D) as an internal standard (0.0 ppm). After homogenization, samples were placed into 5 
mm NMR tubes (Wilmad® NMR tubes 5 mm diam. precision). 1H NMR spectra were recorded at 300 
K on an Avance III Ultrashield Magnet 600 MHz spectrometer (Bruker, Rheinstetten, Germany) with 
5 mm TCI Cryoprobe 1H[13C/15N], operating at a proton frequency of 600.20 MHz. One-
dimensional 1H pulse experiments were carried out using the “zgcppr” sequence with 
presaturation, using composite pulse to suppress the residual water peak. Solvent presaturation 
with irradiation power of 50 Hz was applied during recycling delay (RD = 2 s). The 90° pulse length 
was calibrated and was 9 ms. The spectral width was 7 kHz (12 ppm) and a total of 128 transients 
were collected into 36 k data points for each 1H spectrum. The exponential line broadening applied 
before Fourier transformation was of 0.3 Hz. The frequency domain spectra were phased and 
baseline-corrected using TopSpin software (version 2.1, Bruker). 
 2D 1H-1H homonuclear correlation spectroscopy (COSY) and 2D 1H-13C heteronuclear single-
quantum correlation (HSQC) spectroscopy were conducted to assist metabolite assignments. The 
acquired 1H NMR spectra were phased, baseline-corrected, and referenced to the chemical shift of 
TSP signal at 0.0 ppm. References of pure compounds from the metabolic profiling AMIX spectra 
database (Bruker), Human Metabolome Database (HMDB; (Wishart et al., 2007, 2013)), and 
Chenomx database, from Chenomx NMR Suite 7.0 (Chenomx Inc.., Edmonton, Alberta, Canada) 
were used for metabolite identification. In addition, we assigned metabolites by COSY (1H–1H) and 
HSQC (1H–13C) 2D NMR experiments and by correlation with pure compounds run in-house. After 
baseline correction, specific 1H NMR regions identified in the spectra were integrated using the 
AMIX 3.9 software package.  
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2.4.5 Metabolite extraction and derivatization for GC-TOF/MS 
 Seeing that the amount of sperm cells necessary to perform GC-MS is low (15 millions), 
individual samples (3 normozoospermic and 3 asthenozoospermic samples) were analysed. Sperm 
pellets were resuspended in 500 µL of cold methanol/water (8:1 v/v), followed by a quick liquid 
sonication (5 min) and an incubation at 4 °C during 10 min for protein precipitation. After that the 
samples were centrifuged at 22,640 g for 15 min at 4 °C. The supernatants were lyophilized, 
derivatized with methoxyamine hydrochloride, pyridine and N-methyl-N-
(trimethylsilyl)trifluoroacetamide and enriched with FAMEs (C8:0 to C30:0, NuChekPrep) as internal 
standard. 
 
2.4.6 GC-TOF/MS analysis 
 Samples were automatically injected into a GC–MS system (Pegasus® 4D GCxGC-MS/TOF; 
LECO Corporation, St. Joseph, MI, USA). The chromatographic column was a J&W Scientific DB 5-MS 
stationary phase column (30 m x 0.25 mm i.d., 0.25 µm film) (Agilent Technologies, Sta. Clara, CA, 
USA). Mobile phase was helium. Injected sample volume was of 10 µL. Injection mode was splitless 
and flow rate was 1 mL/min. Injector temperature was 250 °C. Temperature gradient was held at 
70 °C for 1 min, then increased to 325 °C at a rate of 10 °C/min and held at 325 °C for 9.5 min. Total 
time of the analysis was 36 min. Ionization performed was electron impact (EI) at 70eV. Acquisition 
was carried out in scan mode (mass scanning range of 35 to 700 m/z). Data analyses were 
performed using XCMS on-line.  
 
2.4.7 Metabolites annotation and bioinformatics analysis  
 The metabolites identified with the two metabolomics techniques (1H-NMR and GC-
TOF/MS) were classified according to their super class using the information available at the Human 
Metabolome Database version 3.6 (HMDB) website (http://www.hmdb.ca) (Wishart et al., 2007, 
2013) and PubChem Compound (http://www.ncbi.nlm.nih.gov/pccompound) website. The total list 
of metabolites was also analysed using the bioinformatic tool Metabolites Biological Role (MBRole; 
http://csbg.cnb.csic.es/mbrole/) in order to identify overrepresented or enriched biological 
pathways that could be putatively active (P-values < 0.05 were considered significant) (Chagoyen 
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and Pazos, 2011). These pathway results were based on the Small Molecule Pathway Databese 
(SMPDB; http://smpdb.ca) (Frolkis et al., 2010; Jewison et al., 2014). 
 Combined analyses of protein and metabolite datasets were also performed to integrate 
the human sperm metabolomics data described here with the recently compiled human sperm 
proteome (Amaral et al., 2014a), in order to investigate significantly represented pathways. 
Towards this goal the web based Integrated Molecular Pathway-Level Analysis (IMPaLA; 
http://impala.molgen.mpg.de (Kamburov et al., 2011)) was used. IMPaLA combines the analysis 
using a comprehensive basis of biochemical pathways currently taken from 11 publicly available 
resources. The joint P-values (integrated with Fisher’s method) and joint Q-values (the False 
Discovery Rate (FDR) which results from correcting the P-values for multiple testing using Benjamini 
and Hochberg correction) were considered significant if less than 0.01. In order to reduce the list of 
pathways, we restricted the results to those based on Reactome (Milacic et al., 2012; Croft et al., 
2014). 
 
2.4.8 Statistical analysis 
 Statistical analysis was carried out using SPSS for Mac OS (version 20.0, Chicago, IL, USA). 
All variables were checked for normal distribution using the one-sample Kolmogorov-Smirnov test 
and for variance homogeneity using Levene’s test. Comparison of motility and vitality between 
samples (i.e., asthenozoospermic versus normozoospermic samples) was performed using 
Student’s T-test. P values < 0.05 were considered significant. 
 
 45 
 
 
 
 
 
 
 
CHAPTER III. RESULTS 
 
 
 
  
 46 
 
 
 
 47 
CHAPTER III. RESULTS 
3.1 Human Sperm Differential Proteomics 
 
3.1.1 Motility, vitality and P1/P2 ratio of the selected samples  
 As previously stated (subchapter 2.3.3), the selection of five asthenozoospermic and 5 
normozoospermic samples was based on some parameters with the objective to focus as much as 
possible on the investigation of human sperm motility (Fig 3.1).  
 Therefore, the percentage of progressive motile sperm was significantly lower in 
asthenozoospermic samples (mean ± SDM = 18.7 ± 4.33%) than in normozoospermic ones (70.4 ± 
0.81%; p = 0.008), with no statistical differences in the percentage of live sperm (p = 0.093; Fig 3.1 
A). The analysis of the protamination levels of the selected samples through P1/P2 ratio, also reveal 
no statistical differences between asthenozoospermic (mean ± SDM = 1.69 ± 0.33) and 
normozoospermic (1.63 ± 0.36) samples (p = 0.776; Fig 3.1 B). 
 
 
Figure 3.1 – Motility, vitality and Protamine 1 to Protamine 2 (P1/P2) ratio of the selected samples for 
differential proteomic analysis.  
(A) 5 normozoospermic and 5 asthenozoospermic samples were selected, considering statistical significant 
differences on motility (P value < 0.01) and no differences on the percentage of live sperm (P value > 0.05; 
bars graph: blue – normozoospermic and red – asthenozoospermic samples). (B) Protamine 1 to protamine 2 
(P1/P2) ratio of the 5 asthenozoospermic and 5 normozoospermic samples was also examined and no 
differences were found (p = 0.776). 
 
3.1.2 Protein identification and quantification 
With the aim of determining the molecular basis of human sperm motility deficiencies at 
the protein level, we have performed the quantitative proteomic comparison between sperm 
samples differing in motility, asthenozoospermic samples versus normozoospermic samples (Fig. 
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3.2). Noteworthy, and to the best of our knowledge, the high throughput quantitative proteomics 
approach employed (protein labelling using TMT 6-plex coupled to LC-MS/MS analyses) was used 
here for the first time to study sperm motility. LC-MS/MS resulted in the identification of a total of 
1157 proteins in the pooled sperm samples (supplementary table S1) of which 29 proteins not 
previously described in human sperm cells comparing with the most complete proteomic lists 
published until date using LC-MS/MS (Baker et al., 2007, 2013; de Mateo et al., 2011, 2013; Amaral 
et al., 2013a, 2014a; Wang et al., 2013; Azpiazu et al., 2014; Castillo et al., 2014b). 
 
 
Figure 3.2 – Representative example of a MS/MS spectrum of one peptide derived from one of the 
detected differential proteins (tektin-5).  
The dotted rectangle show the reporter ions region in greater detail: the intensity of each reporter ion 
indicates the relative proportion of the peptide in the different samples. 
 
3.1.3 Differentially abundant proteins in asthenozoospermic samples 
Comparison of the proteomes of asthenozoospermic and normozoospermic samples 
resulted in the identification of 80 differentially expressed proteins (the ratios of the protein levels 
of asthenozoospermics to normozoospermics - Asthenos/Normos - ranged from 0.537 to 2.491; 
Table 3.1). The quantification values (means ± standard deviation) of each differential protein, 
together with the associated P values for the comparative analyses are listed in supplementary 
material (Supplementary table S2). Moreover, the peptides used for identification/quantification of 
each differential protein, along with their FDR, are also reported (Supplementary table S3). 
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Table 3.1 – List of proteins detected at significantly different amounts in asthenozoospermic and 
normozoospermic samples.  
Results are expressed as ratios of protein levels of asthenozoospermics to normozoospermics. 
UniprotKB/ 
Swiss-Prot 
accession 
number 
Protein name Gene names 
Ratio 
Asthenos/ 
Normos 
Q9P2T0 Testicular haploid expressed gene protein THEG 0.537 
Q13642 Four and a half LIM domains protein 1 FHL1; SLIM1 0.573 
O95831 Apoptosis-inducing factor 1, mitochondrial AIFM1; AIF; PDCD8 0.635 
Q6UWQ5 Lysozyme-like protein 1 LYZL1; LYC2; UNQ648/PRO1278 0.656 
P55060 Exportin-2 CSE1L; CAS; XPO2 0.670 
Q96M32 Adenylate kinase 7 AK7 0.673 
P10253 Lysosomal alpha-glucosidase GAA 0.678 
Q92526 T-complex protein 1 subunit zeta-2 CCT6B 0.688 
P48047 ATP synthase subunit O, mitochondrial ATP5O; ATPO 0.695 
Q3ZCQ8 
Mitochondrial import inner membrane 
translocase subunit TIM50 
TIMM50; TIM50; PRO1512 0.703 
Q96KX0 Lysozyme-like protein 4 LYZL4; LYC4 0.705 
Q99798 Aconitate hydratase, mitochondrial  ACO2 0.712 
P55786 Puromycin-sensitive aminopeptidase NPEPPS; PSA 0.719 
Q9H4K1 RIB43A-like with coiled-coils protein 2 RIBC2; C22orf11 0.725 
Q15172 
Serine/threonine-protein phosphatase 2A 56 kDa 
regulatory subunit alpha isoform  
PPP2R5A 0.726 
Q9NR28 Diablo homolog, mitochondrial DIABLO; SMAC 0.731 
P13667 Protein disulfide-isomerase A4 PDIA4; ERP70; ERP72 0.740 
Q8N7U6 EF-hand domain-containing family member B EFHB 0.741 
P36776 Lon protease homolog, mitochondrial LONP1; PRSS15 0.743 
P06744 Glucose-6-phosphate isomerase GPI 0.744 
P06576 ATP synthase subunit beta, mitochondrial ATP5B; ATPMB; ATPSB 0.748 
Q96M91 Coiled-coil domain-containing protein 11 CCDC11 0.749 
Q96MR6 WD repeat-containing protein 65 WDR65 0.757 
P10515 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 
DLAT; DLTA 0.758 
Q5T655 Coiled-coil domain-containing protein 147 CCDC147; C10orf80 0.770 
P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  
DLST; DLTS 0.778 
O75190 DnaJ homolog subfamily B member 6 DNAJB6; HSJ2; MRJ; MSJ1 0.786 
Q5JVL4 EF-hand domain-containing protein 1 EFHC1 0.789 
P49841 Glycogen synthase kinase-3 beta GSK3B 0.791 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 
CAND1; KIAA0829; TIP120; 
TIP120A 
0.791 
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Q4G0X9 Coiled-coil domain-containing protein 40 CCDC40; KIAA1640 0.792 
Q9BRQ6 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein 6, mitochondrial 
CHCHD6; CHCM1 0.792 
Q86Y39 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 11 
NDUFA11 0.793 
P40939 
Trifunctional enzyme subunit alpha, 
mitochondrial  
HADHA; HADH 0.796 
P41250 Glycine--tRNA ligase GARS 0.797 
P14314 Glucosidase 2 subunit beta PRKCSH; G19P1 0.800 
Q969V4 Tektin-1 TEKT1 0.812 
Q14697 Neutral alpha-glucosidase AB GANAB; G2AN; KIAA0088 0.822 
Q6BCY4 NADH-cytochrome b5 reductase 2 CYB5R2 0.824 
P46459 Vesicle-fusing ATPase NSF 0.837 
P11177 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial 
PDHB; PHE1B 0.846 
Q14203 Dynactin subunit 1 DCTN1 0.846 
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 USP7; HAUSP 0.847 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial IARS2 0.847 
Q9Y371 Endophilin-B1 SH3GLB1; KIAA0491; CGI-61 0.849 
O00330 
Pyruvate dehydrogenase protein X component, 
mitochondrial 
PDHX; PDX1 0.858 
Q8N1V2 WD repeat-containing protein 16 WDR16; WDRPUH 0.863 
P22234 Multifunctional protein ADE2 PAICS; ADE2; AIRC; PAIS 0.867 
Q15631 Translin TSN 0.884 
Q96M29 Tektin-5 TEKT5 0.892 
P29218 Inositol monophosphatase 1 IMPA1; IMPA 1.107 
Q9GZT6 
Coiled-coil domain-containing protein 90B, 
mitochondrial 
CCDC90B; CUA003; MDS011; 
MDS025 
1.152 
P67870 Casein kinase II subunit beta CSNK2B; CK2N; G5A 1.199 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial COX5B 1.204 
Q96DE0 U8 snoRNA-decapping enzyme NUDT16 1.211 
P54652 Heat shock-related 70 kDa protein 2 HSPA2 1.219 
P80303 Nucleobindin-2 NUCB2; NEFA 1.225 
P20933 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase AGA 1.249 
P57105 Synaptojanin-2-binding protein SYNJ2BP; OMP25 1.278 
P30041 Peroxiredoxin-6 PRDX6; AOP2; KIAA0106 1.330 
P60174 Triosephosphate isomerase TPI1; TPI 1.333 
Q8N0U8 
Vitamin K epoxide reductase complex subunit 1-
like protein 1 
VKORC1L1 1.344 
Q8NA82 Probable E3 ubiquitin-protein ligase MARCH10 MARCH10; RNF190 1.354 
Q8NBU5 ATPase family AAA domain-containing protein 1 ATAD1; FNP001 1.390 
P28070 Proteasome subunit beta type-4 PSMB4; PROS26 1.397 
Q96AJ9 
Vesicle transport through interaction with t-
SNAREs homolog 1A 
VTI1A 1.417 
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Q9H4Y5 Glutathione S-transferase omega-2 GSTO2 1.449 
Q8IZS6 Tctex1 domain-containing protein 3 TCTE3; TCTEX1D3 1.482 
Q6UW68 Transmembrane protein 205 OS=Homo sapiens TMEM205; UNQ501/PRO1018 1.496 
P01034 Cystatin-C CST3 1.496 
P60981 Destrin DSTN; ACTDP; DSN 1.500 
P24666 
Low molecular weight phosphotyrosine protein 
phosphatase 
ACP1 1.508 
Q9P0L0 
Vesicle-associated membrane protein-associated 
protein A 
VAPA; VAP33 1.515 
O43674 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 5, mitochondrial 
NDUFB5 1.566 
P26885 Peptidyl-prolyl cis-trans isomerase FKBP2 FKBP2; FKBP13 1.606 
Q8WY22 BRI3-binding protein BRI3BP; KG19 1.645 
P32119 Peroxiredoxin-2 PRDX2; NKEFB; TDPX1 1.875 
P02649 Apolipoprotein E APOE 1.900 
P61088 Ubiquitin-conjugating enzyme E2 N UBE2N; BLU 1.935 
P15309 Prostatic acid phosphatase ACPP 2.491 
 
 
In order to obtain a comparative visualization of the levels of the differentially expressed 
proteins in each individual sample, results were displayed in a heat map (Fig. 3.2). Of note and with 
a few exceptions, similar trends for each differential protein were detected in the 5 
asthenozoospermic samples when compared to the 5 normozoospermic samples, and two patterns 
of protein expression levels are perfectly distinguishable in the heat map. Moreover, almost all 
asthenozoospermic samples clustered together, forming a group distinct from that formed by 
normozoospermic samples (Fig. 3.3).  
 
 
 
Figure 3.3 – Heat maps of the levels of the differentially expressed proteins detected in each individual 
sample.  
Comparison between asthenozoospermic and normozoospermic samples. Hierarchical clustering analysis was 
performed according to the Pearson distance and Ward’s minimum variance aggregation method.  
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3.1.4 UniProt classification of the differentially abundant proteins in asthenozoospermic samples 
 The categorization of the 80 differential proteins according to the information available at 
the Uniprot Knowledgebase concerning cellular localization (Fig. 3.4 - pie graph) revealed that the 
most represented groups of proteins were those localized to the mitochondrion (29%) and the 
cytoplasm (20%). Looking to the abundance of proteins on each cellular localization (Fig. 3.4 – bars 
graph), the trend between the different cellular locations was almost always the same (with 
exception Cell membrane / Secreted proteins), with a higher number of proteins in less-abundance 
in asthenozoospermic samples compared to normozoospermic samples. 
 
 
Figure 3.4  – Classification of the differential proteins according to their subcellular localization using the 
information available at the UniProtKB/Swiss-Prot web site.  
The pie graph represents the percentage of deregulated proteins in asthenozoospermic samples in 
comparison with normozoospermic samples concerning the subcellular localization. The bars graph 
represents the number of deregulated proteins in asthenozoospermic samples in comparison with 
normozoospermic samples, which were less (green) or more (red)-abundant in asthenozoospermic samples, 
in each subcellular localization. 
 
As for the main cellular functions (Fig. 3.5), a great proportion of the differential proteins 
have roles in metabolism and energy production (26% - pie graph). Besides that, some of the 
derregulated proteins in low motility sperm were found to be involved in functions as sperm tail 
structure and motility (6%), signaling (8%) and mitochondrial maintenance (5%; Fig. 3.5). Again, 
looking to the abundance of proteins on each particular function group (Fig. 3.4 – bars graph), the 
trend between the different cellular locations was almost always the same, with a higher number 
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of proteins in less-abundance in asthenozoospermic samples compared to normozoospermic 
samples. Interestingly, all the proteins associated with mitochondrial maintenance were less-
abundant in asthenozoospermic samples (Fig 3.5). 
 
Figure 3.5 – Classification of the differential proteins according to their main cellular function using the 
information available at the UniProtKB/Swiss-Prot web site.  
The pie graph represents the percentage of deregulated proteins in asthenozoospermic samples in 
comparison with normozoospermic samples concerning their main cellular function. The bars graph 
represents the number of deregulated proteins in asthenozoospermic samples in comparison with 
normozoospermic samples, which were less (green) or more (red)-abundant in asthenozoospermic samples, 
in each main cellular function. 
 
3.1.5 Gene ontology terms analysis and cellular pathways enrichment analyses  
The Gene Ontology (GO) terms and cellular pathways enrichment analyses confirmed that 
the most detected enriched GO terms related to cellular component were associated with the 
mitochondrion (Table 3.2; adjusted P values after Benjamini correction < 0.05). Concerning GO 
biological process terms enrichment and Reactome pathways analysis, almost all significant terms 
were related to energy metabolism, including pathways as pyruvate metabolism and TCA cycle. 
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Table 3.2 – Enriched Gene Ontology terms and cellular pathways altered in low motility sperm.  
Data from asthenozoospermic versus normozoospermic samples were analyzed using DAVID software. P-
values < 0.05 after Benjamini correction were considered significant. 
Category Term/Pathway Identifier 
Adjusted p-
value 
(Benjamini 
correction) 
Gene Ontology Term Celullar 
Component (GOTERM_CC_FAT) 
Mitochondrial part GO:0044429 3.55E-08 
Mitochondrion GO:0005739 1.37E-06 
Mitochondrial lumen GO:0031980 7.16E-05 
Mitochondrial matrix GO:0005759 7.16E-05 
Mitochondrial envelope GO:0005740 1.20E-03 
Organelle envelope GO:0031967 1.13E-03 
Envelope GO:0031975 9.75E-04 
Mitochondrial membrane GO:0031966 1.36E-02 
Gene Ontology Term Biological 
Process (GO_BP_FAT) 
Generation of precursor metabolites and 
energy 
GO:0006091 5.13E-05 
Pyruvate metabolic process GO:0006090 1.18E-02 
Cell redox homeostasis GO:0045454 3.85E-02 
Reactome Pathway 
Integration of energy metabolism REACT_1505 1.62E-06 
Pyruvate metabolism and TCA cycle REACT_1046 2.21E-04 
Metabolism of carbohydrates REACT_474 2.08E-02 
 
3.1.6 Western blot analysis: Tektin 1 and WDR 16  
 Through western blot analysis the presence of two differentially expressed proteins, tektin 
1 (Tekt 1 – 55 kDa) and WD repeat-containing protein 16 (WDR 16 – 46 kDa), was also confirmed in 
protein extracts from independent samples: four normozoospermic (N1-N4) and four 
asthenozoospermic (A1-A4) samples (Fig 3.6). Moreover, the comparison of the ratios of protein 
level of asthenozoospermic to normozoospermic (ratio Ast/Nor) resulted in similar values tendency 
of those obtained by differential proteomics (ratio Ast/Nor: Tek1 = 0.908; WDR16 = 0.690). 
 
Figure 3.6 – Immunoblotting detection of tektin 1 (Tekt 1 – 55 kDa) and WD repeat-containing protein 16 
(WDR 16 – 46 kDa).  
The presence of two differentially expressed proteins were detected in protein extracts from four 
normozoospermic samples (N1-N4) and four asthenozoospermic samples (A1-A4). 
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3.1.7 Compiled list of differentially abundant proteins in asthenozoospermic samples 
 Comparing the list of the deregulated proteins indicated in table 3.1, with the compiled 109 
proteins described in previous comparative proteomic studies as being differentially abundant in 
asthenozoospermic samples (Zhao et al., 2007; Martínez-Heredia et al., 2008; Chan et al., 2009; 
Siva et al., 2010; Parte et al., 2012), just five proteins were common: tektin-1, inositol 
monophosphatase 1, heat shock-related 70 kDa protein 2, triosephosphate isomerase and prostatic 
acid phosphatase. This considerably increases the total list to a total of 184 deregulated proteins in 
asthenozoospermic samples (Supplementary table S4).  
 Concerning their main functions, not surprisingly the biggest percentage of deregulated 
proteins remain to the metabolism and energy production (22%) group, followed by protein 
metabolism (21%), sperm tail structure and motility related proteins (18%) and by the group of 
proteins evolved in the spermatogenesis / sperm maturation /seminal plasma / sperm-oocyte 
interaction (11%) (Fig 3.7).  
 
Figure 3.7 – Classification of the compiled list of 185 differentially abundant proteins in asthenozoospermic 
samples according to their main cellular function using the information available at the UniProtKB/Swiss-
Prot web site.  
The pie graph represents the percentage of the 185 deregulated proteins in asthenozoospermic samples in 
comparison with normozoospermic samples grouped according to their main cellular function.  
 
3.2 Human Sperm Metabolomics 
 By performing two complementary untargeted metabolomics techniques, nuclear magnetic 
resonance (NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS), we were 
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able to identify a total of 69 metabolites with absolute certainty, in human sperm extracts. Using 
NMR, 42 metabolites were identified with the information of names and structures. Additionally, 
evidence for 30 other potential metabolites was detected, but with insufficient spectral 
information to unequivocally identify them. In the case of GC-MS, 27 metabolites were identified. 
Evidence for additional 120 putative metabolites was also obtained, but with insufficient 
information to confirm their identity. These two strategies resulted in an overlap of four 
metabolites only (Fig 3.8).  
 
 
 
Figure 3.8 – Total number of metabolites identified using the two untargeted metabolomics strategies 
(NMR and GC-MS).  
The Venn diagram represents the total number of identified metabolites using both techniques as well as the 
intersection between them with 4 metabolites in common. 
 
 All the metabolites identified, either by NMR or GC-MS, were identified in the two sets of 
samples (normozoospermic and asthenozoospermic samples).  
 
3.2.1 Metabolites identified by nuclear magnetic resonance (NMR) spectroscopy 
 A representative 1H NMR spectrum showing the metabolic fingerprint of human sperm 
extracts is represented in Fig. 3.9. Glycerophosphocholine, acetylcarnitine and trimethylamine N-
oxide were dominant in all human sperm extracts spectra obtained (Fig 3.9A). With this technique 
we were able to identify a total of 42 low weight molecules (Table 3.3).  
 The identity of some of these metabolites was further confirmed by 2D NMR experiments: 
1H-1H homonuclear correlation spectroscopy (COSY; Fig. 3.9B) and by 1H-13C heteronuclear single-
quantum correlation spectroscopy (HSQC; Fig. 3.9C).  
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Figure 3.9 – Representative NMR spectra (600 MHz) of extracts from human sperm cells.  
(A) Representative 1H NMR spectrum of extracts from a normozoospermic pool of samples. Some of the 
identified metabolites are indicated. (B) Representative 2D NMR spectra - 1H-1H homonuclear correlation 
spectroscopy (COSY) – of human sperm extracts from a pool of normozoospermic samples used for the 
confirmation of some of the metabolites assignment. (C) Representative 2D NMR spectra – 1H-13C 
heteronuclear single-quantum correlation (HSQC) spectroscopy – of human sperm extracts from a pool of 
samples, as a representative 2D HSQC NMR spectra, used for the confirmation of some of the metabolites 
assignment. 
 
The classification of the metabolites identified according to their super class revealed that 
the majority of them belong to the Amino acids, peptides and analogues super class (i.e. alanine, 
arginine, creatine, glutamine, N-acetyltyrosine, tyrosine, valine), followed by the Lipids super class 
(acetylcarnitine, glycerophosphocholine, butyrate, caprate, caprylate, 2-methyl glutarate and 2-
hydroxy-3-methylvalerate). Moreover, several Organic acids and derivatives (i.e. lactate, acetate, 
formate, glycolate, isobutyrate, azelate, 3-hydroxyisobutyrate, 2-oxoglutarate; 3-hydroxybutyrate) 
as well as Aliphatic acyclic compounds (i.e. phosphocholine, putrescine, creatinine, trimethylamine 
N-oxide) were identified, among others (see Table 3.3). 
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3.2.2 Metabolites identified by mass spectroscopy (MS) 
 Using the GC-MS approach we were able to identify 27 metabolites in human sperm 
sample extracts (Table 3.4). Of these, only 4 were also identified by NMR: carnitine, L-threonine, 
gamma-aminobutyric acid and oxoglutaric acid). Importantly, by using MS, we were able to add two 
more amino acids (glycine and serine) to the list of sperm metabolites, making this class in the most 
represented overall from the total list of low weigh molecules described in human sperm extracts 
(see below). We have also detected five lipids (cholesterol, palmitoleic acid, demosterol, 2-
monopalmitin, mercaptoacetic acid), which substantially increased the number of total lipids 
identified.  
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3.2.3 Overall metabolite Super Class and enriched gene ontology term pathways 
 As already stated all metabolites identified by the two complementary techniques were 
categorized in super classes according to the information available in the HMDB and PubChem 
database (Fig. 3.10 and Tables 3.3 and 3.4). The more represented super classes of metabolites 
were the Amino acids, peptides and analogues with a total of 18 metabolites (14 by 1H-NMR and 4 
by GC-MS) followed by Lipids super class with a total of 12 metabolites (7 by 1H-NMR and 5 by GC-
MS). Some Organic acids and derivatives were also identified (8 by 1H-NMR and 1 by both 
techniques). 
 
Figure 3.10  – Number of metabolites identified per class with the two complementary techniques.  
A total of 69 metabolites were identified by 
1
H-NMR spectroscopy (dark gray), by GC-MS (middle gray) or by 
both techniques (light gray) and were classified according to their super class using the information available 
at the Human Metabolome Database (HMDB) and Pubchem websites.  
 
Among other pathways the Gene Ontology (GO) terms and cellular pathways enrichment 
analyses performed with MBRole revealed the metabolism of some amino acids (such as alanine, 
glycine, serine, threonine), the glucose/alanine cycle, beta-oxidation of very long chain fatty acids 
and gluconeogenesis as important metabolic pathways for the human sperm processes (Table 3.5; 
P values < 0.05).  
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Table 3.5 – Overrepresented pathways using the metabolites identified in human sperm extracts.  
All the metabolites identified, through the correspondent human metabolome database (HMDB) codes, were 
analysed using the bioinformatics tool MBRole to perform an overrepresentation analysis for the cellular 
pathways, based on the small molecule pathway database (SMPDB). P-values < 0.05 were considered 
significant. 
SMPDB Pathway P value Compounds 
Transcription/Translation 7.30E-08 
HMDB00288 HMDB00641 HMDB00517 
HMDB00161 HMDB00167 HMDB00158 
HMDB00883 HMDB00172 HMDB00687 
HMDB00045 
Urea Cycle 1.36E-04 
HMDB00641 HMDB00161 HMDB00517 
HMDB00045 HMDB00208 HMDB01341 
Ammonia Recycling 7.94E-04 
HMDB00208 HMDB01341 HMDB00641 
HMDB00123 HMDB00187 
Beta Oxidation of Very Long Chain Fatty 
Acids 
0.003 
HMDB00511 HMDB00062 HMDB00482 
HMDB00201 
Glucose-Alanine Cycle 0.014 HMDB00122 HMDB00208 HMDB00161 
Alanine Metabolism 0.027 HMDB00161 HMDB00208 
Gluconeogenesis 0.029 
HMDB00190 HMDB00122 HMDB01341 
HMDB00208 
Glycine, Serine and Threonine 
Metabolism 
0.026 
HMDB00123 HMDB00187 HMDB00064 
HMDB00167 
Glutamate Metabolism 0.043 HMDB00641 HMDB00208 HMDB00112 
 
3.3 Combined analysis of the human sperm proteome and metabolites 
The combined analysis of the metabolites identified in this work together with the recently 
compiled human sperm proteome (Amaral et al., 2014a) (performed with IMPaLA) resulted in a 
very large number of enriched cellular pathways. Therefore, we decided to restrict the list to those 
having a joint false discovery rate value after Benjamini’s correction < 1 % and at least two 
metabolites identified per pathway, and finally, by limiting the results only to the Reactome 
identified pathways. By doing so and as expected, Metabolism turned out to be the most significant 
pathway (Table 3.6; P=3.15E-49; Q=8.96E-46). The most significant subtypes of metabolism 
detected were: the metabolism of carbohydrates (Q=3.35E-14), the metabolism of lipids and 
lipoproteins (Q=1.62E-07), the citric acid (TCA) cycle and respiratory electron transport (Q=1.66E-
27), the metabolism of nucleotides (Q=3.48E-08), the metabolism of amino acids and derivatives 
(Q=3.77E-12), and biological oxidations (Q=2.47E-05). There were also some other pathways 
significantly overrepresented (Table 3.6): transmembrane transport of small molecules (Q=3.6E-
11), transport of glucose and other sugars, bile salts and organic acids, metal ions and amine 
compounds (1.08E-07), and signal transduction (Q=9.70E-05). 
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Table 3.6 – Combined analysis of the human sperm proteome and the identified metabolites.  
A selection of some of the most statistically significant Reactome pathways derived from the analysis of the 
compiled list of human sperm proteins (Amaral et al., 2014) and the metabolites identified in the present 
work. P values (after Fisher’s method) and Q values less than 0.01 were considered significant. The P and Q 
values are derived from the joint analysis (proteins and metabolites). The number of overlapping proteins 
and metabolites considered in each pathway are also indicated. 
Reactome pathway 
Number of 
overlapping 
proteins 
Number of 
overlapping 
metabolites 
P value 
(Fisher’s 
method) 
Q value 
(Benjamini's 
correction) 
METABOLISM 750 35 3.15E-49 8.96E-46 
Metabolism of carbohydrates 154 6 4.59E-16 3.35E-14 
 Glucose metabolism 55 5 2.94E-16 2.38E-14 
 Gluconeogenesis 27 4 6.79E-10 1.50E-08 
 
Glycogen breakdown 
(glycogenolysis) 
14 3 4.39E-07 5.11E-06 
Metabolism of lipids and lipoproteins 228 17 1.04E-08 1.62E-07 
 Phospholipid metabolism 74 8 5.05E-09 8.15E-08 
 
Glycerophospholipid 
biosynthesis 
44 8 4.75E-07 5.51E-06 
 Peroxisomal lipid metabolism 16 5 1.08E-05 8.72E-05 
 
Fatty acid, triacylglycerol and 
ketone body metabolism 
51 5 6.83E-05 0.000455 
 Cholesterol biosynthesis 14 5 0.000161 0.000909 
 Triglyceride Biosynthesis 25 4 0.000173 0.000964 
 
Lipid digestion, mobilization 
and transport 
25 4 0.000463 0.00238 
 
Beta-oxidation of very long 
chain fatty acids 
6 2 0.000765 0.00368 
 
Mitochondrial Fatty Acid Beta-
Oxidation 
12 2 0.00203 0.00825 
The citric acid (TCA) cycle and 
respiratory electron transport 
112 5 1.75E-30 1.66E-27 
 
Pyruvate metabolism and 
Citric Acid (TCA) cycle 
35 4 2.94E-11 9.60E-10 
 Citric acid cycle (TCA cycle) 19 3 2.06E-09 3.60E-08 
 Pyruvate metabolism 16 3 5.07E-06 4.53E-05 
Metabolism of nucleotides 54 8 1.97E-09 3.48E-08 
 Purine metabolism 25 6 7.54E-07 8.37E-06 
Metabolism of amino acids and 
derivatives 
80 20 7.70E-14 3.77E-12 
 Creatine metabolism 4 7 1.13E-07 1.39E-06 
 Metabolism of polyamines 10 4 0.000406 0.00214 
 Urea cycle 6 4 0.000725 0.00352 
Biological oxidations 46 18 2.66E-06 2.47E-05 
OTHERS     
Transmembrane transport of small 
molecules 
205 23 8.58E-13 3.64E-11 
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Transport of glucose and other 
sugars, bile salts and organic acids, 
metal ions and amine compounds 
22 14 6.80E-09 1.08E-07 
Signal Transduction 516 15 1.22E-05 9.70E-05 
 
3.4 Comparison of metabolic signatures of normozoospermic and asthenozoospermic 
pool of samples  
 As preliminary analysis, the comparison of the metabolic fingerprint (1H-NMR spectra) of a 
normozoospermic pool of samples (150 million sperm) and an asthenozoospermic pool of samples 
(150 million sperm) was done. The metabolic signatures of the different pools revealed to be 
similar, with the same majority metabolites. However, the concentrations (i.e. intensity of the 
picks) of some of the metabolites were different (Fig 3.11).  
 
Figure 3.11  – Representative 
1
H-NMR spectra (600 MHz) of extracts from human sperm cells.  
(A) 
1
H-NMR spectrum of extracts from normozoospermic pool of samples. (B) 
1
H NMR spectrum of extracts 
from asthenozoospermic pool of samples. Some of the identified quantified metabolites are indicated. Both 
spectra have the same reference (3-(Trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt - TSP) with the same 
peak intensity as the concentration added was the same in the two pools of samples. 
 
 In order to visualize which metabolites were present in different amount in 
asthenozoospermic pool compared to normozoospermic pool, the ratio of metabolite 
concentrations asthenozoospermic to normozoospermic was calculated and logarithmized (Log 10 
([Astheno]/[Normo]) (Fig 3.12).   
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Figure 3.12 – Metabolites identified in variable concentration in the asthenozoospermic pool of samples 
compared to the normozoospermic pool of samples.  
The graph represents the logarithmic concentrations ratio of metabolites quantified in asthenozoospermic to 
normozoospermic pools of samples (Log 10 ([Astheno]/[Normo]). The metabolites with ratio equal to zero 
were excluded from the graphic. 
 
 The N-Acetiltyrosine appeared as the metabolite less abundant in asthenozoospermic pool 
(Log10 ratio = −1.58) with the higher difference between the two pools of samples, followed by 
others such as, tyrosine, trimethylamine N-oxide, putrescine, sn-glycero-3-phosphocholine and O-
acetylcarnitine (log ratios = −0.83; −0.65; −0.57; −0.26 and −0.26 respectively) (Log10 3.10). Not 
surprisingly, the majority of the quantified metabolites were present in lower concentration in the 
asthenozoospermic pool compared to the normozoospermic pool of samples (Fig 3.11 and 3.12), 
including the quantified IMP, AMP and ADP (Log10 ratios = −0.73; −0.44 and −0.51, respectively). On 
the other hand, acetate, propylene glycol and formate were detected in higher concentration in the 
asthenozoospermic pool extracts (Log10 ratios = 0.02; 0.16; 0.39, respectively) (Fig 3.12). 
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CHAPTER IV. DISCUSSION 
4.1 Human sperm differential proteomics – insights about human sperm motility  
Determining what distinguishes motile from immotile sperm at the proteome level is a 
crucial approach to appreciate which proteins and cellular pathways play a role in male gamete 
motility regulation. In this study we have used, for the first time, protein TMT labelling coupled to 
LC-MS/MS to compare the proteome of sperm samples differing in motility. The results of this 
study were further confirmed by a complementary strategy (Amaral et al., 2014b). Briefly, five 
normozoospermic samples were fractionated in two sperm subpopulations (one more motile and 
one less motile) using the swim-up technique, conventionally used in the clinic following the WHO 
recommendations (WHO, 2010). After that, protein extraction, TMT labelling and LC-MS/MS were 
identical to what was done in the experiments described here (sub-chapter 2.3).  
It is important to note that the samples used for this experiment were carefully selected 
with the main objective of focus our study exclusively in human sperm motility. Keeping this in 
mind, we have tried to exclude the influence of other parameters, such as contamination with 
other cells, morphology, vitality and also P1/P2 ratio. The reasoning behind the investigation of this 
last parameter was the possible influence that different protamine levels can have in nuclear DNA 
conformation, interfering not only in DNA damage status but also in head shape, thus potentially 
disturbing sperm motility. In fact, on the literature we can find some studies indicating a possible 
correlation between altered levels of protamines and decreased sperm motility (Mengual et al., 
2003; Aoki et al., 2006). However, in our selected samples there was no difference between the 
P1/P2 ratio of the asthenozoospermic and the normozospermic ones groups.  
Interestingly, the categorization of the 80 differential proteins according their cellular 
localization showed that many of the deregulated proteins (29%) are localized to mitochondria, and 
the majority of them were founded as less-abundant in asthenozoospermic samples. As expected, 
we have also found proteins related to flagellum/ cytoskeleton as deregulated and less-abundant in 
sperm with motility disruption. In fact, the involvement of structural proteins (i.e. tektins) in sperm 
motility is well documented and thus finding two members of this family in the list of differential 
proteins was unsurprising. Tektins are structural components of flagellar and cilliary microtubules, 
with a molecular structure very similar to that of intermediate filament proteins and lamins but 
that, unlike these proteins, associate with tubulins, contributing to microtubules stability (reviewed 
in (Amos, 2008)). Mammalian tektins 1 and 5 are almost exclusively testis-specific and may play a 
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role in flagellar formation during spermiogenesis (Xu et al., 2001; Roy et al., 2004; Cao et al., 2011). 
Different tektins were shown to localize to the mammalian sperm flagellum (Wolkowicz et al., 
2002; Oiki et al., 2014), where some may be linked with the outer dense fibers or with the 
mitochondria, instead of being associated with microtubules (Iida et al., 2006; Murayama et al., 
2008). Whatever the case may be, tektin genes mutations and tektin disruption (in humans and 
mice models, respectively), seem to be associated with decreased sperm motility and male 
infertility or subfertility, without affecting females (Tanaka et al., 2004a; Roy et al., 2007, 2009; 
Zuccarello et al., 2008). Interestingly, orthologues of both tektin-3 (identified as deregulated using 
the subpopulations strategy; data not shown) and coiled-coil domain-containing protein 11 
(CCDC11; a protein that we have also detected at deregulated levels in low motility sperm) were 
show to belong to the ciliome of Xenopus epithelial cells (Hayes et al., 2007). Although the exact 
function of CCDC11 is unknown, this protein seems to be an interacting partner of KIF3A motor 
protein (a heterotrimeric kinesin II subunit) in mice spermatogenesis (Lehti et al., 2013). Seeing that 
KIF3A participates in axoneme formation both in somatic ciliated cells and sperm flagellum, it is 
tempting to hypothesize that CCDC11 is also involved in flagellum formation during mammalian 
spermiogenesis. 
Additionally, our outcomes point to the idea that the majority of proteins deregulated in 
sperm samples with motility defects are those with roles in metabolism and energy production. 
Indeed, most of the GO biological process terms and Reactome pathways detected by David were 
related to energy metabolism. ATP is obviously needed to fuel sperm motility and thus the levels of 
any enzymes participating in ATP-producing cellular pathways contributing to flagellar movement 
need to be tightly regulated in the male gamete. What is not totally clear is what the actual 
contribution of the distinct ATP-producing pathways to the generation of the energy that enables 
sperm to move forward is. As discussed previously (subchapter 1.1.4.2), the energy debate usually 
disputes mainly glycolysis and mitochondrial oxidative phosphorylation (OXPHOS), with the 
majority of data pointing to glycolysis as the main pathway fuelling sperm motility in mice and 
humans (Ramalho-Santos et al., 2009; Amaral et al., 2011, 2013b). But in fact an increasing body of 
data is suggesting that other pathways may also be involved (Amaral et al., 2013a, 2014a). 
Our outcomes support the idea that several metabolic pathways contribute to sperm 
motility regulation. It was indeed interesting to determine that low motility sperm have altered 
levels of so many post-glycolytic enzymes, which clearly suggests that glycolysis may not be the sole 
player in this process. Pyruvate metabolism and tricarboxylic acid cycle link glycolysis to other 
pathways, such as OXPHOS and beta-oxidation of fatty acids. OXPHOS relies on the activity of the 
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mitochondrial electron transfer chain (ETC) complexes and on the maintenance of a mitochondrial 
membrane potential (MMP) across the inner mitochondrial membrane. Importantly low levels of 
several ETC proteins (complexes I, IV and V) were detected in low motility sperm, suggesting that 
the whole ETC may be deregulated. In agreement, both MMP and the levels of other complex IV 
subunits were positively correlated with human sperm motility (Amaral et al., 2007; Amaral and 
Ramalho-Santos, 2010). Interesting, in a patient harbouring a mitochondrial DNA point mutation 
causing reduced activity of the ETC complex I, and whose sperm presented low motility, the 
presence of succinate (a substrate for complex II) in the culture medium was enough to restore the 
ability of sperm to move (Folgerø et al., 1993). Furthermore, the incubation of human sperm with 
different ETC complexes inhibitors in the presence of glucose (thus in conditions supporting 
glycolysis) resulted in a rapid drop of sperm motility (Ruiz-Pesini et al., 2000; St John et al., 2005). 
On the other hand, and also in accordance with the proteomic data obtained in the present study, 
Amaral and co-workers have recently shown that inhibition of mitochondrial beta-oxidation impairs 
human sperm motility (without affecting sperm viability) in a concentration- and time-dependent 
manner, at least in the absence of exogenous substrates (Amaral et al., 2013a).  Furthermore and in 
addition to catabolic pathways, fatty acids anabolic pathways may also be relevant for sperm 
function (Amaral et al., 2014a), in particular for sperm motility (current study). That condensing 
mouse spermatids are capable of synthesizing fatty acids were previously shown by others (Grogan 
and Lam, 1982). The same may be true for human sperm, which may have the capacity to 
synthesize fatty acids and use them to obtain some of the energy needed to fuel motility. 
Furthermore, and although the literature suggests that glycolysis plays the preponderant role in 
mammalian sperm motility (and in fact enzymes involved in all glycolytic steps were detected and 
quantified), it is nevertheless interesting that very few enzymes directly implicated in this pathway 
were identified as differentially expressed between samples with distinct motility, obtained with 
two different strategies, while other pathways involved in energy metabolism seem more 
represented. Taken together, these data strongly suggest that the correct functioning of other 
metabolic pathways apart from glycolysis is critical for the ability of sperm to move.  
Remarkably, the two lists of differential proteins that result from both strategies 
(asthenozoospermic vs normozoospermic samples and more- and less-motile subpopulations) have 
a lot in common. First of all, the categorization of proteins according to both cellular localization 
and function resulted in very similar distributions, suggesting, for instance, that proteins involved in 
metabolism and energy production, and notably mitochondrial proteins, are typically deregulated 
in non-motile sperm. Excitingly, a number of protein families and of proteins participating in 
specific cellular pathways were also commonly detected in both comparisons (Amaral et al., 
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2014b). These include cytoskeletal proteins and proteins involved in energy metabolism, protein 
metabolism and vesicle trafficking. Noteworthy, the detection of similar proteomic alterations in 
the two complementary technical approaches provides a substantial confirmation that these 
protein families/cellular pathways might indeed be involved in sperm motility regulation. 
Moreover and as also described in previous proteomics studies investigating deregulated 
proteins in less motile sperm, we have detected proteins with functions in protein metabolism 
(specifically in protein folding and degradation) as differentially abundant proteins. Heat shock 
proteins, together with other chaperones, mediate protein folding and prevent protein 
aggregation. This is the case of human heat shock-related 70 kDa protein 2 (HSPA2), detected as 
differential protein in both our study and studies from others (Martínez-Heredia et al., 2008; Siva et 
al., 2010; Parte et al., 2012). This protein is constitutively expressed at low levels in most tissues, 
but at higher levels in the testis (Bonnycastle et al., 1994; Son et al., 1999). Targeted disruption of 
this protein in mice models resulted in germ cell apoptosis and male infertility, with failed meiosis 
in HSPA2 homozygous knockout male mice (Dix et al., 1996), providing evidence of its importance 
for normal spermatogenesis. As a matter of fact, HSPA2 expression seems to be lower in men with 
abnormal spermatogenesis (Huszar et al., 2000; Son et al., 2000). Our data add further evidence 
that HSPA2 levels are correlated with human sperm motility.  Interestingly, one of the binding 
partners of HSP70s seems to be the product of a testis-specific transcript of WD repeat-containing 
protein 16 (WDR16; (Silva et al., 2005)) that we also have detected at lower levels in low motile 
sperm.  
The proteasome is a proteinase complex with ATP-dependent proteolytic activity that 
mediates protein turnover, and the implication of the ubiquitin-proteasome pathway in sperm 
function is very well documented (Sutovsky, 2011; Hou and Yang, 2013). Proteasome alpha subunit 
proteins were previously reported to have a role in sperm capacitation (Arcelay et al., 2008) and 
motility (Siva et al., 2010) and here we show that altered levels of proteasome beta subunit 
proteins are also associated with reduced sperm motility phenotype. Moreover, we have also 
found cullin-associated neddylation/NEDD8-dissociated protein 1 (CAND1) at reduced levels in 
asthenozoospermic samples. CAND1 is a cullin 1 binding protein that regulates the formation of the 
“Skp, cullin, F-box containing complex” (SCF) ubiquitin E3 ligase complex, controlling the protein 
levels of many regulatory proteins (Liu et al., 2002; Zheng et al., 2002), and may also participate in 
centrosome duplication regulation and prostate cancer development  (Korzeniewski et al., 2012).  
 79 
 Furthermore, proteins involved in vesicle trafficking were also found at altered levels in 
sperm with impaired motility. The occurrence of membrane trafficking events during 
spermiogenesis has been clearly established, specifically in the biogenesis of the acrosome 
(reviewed in (Amaral et al., 2014a)). Vesicle trafficking proteins also participate in sperm fusion 
events and indeed the vesicle-fusing ATPase (NSF) detected here to be under expressed in low 
motility samples was suggested to be useful to predict stallion fertility (Gamboa and Ramalho-
Santos, 2005). Nevertheless, the altered levels of these proteins in sperm with motility defects may 
simply mirror a defective spermiogenesis process. 
 Additionally, and not surprisingly, proteins implicated in signalling pathways appeared 
deregulated in asthenozoospermic samples. As discussed, there are several signalling pathways 
presumably involved in sperm motility acquisition and maintenance. Even so, further studies are 
needed to better decipher many of these pathways and their actual meanings in human sperm 
function. One of these proteins, also found in lower amounts in asthenozoospermic samples, was 
glycogen synthase kinase 3B (GSK3B). The GSK3 is a serine/threonine protein kinase, which has two 
isoforms (GSK3A and GSK3B) and works as a key component of many cellular processes, not only in 
glucose regulation but also in immune responses, cell proliferation, migration and apoptosis (Jope 
and Johnson, 2004; Kaidanovich-Beilin and Woodgett, 2011; Beurel et al., 2014). Furthermore, it 
seems to be involved in sperm motility (Vijayaraghavan et al., 1996, 2000; Smith et al., 1999; 
Aparicio et al., 2007). It was previously reported that immotile caput sperm contain six-fold higher 
GSK3 activity than motile caudal sperm (Somanath et al., 2004). More recently, a targeted KO 
approach for GSK3a resulted in infertile mice with compromised sperm motility, which undoubtedly 
shows their implication in this mechanism (Bhattacharjee et al., 2015). Although more studies are 
needed to investigate the specific function of GSK3B, our results are in accordance with the 
literature showing the GSK3 might be an important player in human sperm motility regulation. 
 The low number of deregulated proteins in common between our study and the previous 
ones (Zhao et al., 2007; Martínez-Heredia et al., 2008; Chan et al., 2009; Siva et al., 2010; Parte et 
al., 2012) (only 5 proteins) was probably due to the different techniques and parameters used to 
perform the analyses. Our work was based in a high-throughput proteomic technique coupled to 
the use of a high sensitive way to label and quantify proteins in independent samples. However, it 
is also interesting to analyse the compiled list of 185 proteins detected as deregulated in 
asthenozoospermic samples. Not surprisingly, when characterized by their main function, the 
majority of these proteins have roles in metabolism and energy production. Looking in more detail 
to the pathways in which these deregulated proteins are involved in, we can find some related to 
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glycolysis and mitochondrial OXPHOS, and also many others involved in pyruvate metabolism, TCA 
cycle, lipid metabolism, fatty acids beta-oxidation, mitochondrial ETC, amino acid metabolism, 
among others. These evidences reinforce the idea that many metabolic pathways are involved in 
the regulation of human sperm metabolism.  
 Interestingly, triosephophate isomerase (TPI) is commonly dettected as a deregulated 
protein in low-motile sperm (Zhao et al., 2007; Siva et al., 2010; Parte et al., 2012; Amaral et al., 
2014b). TPI is a very important glycolytic enzyme that is required to convert dihydroxyacetone 
phosphate to glyceraldehyde 3-phosphate. This conversion is highly efficient and very reversible 
taking part in the gluconeogenesis process too (Orosz et al., 2006). Moreover, this enzyme (TPI1) 
has been studied in human, mice and rat male germ lines and seemed to be important during the 
spermatogenic process (Russell and Kim, 1996; Auer et al., 2004; Ijiri et al., 2013). Thus, although 
more studies will be needed to investigate the real role of TPI in sperm function, it seems to have 
an important role in the regulation of human sperm motility. 
 Another important group of proteins is the one related to sperm tail structure and motility. 
In this specific case the advantage of compiling the list of deregulated proteins described in the 
different studies is evident, with an increase of proteins involved in these functions from 6% (in our 
study) to 18% (in the compiled list). The majority of proteins included in this group were described 
by Parte and colleagues and are mainly tubulins. As main components of the microtubules, tubulins 
assume an important role in sperm flagellum structure and movement (Mohri, 1968). It is also 
known that both α- and β-tubulins undergo several posttranslational modifications such as 
tyrosylation/detyrosylation, and acetylation/deacetylation (Hammond et al., 2008). Moreover, an 
association between low levels of acetylated α-tubulin and asthenozoospermia was recently 
described, suggesting an important role of tubulin acetylation on sperm motility (Bhagwat et al., 
2014).  
 The compilation of all the proteins described on the literature as being disrupted in 
asthenozoospermic patients is an excellent exercise through the clarification of the molecular 
mechanisms behind human sperm motility. In this way, we are trying to join all the already known 
pieces of the puzzle to see, in the future, the whole picture. Overall, our data suggest that proteins 
involved in cytoskeleton, energy metabolism, protein folding and degradation and vesicle 
trafficking are, with a few exceptions, consistently altered in low motility sperm. The exception 
(one asthenozoospermic sample that clustered with the normozoospermic samples) might indicate 
that in addition to alterations in protein levels, low motility sperm might also be typified by other 
molecular deregulations, most probably at the metabolome level. Indeed, our results strongly 
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support the emerging idea that several bioenergetics metabolic pathways (including glycolysis, the 
tricarboxylic acid cycle, mitochondrial OXPHOS and fatty acids beta-oxidation) contribute to sperm 
motility (de)regulation. In the future, it will be interesting to further explore the potential use of the 
detected proteins and pathways towards their potential diagnostic and prognostic use and perhaps 
to pinpoint novel therapeutic targets. 
 
4.2 Human sperm endogenous metabolites – the first little step towards human sperm 
metabolome 
 As already mentioned, the use of genomic, transcriptomic and proteomic technologies are 
significantly contributing to characterize and better understand the human sperm at the molecular 
level (Jodar et al., 2012; Kovac et al., 2013; Amaral et al., 2014a). However, metabolomics, the 
study of small and low molecular weight molecules that are products of metabolism, has not been 
greatly applied in the study and characterization of human sperm cells (Kovac et al., 2013). 
Furthermore, as metabolomics reflects downstream events of gene expression, it is also considered 
to be more closely related to the actual phenotype than either transcriptomics or proteomics 
(Nicholson and Lindon, 2008; Patti et al., 2012), as it can be used to directly monitor biochemical 
activity. 
 Thus, to the best of our knowledge, this was the first time that untargeted metabolomics 
techniques have been performed using human sperm cells extracts to identify their endogenous 
metabolites. Importantly, in the present study, we applied two complementary techniques 
normally used for untargeted metabolomics: nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) (Nicholson and Lindon, 2008; Patti et al., 2012). Using these two strategies we 
were able to identify a total of 69 metabolites, most of them not previously described in human 
sperm. Of note, only 4 metabolites were identified with both techniques, thus highlighting the 
importance of the use of complementary approaches to ultimately complete a metabolic 
characterization of human sperm cells. 
 Although some studies previously used 1H NMR technologies to examine human seminal 
plasma (Gupta et al., 2011a, 2011b, 2013) or circulating plasma metabolic changes (Courant et al., 
2013), in an attempt to correlate metabolites with seminal quality, none of them focussed on the 
mature human sperm cell metabolome. Therefore, this is the first work that describes a metabolic 
fingerprint of human sperm extracts. Interestingly, when compared to the metabolic fingerprint of 
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the rhesus macaque sperm extracts, the major metabolites identified in human were similar, 
namely lactate and acetylcarnitine (Hung et al., 2009; Lin et al., 2009).  
 It is important to note that while the presence of lactate suggests that sperm has active 
glycolysis, carnitine and acetylcarnitine are metabolites usually associated with fatty acid oxidation. 
Acetylcarnitine is an acetic acid ester of carnitine that facilitates the import of acetyl CoA into the 
matrices of mammalian mitochondria, modulating the transfer of fatty acids and acetyl groups into 
mitochondria for beta-oxidation (Rosca et al., 2009). This is in accordance not only with the results 
of overrepresented pathways analysis (using the 69 metabolites described) but also with our 
proteomic results (sub-chapter 4.1) and other previous proteomic and functional analyses (Amaral 
et al., 2014a). In fact, earlier studies have also shown that the levels of carnitine and acetylcarnitine 
in the epididymis, seminal plasma and spermatozoa are much higher when compared with those 
found in circulating plasma (Jeulin and Lewin, 1996). This suggests a possible role of these 
molecules not only in human sperm maturation but also in sperm function, directly in energetic 
metabolism, and possibly as anti-apoptotic and antioxidant factors (Jeulin and Lewin, 1996; Ng et 
al., 2004). The role of lipid metabolism in the production of energy to supply human sperm function 
was already suggested in previous studies (Amaral et al., 2014a, 2014b) and, accordingly, the 
incubation of these cells with a fatty acid oxidation inhibitor (etomoxir) drastically affected human 
sperm motility, highlighting the importance of mitochondrial fatty acid metabolism to fuel human 
sperm (Amaral et al., 2013a). 
 Furthermore, we identified larger number of metabolites belonging to the “amino acids, 
peptides and analogues” super class. In goat a high content of free amino acids was found in the 
ejaculate and the epididymal fluid, where these molecules could serve as chelating agents, in 
particular for toxic metals, and/or as oxidizable substrates for sperm (Patel et al., 1998, 1999). In 
human sperm cells, amino acids could also serve as endogenous substrates, whereas their presence 
in human semen (Hernvann et al., 1986) could be related to functions similar to those described in 
goat semen. However, further studies would be needed to validate this assumption. 
 Concerning the application of both untargeted metabolomics techniques it is important to 
note that, in general, both have advantages and disadvantages (Patti et al., 2012). For example, in 
order to obtain good NMR spectra, with defined resonances and intensities for peak assignment 
and metabolite identification, in the 1D (1H-NMR) and 2D (COSY and HSQC), a high amount of cells 
was required (150 million) driving us to the need of using pools of samples. On the other hand, the 
GC-TOF/MS revealed to be more sensitive and therefore a lower amount of cells (15 million) were 
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needed, allowing the analysis of independent sperm samples. Nevertheless, the GC-TOF/MS 
resulted in the identification of less but different types of small molecules, which confirms the 
advantage of using of both techniques, even taking into account the major limitations of each one. 
Hence, the application of these two complementary techniques seems to constitute a promising 
strategy to investigate human sperm metabolism and to better understand the physiology (and 
pathophysiology) of the male gamete. Moreover and while it is certainly premature to try to make 
an estimation of the number of human sperm endogenous metabolites at this stage, the 
comprehensive list of sperm metabolites might be considerably larger than the one described here. 
The use of other complementary techniques in future studies, such as liquid chromatography (LC)-
MS, as well as of different extraction methods, could contribute to the identification of more 
metabolites towards further completing the human sperm metabolome. It would also be 
interesting to investigate whether there are differences in the relative abundance of the different 
metabolites in sperm cells from human samples with distinct phenotypes (e.g., differing in motility 
and/or in fertilization ability) or collected from individuals at different ages or with different diets. 
Moreover, it would be also interesting to follow the integration of exogenous metabolites, using 
tracers (i.e. labeled substrates, as glucose or fatty acids) as it has been performed using boar sperm 
(Marin et al., 2003). 
 Furthermore, as metabolomics is also one of the emerging “omic” sciences, and new 
approaches are in constant evolution, metabolomics might be applied to address different 
questions in biology of reproduction, in particular to better understand the molecular bases of 
human sperm physiology and (dys)functionality.  
  
4.3 Combined analysis of human sperm endogenous metabolites and the human sperm 
compiled proteome – the importance of the integration of metabolomics and proteomics 
analysis 
 The pathway-level analysis is a powerful method enabling interpretation of post-genomic 
data (i.e. proteins and metabolites) at a higher level than that of individual biomolecules. Taking 
this into account, many scientists are currently developing numerous bioinformatics tools to let this 
kind of analysis be possible and feasible, with an increasing confidence, using curated databases 
and applying statistical methods to restrict the results and increase their significance (Henry et al., 
2014). The Integrated Molecular Pathway Level Analysis (IMPALA) is a web tool for the joint 
pathway analysis of transcriptomics or proteomics and metabolomics data that performs over-
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representation or enrichment analysis with user-specified lists of metabolites and genes or 
proteins, using over 3000 pre-annotated pathways from 11 databases (Kamburov et al., 2011).  
 In the present work and using IMPALA, we performed the combined analysis of the 69 
metabolites identified by untargeted metabolomics approaches and the recently compiled human 
sperm proteome (Amaral et al., 2014a). This resulted in a very large number of enriched cellular 
pathways, which, after selection, resulted in the most probable significant ones. Not surprisingly, 
Metabolism turned out to be the most significant pathway. Moreover, these results contribute to 
reinforce the importance not only of the metabolism of lipids and lipoproteins but also the possible 
significance of pathways like the citric acid (TCA) cycle, respiratory electron transport, the 
metabolism of nucleotides, as well as the metabolism of amino acids and derivatives and biological 
oxidations for the correct human sperm functionality. Inside the category of metabolism of 
carbohydrates, it was particularly interesting to detect glycogen metabolism as a putative pathway 
operating in human sperm, since despite the lack of experiments in humans, this was previously 
showed to be active in dog sperm (Ballester et al., 2000; Palomo et al., 2003; Albarracín et al., 
2004). 
 However, and since the human sperm metabolome is certainly much more extensive that 
the list described here, this would be very interesting to perform more descriptive and comparative 
studies to amplify this list and increase the statistical power of this kind of analysis. For instance, 
the integrated analysis of differential proteome and metabolome of less- and more-motile sperm 
cells and also the respective analysis of their interectomes will most probably contribute to a more 
detailed knowledge of the molecular basis of human sperm motility, as well as to define novel 
therapeutic targets. 
 
4.4 The comparison between the metabolic signatures of extracts of normozoospermic 
and asthenozoospermic pool of samples – a preliminary look to possible important 
metabolites to human sperm motility 
 As preliminary analysis, in the present work we have performed the comparison between 
the metabolic fingerprints of extracts of two pools of samples with different motility using NMR. 
Interestingly, the metabolic signatures of the two pools revealed to be similar, with the same 
majority metabolites. However, the concentrations (i.e. intensity of the picks) of some of these 
were different.  
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 The majority of the identified and quantified metabolites appeared in less quantity in the 
asthenozoospermic pool extracts. Acetyltyrosine (a side chain reaction of tyrosine) and tyrosine 
were the metabolites that appeared as more differently abundant in the extracts of 
asthenozoospermic pool, with lower quantity when compared to normozoospermic ones. 
Interestingly, tyrosine is an essential amino acid that readily crosses barriers (i.e. blood-brain 
barrier) since it is a precursor for neurotransmitters as dopamine, norepinephrine and epinephrine 
(also known as adrenalin). This could suggest a possible involvement of this metabolite in the 
synthesis of some transmitters, as dopamine and epinephrine, that could be involved in sperm 
motility mechanism, as it seems to happen in stallion sperm (Urra et al., 2014).  
 Another metabolite detected in lower abundance in asthenozoospermic samples was 
trimethylamine N-oxide, an oxidation product of trimethylamine that could derive from choline, 
which in turn can be derived from dietary phosphatidylcholines or carnitine. Trimethylamine N-
oxide is known to act as an osmolyte that counteracts the effects of increased concentrations of 
other molecules (i.e. urea in the kidneys) (Meersman et al., 2009). This could suggest a similar 
function in sperm cells, as a protection of external environment, but further experiments are 
needed to test this hypothesis. 
 Interestingly, putrescine was also found in lower concentration in asthenozoospermic 
samples. The presence of this polyamine and others (as spermidine and spermine, of which 
putrescine is a precursor) in semen and sperm and their abundance during spermatogenesis, is well 
documented (Oliva et al., 1982; Lefèvre et al., 2011). Putrescine also appears to be a growth factor 
necessary for cell division and embryogenesis (Lefèvre et al., 2011). Moreover, polyamines seem to 
have a direct role in sperm motility, since the addition of polyamines or L-arginine to human 
spermatozoa with reduced or no motility increases sperm motility (Morales et al., 2003). 
 Furthermore, and not surprisingly, acetylcarnitine also appeared in lower concentration in 
the extracts of less motile human sperm. Since the inner mitochondrial membrane is not 
permeable to long-chain fatty acids or acyl-coenzyme A (CoA) derivatives, acetylicarnitine esters 
transport these fatty acyl groups across the inner mitochondrial membrane. Thus, as already 
mentioned, acetylcarnitine plays a critical role in the regulation of β-oxidation (Jeulin and Lewin, 
1996). This seems to be in accordance with the earlier discussed importance of lipid metabolism 
and fatty acids oxidation in human sperm function, namely in human sperm motility (Jeulin and 
Lewin, 1996; Amaral et al., 2013a). In fact, the outcomes of the differential proteomics studies 
using asthenozoospermic samples (ours included) also point out to a deregulation of mitochondrial 
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proteins and proteins involved in fatty acids oxidation and lipid metabolism (sub-chapter 4.1). 
Additionally, previous studies already showed a significant increase on the percentage of human 
sperm motility after adding acetyl-L-carnitine to the incubation medium (Jeulin and Lewin, 1996). 
Based on that, the oral supplementation of asthenozoospermic patients with carnitine to increase 
sperm motility was proposed (Garolla et al., 2005). In conclusion, acelyl-L-carnitine seems to be a 
very important metabolite involved in the regulation of human sperm motility (Jeulin and Lewin, 
1996). Thus, in future studies, it would be interesting to further clarify the molecular mechanisms in 
which this metabolite is involved, as well as to study the possibility of using this and other 
metabolites as biomarkers of sperm (dys)function and hopefully to develop efficient therapies. 
 Also without surprise, the nucleosides IMP, AMP and ADP revealed to be present in lower 
concentration in the extracts of asthenozoospermic pool of samples when compared to 
normozoospermic one. The lower availability of the ATP precursors may indicate an imbalance in 
the energetic state of the cell, which possibly correlates with the impairment of sperm motility. 
 On the other hand, formate was found to be in higher concentration in asthenozoospermic 
extracts. Formate is an intermediate in normal metabolism taking part in the metabolism of one-
carbon compounds (Reda et al., 2008). It is typically produced as a by-product in the production of 
acetate, another metabolite present in higher amount in less motile sperm. Of note, this metabolite 
is responsible for both metabolic acidosis and disrupting mitochondrial electron transport and 
energy production by cytochrome oxidase inhibition, which results in ATP depletion and drives the 
cells to death (Nicholls, 1976). Moreover, the inhibition of cytochrome oxidase by formate may also 
cause cell death by increasing the production of cytotoxic reactive oxygen species (ROS). All these 
effects could be involved in mitochondrial disruption and subsequently have an effect on sperm 
motility, as previously discussed. 
 Nevertheless, all of these results are really preliminary and further investigations are 
absolutely needed. Hereafter it would be very interesting to look to the metabolomic signatures of 
different human sperm pathologies, particularly asthenozoospermia, using more samples and 
methods, to describe and quantify metabolites. Those strategies will certainly go through the 
performance of differential metabolomics, using higher number of samples in order to increase the 
statistical power of the study and also to decrease the variability between independent samples. 
This will lead to a better understanding of the metabolomic basis of human sperm motility.  
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CHAPTER V. CONCLUSIONS 
In conclusion, we have applied for the first time a high-throughput differential proteomic 
strategy to identify proteins involved in sperm motility (de)regulation and we have detected 80 
differentially abundant proteins in asthenozoospermic samples compared to normozoospermic 
samples. Our data suggest that proteins involved in cytoskeleton, energy metabolism, protein 
folding and degradation and vesicle trafficking are, with a few exceptions, consistently altered in 
low-motile sperm. Furthermore, our results strongly support the emerging idea that several 
bioenergetics metabolic pathways, including glycolysis, the tricarboxylic acid cycle, mitochondrial 
OXPHOS and fatty acids beta-oxidation, contribute to sperm motility (de)regulation. In the future, it 
will be interesting to further explore the potential use of the detected proteins and pathways 
towards their potential diagnostic and prognostic use and perhaps to pinpoint novel therapeutic 
targets. 
 On the other hand, and to the best of our knowledge, here we have described for the first 
time a list of 69 endogenous metabolites of human sperm extracts, applying two complementary 
techniques normally used for untargeted metabolomics: nuclear magnetic resonance (NMR) and 
mass spectrometry (MS). Here we presented for the first time a metabolic fingerprint of human 
sperm extracts in NMR spectra. Of note, only 4 metabolites were identified with both techniques, 
which highlights the importance of the use of complementary approaches to ultimately complete a 
metabolic characterization of sperm cells. 
 We have also performed a first metabo-proteomic analysis, combining the 69 described 
metabolites and the previously compiled sperm proteome (Amaral et al., 2014a). This analysis 
reinforces the importance of metabolic pathways as fatty acids beta-oxidation and lipid metabolism 
for the correct human sperm functionality. However, and taking into account that sperm 
metabolome is certainly much more extensive that we described here, it will be very important to 
perform more descriptive and comparative studies to amplify these lists and increase the statistical 
power of this kind of analysis. 
 Lastly, and as preliminary results, we presented some different concentrated metabolites in 
extracts of asthenozoospermic samples compared to normozoospermic samples. Here, the majority 
of the metabolites revealed to be in lower concentration in less motile sperm, pointing out to some 
possibilities and hypothesis of metabolic disruptions in sperm motility, that certainly need further 
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investigation. The use of more samples and complementary technique (as GC- and LC-MS) will be 
important to metabolically characterize sperm pathologies, as asthenozoospermia, and better 
understand molecular mechanisms, in a physiological point of view. Furthermore, the integrated 
analysis of differential proteome and metabolome of asthenozoospermic and normozoospermic 
samples coupled to the analysis of their interectomes will probably contribute for to the 
unrevealing of the molecular basis of human sperm motility, as well as novel therapeutic targets. 
With this knowledge we will be in the future to easily modulate sperm metabolism and function, 
using for instance suitable mediums or supplementation to improve sperm performance in infertile 
patients. 
 Although clearly still in its infancy, the application of metabolomics to the study of human 
spermatozoa has a huge potential, and its application as a phenotypic readout can be an important 
key to understand fundamental biological processes acting in human sperm cells. Another 
challenging area it will be the application of metabo-proteomics strategies to the study of human 
sperm. For that propose, the use of high-throughput technologies (either in proteomics as in 
metabolomics field) coupled to the constantly improved bioinformatics tools, will definitely lead us 
to better comprehend distinct male reproductive pathologies, including molecular basis of motility, 
and perhaps to discover new (in)fertility biomarkers. Here, we have just taken the first step. 
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Supplementary Table S1 – Complete list of identified proteins (1157) in Asthenozoospermic vs. 
Normozoospermic samples differential proteomics experiment.  
For all proteins shown in this table at least two peptides have been identified with a false discovery rate (FDR) 
< 1%. Asterisks (*) note proteins not previously described in human sperm cells, comparing with the most 
complete proteomic lists published till date using LC-MS/MS (Baker et al, 2007; 2013; de Mateo et al, 2011; 
2013; Amaral et al., 2013; 2014; Wang et al, 2013; Azpiazu et al., 2014; Castillo et al, 2014). Note: the table 
with all the MS details for each protein is available free of charge via http://pubs.acs.org. 
(http://pubs.acs.org/doi/suppl/10.1021/pr500652y) 
 
UniprotKB/ 
SwissProt 
Accession 
Number 
Protein Description 
Σ Protein 
Coverage 
(%) 
MW 
[kDa] 
calc. 
pI 
O00233 26S proteasome non-ATPase regulatory subunit 9 * 21.97 24.70 6.95 
P0CW22 40S ribosomal protein S17-like * 42.22 15.50 9.85 
P18077 60S ribosomal protein L35a * 27.27 12.50 11.06 
Q8NEV1 Casein kinase II subunit alpha 3 * 32.74 45.20 8.50 
A6NHG4 D-dopachrome decarboxylase-like protein * 60.45 14.20 6.29 
P47813 
Eukaryotic translation initiation factor 1A, X-
chromosomal * 
18.06 16.50 5.24 
O14602 
Eukaryotic translation initiation factor 1A, Y-
chromosomal * 
18.06 16.40 5.24 
B5ME19 
Eukaryotic translation initiation factor 3 subunit C-like 
protein * 
3.28 105.40 5.64 
O94808 
Glutamine--fructose-6-phosphate aminotransferase 
[isomerizing] 2 * 
2.49 76.90 7.37 
P48668 Keratin, type II cytoskeletal 6C * 50.71 60.00 8.00 
Q5XKE5 Keratin, type II cytoskeletal 79 * 20.75 57.80 7.20 
P31025 Lipocalin-1 * 23.86 19.20 5.58 
P0DKB6 Mitochondrial pyruvate carrier 1-like protein * 63.97 15.10 9.94 
A6NHN6 
Nuclear pore complex-interacting protein family 
member B15 * 
5.64 51.20 10.49 
E9PJ23 
Nuclear pore complex-interacting protein family 
member B6 * 
5.88 49.10 10.36 
O75200 
Nuclear pore complex-interacting protein family 
member B7 * 
6.04 47.70 10.33 
E9PQR5 
Nuclear pore complex-interacting protein family 
member B8 * 
5.79 49.60 10.13 
F8W1W9 
Nuclear pore complex-interacting protein family 
member B9 * 
5.83 49.20 10.43 
P0CG47 Polyubiquitin-B * 58.95 25.70 7.43 
O15212 Prefoldin subunit 6 * 17.05 14.60 8.88 
Q7Z333 Probable helicase senataxin * 0.75 302.70 7.17 
O14737 Programmed cell death protein 5 * 28.00 14.30 6.04 
Q6NXS1 Protein phosphatase inhibitor 2-like protein 3 * 13.17 23.00 4.92 
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Q7Z2V1 Protein TNT * 18.89 23.10 6.92 
P0DJD1 RANBP2-like and GRIP domain-containing protein 2 * 0.74 197.20 6.20 
Q9NRW1 Ras-related protein Rab-6B * 27.88 23.40 5.53 
Q8NFU3 
Thiosulfate sulfurtransferase/rhodanese-like domain-
containing protein 1 * 
20.00 12.50 6.07 
Q8N5N4 Uncharacterized protein C3orf22 * 16.31 15.70 9.85 
P61421 V-type proton ATPase subunit d 1 * 5.41 40.30 5.00 
Q15120 
[Pyruvate dehydrogenase (acetyl-transferring)] kinase 
isozyme 3, mitochondrial 
6.40 46.90 8.37 
Q86YW0 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase zeta-1 
4.61 70.40 9.04 
P61604 10 kDa heat shock protein, mitochondrial 22.55 10.90 8.92 
P62258 14-3-3 protein epsilon 22.35 29.20 4.74 
P61981 14-3-3 protein gamma 24.29 28.30 4.89 
P31947 14-3-3 protein sigma 25.00 27.80 4.74 
P27348 14-3-3 protein theta 23.27 27.70 4.78 
P63104 14-3-3 protein zeta/delta 35.10 27.70 4.79 
Q9UJ83 2-hydroxyacyl-CoA lyase 1 3.81 63.70 7.36 
Q6N063 
2-oxoglutarate and iron-dependent oxygenase domain-
containing protein 2 
4.86 39.00 5.68 
Q02218 2-oxoglutarate dehydrogenase, mitochondrial 23.56 115.90 6.86 
P12694 
2-oxoisovalerate dehydrogenase subunit alpha, 
mitochondrial 
8.54 50.40 8.27 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial 13.73 36.00 9.28 
P62333 26S protease regulatory subunit 10B 31.88 44.10 7.49 
P62191 26S protease regulatory subunit 4 19.55 49.20 6.21 
P17980 26S protease regulatory subunit 6A 18.45 49.20 5.24 
P43686 26S protease regulatory subunit 6B 13.88 47.30 5.21 
P35998 26S protease regulatory subunit 7 24.02 48.60 5.95 
P62195 26S protease regulatory subunit 8 25.86 45.60 7.55 
Q99460 26S proteasome non-ATPase regulatory subunit 1 8.92 105.80 5.39 
O00231 26S proteasome non-ATPase regulatory subunit 11 18.72 47.40 6.48 
O00232 26S proteasome non-ATPase regulatory subunit 12 14.91 52.90 7.65 
Q9UNM6 26S proteasome non-ATPase regulatory subunit 13 33.51 42.90 5.81 
O00487 26S proteasome non-ATPase regulatory subunit 14 17.74 34.60 6.52 
Q13200 26S proteasome non-ATPase regulatory subunit 2 18.50 100.10 5.20 
Q16401 26S proteasome non-ATPase regulatory subunit 5 4.96 56.20 5.48 
Q15008 26S proteasome non-ATPase regulatory subunit 6 15.17 45.50 5.62 
P51665 26S proteasome non-ATPase regulatory subunit 7 14.81 37.00 6.77 
P48556 26S proteasome non-ATPase regulatory subunit 8 16.86 39.60 9.70 
P82909 28S ribosomal protein S36, mitochondrial 36.89 11.50 9.99 
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 28.35 26.90 7.78 
P42765 3-ketoacyl-CoA thiolase, mitochondrial 11.59 41.90 8.09 
P25325 3-mercaptopyruvate sulfurtransferase 40.74 33.20 6.60 
O95861 3'(2'),5'-bisphosphate nucleotidase 1 14.29 33.40 5.69 
P49189 4-trimethylaminobutyraldehyde dehydrogenase 14.37 53.80 5.87 
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P62263 40S ribosomal protein S14 17.22 16.30 10.05 
P62244 40S ribosomal protein S15a 53.85 14.80 10.13 
P62269 40S ribosomal protein S18 13.16 17.70 10.99 
P39019 40S ribosomal protein S19 13.79 16.10 10.32 
P60866 40S ribosomal protein S20 34.45 13.40 9.94 
P63220 40S ribosomal protein S21 32.53 9.10 8.50 
P62857 40S ribosomal protein S28 21.74 7.80 10.70 
P23396 40S ribosomal protein S3 30.45 26.70 9.66 
P22090 40S ribosomal protein S4, Y isoform 1 6.08 29.40 10.24 
P62081 40S ribosomal protein S7 15.46 22.10 10.10 
P46781 40S ribosomal protein S9 24.23 22.60 10.65 
P08865 40S ribosomal protein SA 10.17 32.80 4.87 
O14841 5-oxoprolinase 12.11 137.40 6.58 
P54619 5'-AMP-activated protein kinase subunit gamma-1 14.20 37.60 6.92 
Q8TCD5 5'(3')-deoxyribonucleotidase, cytosolic type 30.85 23.40 6.64 
Q01813 6-phosphofructokinase type C 27.81 85.50 7.55 
P08237 6-phosphofructokinase, muscle type 7.05 85.10 7.99 
P52209 6-phosphogluconate dehydrogenase, decarboxylating 9.11 53.10 7.23 
O95336 6-phosphogluconolactonase 49.61 27.50 6.05 
P10809 60 kDa heat shock protein, mitochondrial 19.55 61.00 5.87 
P05388 60S acidic ribosomal protein P0 14.51 34.30 5.97 
P62913 60S ribosomal protein L11 36.52 20.20 9.60 
P30050 60S ribosomal protein L12 56.36 17.80 9.42 
Q02543 60S ribosomal protein L18a 10.80 20.70 10.71 
P35268 60S ribosomal protein L22 21.88 14.80 9.19 
P62888 60S ribosomal protein L30 36.52 12.80 9.63 
P11021 78 kDa glucose-regulated protein 25.99 72.30 5.16 
O60733 85/88 kDa calcium-independent phospholipase A2 2.73 89.80 7.27 
O75969 A-kinase anchor protein 3 34.11 94.70 6.18 
Q5JQC9 A-kinase anchor protein 4 40.63 94.40 6.96 
Q9BWD1 Acetyl-CoA acetyltransferase, cytosolic 28.97 41.30 6.92 
P24752 Acetyl-CoA acetyltransferase, mitochondrial 4.92 45.20 8.85 
O43427 
Acidic fibroblast growth factor intracellular-binding 
protein 
6.04 41.90 6.48 
Q99798 Aconitate hydratase, mitochondrial 19.74 85.40 7.61 
P10323 Acrosin 46.08 45.80 9.07 
Q8NEB7 Acrosin-binding protein 40.88 61.30 5.16 
P26436 Acrosomal protein SP-10 5.66 28.10 4.69 
Q5JWF8 Actin-like protein 10 8.16 26.70 9.32 
Q9Y615 Actin-like protein 7A 17.24 48.60 7.09 
Q8TC94 Actin-like protein 9 24.04 45.60 7.08 
Q9NZ32 Actin-related protein 10 5.04 46.30 7.37 
P61160 Actin-related protein 2 11.17 44.70 6.74 
P59998 Actin-related protein 2/3 complex subunit 4 28.57 19.70 8.43 
Q9BPX5 Actin-related protein 2/3 complex subunit 5-like protein 26.14 16.90 6.60 
Q8TDY3 Actin-related protein T2 18.57 41.70 5.47 
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Q9BYD9 Actin-related protein T3 20.16 41.00 5.82 
Q9H845 
Acyl-CoA dehydrogenase family member 9, 
mitochondrial 
4.35 68.70 7.96 
Q9NPJ3 Acyl-coenzyme A thioesterase 13 12.14 15.00 9.14 
O14734 Acyl-coenzyme A thioesterase 8 14.73 35.90 7.56 
O75608 Acyl-protein thioesterase 1 17.39 24.70 6.77 
O95372 Acyl-protein thioesterase 2 9.96 24.70 7.23 
P13798 Acylamino-acid-releasing enzyme 6.01 81.20 5.48 
P07741 Adenine phosphoribosyltransferase 30.00 19.60 6.02 
P54819 Adenylate kinase 2, mitochondrial 42.26 26.50 7.81 
Q96M32 Adenylate kinase 7 7.88 82.60 4.74 
Q96MA6 Adenylate kinase 8 15.03 54.90 6.15 
Q5TCS8 Adenylate kinase 9 3.45 221.30 5.01 
P00568 Adenylate kinase isoenzyme 1 65.46 21.60 8.63 
Q9Y3D8 Adenylate kinase isoenzyme 6 10.47 20.00 4.58 
Q9HDC9 Adipocyte plasma membrane-associated protein 17.79 46.50 6.16 
P84077 ADP-ribosylation factor 1 33.15 20.70 6.80 
P61204 ADP-ribosylation factor 3 33.15 20.60 7.43 
P40616 ADP-ribosylation factor-like protein 1 19.34 20.40 5.72 
P36404 ADP-ribosylation factor-like protein 2 27.72 20.90 6.34 
Q9NVJ2 ADP-ribosylation factor-like protein 8B 32.26 21.50 8.43 
P12235 ADP/ATP translocase 1 23.15 33.00 9.76 
P05141 ADP/ATP translocase 2 27.52 32.80 9.69 
P12236 ADP/ATP translocase 3 21.81 32.80 9.74 
Q9H0C2 ADP/ATP translocase 4 42.54 35.00 9.89 
O00253 Agouti-related protein 43.94 14.40 7.44 
O00468 Agrin 5.27 217.10 6.39 
O00170 AH receptor-interacting protein 6.67 37.60 6.29 
Q9NRG9 Aladin 7.51 59.50 7.50 
P49588 Alanine--tRNA ligase, cytoplasmic 1.65 106.70 5.53 
Q9BTE6 Alanyl-tRNA editing protein Aarsd1 34.22 45.50 6.42 
P11766 Alcohol dehydrogenase class-3 7.22 39.70 7.49 
P15121 Aldose reductase 23.10 35.80 6.98 
P12814 Alpha-actinin-1 4.60 103.00 5.41 
P61163 Alpha-centractin 16.49 42.60 6.64 
P02511 Alpha-crystallin B chain 17.71 20.10 7.33 
P06733 Alpha-enolase 29.72 47.10 7.39 
Q9BT30 
Alpha-ketoglutarate-dependent dioxygenase alkB 
homolog 7, mitochondrial 
24.89 24.50 7.11 
Q9NTJ4 Alpha-mannosidase 2C1 25.58 115.80 6.57 
Q96IU4 Alpha/beta hydrolase domain-containing protein 14B 11.43 22.30 6.40 
Q8TCU4 Alstrom syndrome protein 1 2.26 460.70 6.28 
Q12904 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1 
18.27 34.30 8.43 
Q13155 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 2 
15.00 35.30 8.22 
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P12821 Angiotensin-converting enzyme 13.63 149.60 6.39 
Q9NU02 
Ankyrin repeat and EF-hand domain-containing protein 
1 
2.84 86.60 8.28 
P04083 Annexin A1 12.14 38.70 7.02 
P07355 Annexin A2 5.90 38.60 7.75 
P12429 Annexin A3 16.41 36.40 5.92 
P08758 Annexin A5 34.38 35.90 5.05 
P03973 Antileukoproteinase 28.79 14.30 8.75 
Q10567 AP-1 complex subunit beta-1 4.21 104.60 5.06 
O95782 AP-2 complex subunit alpha-1 5.53 107.50 7.03 
P53680 AP-2 complex subunit sigma 25.35 17.00 6.18 
P02647 Apolipoprotein A-I 31.09 30.80 5.76 
P05090 Apolipoprotein D 11.64 21.30 5.15 
P02649 Apolipoprotein E 21.45 36.10 5.73 
Q9BUR5 Apolipoprotein O 13.64 22.30 9.13 
O95831 Apoptosis-inducing factor 1, mitochondrial 6.20 66.90 8.95 
P55064 Aquaporin-5 13.96 28.30 8.62 
P54136 Arginine--tRNA ligase, cytoplasmic 3.18 75.30 6.68 
Q5T9G4 Armadillo repeat-containing protein 12 23.82 38.60 7.88 
Q5W041 Armadillo repeat-containing protein 3 4.47 96.30 6.21 
Q5T2S8 Armadillo repeat-containing protein 4 4.02 115.60 7.77 
Q6NXE6 Armadillo repeat-containing protein 6 10.38 54.10 6.24 
P15289 Arylsulfatase A 8.48 53.60 6.07 
P17174 Aspartate aminotransferase, cytoplasmic 32.93 46.20 7.01 
P00505 Aspartate aminotransferase, mitochondrial 28.60 47.50 9.01 
P14868 Aspartate--tRNA ligase, cytoplasmic 14.37 57.10 6.55 
Q6PI48 Aspartate--tRNA ligase, mitochondrial 3.10 73.50 8.02 
Q9ULA0 Aspartyl aminopeptidase 18.95 52.40 7.42 
Q6DD88 Atlastin-3 8.50 60.50 5.66 
P24539 ATP synthase F(0) complex subunit B1, mitochondrial 10.94 28.90 9.36 
P25705 ATP synthase subunit alpha, mitochondrial 45.21 59.70 9.13 
P06576 ATP synthase subunit beta, mitochondrial 30.25 56.50 5.40 
P56385 ATP synthase subunit e, mitochondrial 65.22 7.90 9.35 
P56381 ATP synthase subunit epsilon, mitochondrial 35.29 5.80 9.92 
P48047 ATP synthase subunit O, mitochondrial 25.82 23.30 9.96 
Q99766 ATP synthase subunit s, mitochondrial 27.44 24.80 7.56 
P53396 ATP-citrate synthase 14.44 120.80 7.33 
Q8IW45 ATP-dependent (S)-NAD(P)H-hydrate dehydratase 18.73 36.60 8.06 
O00148 ATP-dependent RNA helicase DDX39A 8.43 49.10 5.68 
Q8NBU5 ATPase family AAA domain-containing protein 1 7.20 40.70 6.90 
Q9NVI7 ATPase family AAA domain-containing protein 3A 2.68 71.30 8.98 
Q9UII2 ATPase inhibitor, mitochondrial 19.81 12.20 9.35 
O75882 Attractin 4.27 158.40 7.31 
O14645 Axonemal dynein light intermediate polypeptide 1 53.49 29.60 8.50 
O95816 BAG family molecular chaperone regulator 2 15.64 23.80 6.70 
Q9UL15 BAG family molecular chaperone regulator 5 34.90 51.20 6.05 
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O75531 Barrier-to-autointegration factor 75.28 10.10 6.09 
P61769 Beta-2-microglobulin 21.01 13.70 6.52 
Q8WTQ1 Beta-defensin 104 37.50 8.50 9.19 
Q8NG35 Beta-defensin 105 26.92 8.90 8.32 
Q9BYW3 Beta-defensin 126 20.72 12.20 9.31 
Q6UWU2 Beta-galactosidase-1-like protein 9.79 74.10 8.92 
P08236 Beta-glucuronidase 7.22 74.70 7.02 
Q3LXA3 
Bifunctional ATP-dependent dihydroxyacetone 
kinase/FAD-AMP lyase (cyclizing) 
12.35 58.90 7.49 
P07814 Bifunctional glutamate/proline--tRNA ligase 4.10 170.50 7.33 
P50583 Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical] 19.73 16.80 5.35 
P07738 Bisphosphoglycerate mutase 24.32 30.00 6.54 
Q13867 Bleomycin hydrolase 6.81 52.50 6.27 
Q9H3K6 BolA-like protein 2 37.21 10.10 6.52 
Q9BQP9 BPI fold-containing family A member 3 12.20 28.40 6.65 
O15382 
Branched-chain-amino-acid aminotransferase, 
mitochondrial 
9.69 44.30 8.65 
Q8WY22 BRI3-binding protein 6.77 27.80 9.44 
Q7KYR7 Butyrophilin subfamily 2 member A1 4.36 59.60 6.48 
Q96BS2 Calcineurin B homologous protein 3 14.02 24.70 4.93 
Q9Y376 Calcium-binding protein 39 18.77 39.80 6.89 
O75952 
Calcium-binding tyrosine phosphorylation-regulated 
protein 
11.76 52.70 4.55 
Q9Y2V2 Calcium-regulated heat stable protein 1 18.37 15.90 8.21 
Q16566 Calcium/calmodulin-dependent protein kinase type IV 5.92 51.90 5.82 
Q13939 Calicin 18.54 66.50 8.18 
Q96JQ2 Calmin 9.88 111.60 4.94 
P62158 Calmodulin 36.24 16.80 4.22 
P17612 cAMP-dependent protein kinase catalytic subunit alpha 29.06 40.60 8.79 
P22612 
cAMP-dependent protein kinase catalytic subunit 
gamma 
27.64 40.40 8.59 
P10644 
cAMP-dependent protein kinase type I-alpha regulatory 
subunit 
30.45 43.00 5.35 
P13861 
cAMP-dependent protein kinase type II-alpha regulatory 
subunit 
53.22 45.50 5.07 
P16152 Carbonyl reductase [NADPH] 1 32.85 30.40 8.32 
Q8WXQ8 Carboxypeptidase A5 7.11 49.00 6.73 
O75976 Carboxypeptidase D 14.86 152.80 6.05 
P43155 Carnitine O-acetyltransferase 9.58 70.80 8.44 
Q92523 Carnitine O-palmitoyltransferase 1, muscle isoform 17.49 87.70 8.62 
P23786 Carnitine O-palmitoyltransferase 2, mitochondrial 20.82 73.70 8.18 
P48729 Casein kinase I isoform alpha 8.31 38.90 9.57 
Q9HCP0 Casein kinase I isoform gamma-1 4.74 48.50 9.01 
P68400 Casein kinase II subunit alpha 42.97 45.10 7.74 
P19784 Casein kinase II subunit alpha' 12.00 41.20 8.56 
P67870 Casein kinase II subunit beta 25.58 24.90 5.55 
P31944 Caspase-14 12.81 27.70 5.58 
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Q9BXW7 Cat eye syndrome critical region protein 5 8.98 46.30 8.13 
P49913 Cathelicidin antimicrobial peptide 43.53 19.30 9.41 
P07858 Cathepsin B 7.96 37.80 6.30 
Q9UBX1 Cathepsin F 13.64 53.30 8.22 
Q9NZ45 CDGSH iron-sulfur domain-containing protein 1 27.78 12.20 9.09 
Q12798 Centrin-1 26.16 19.60 4.88 
Q66GS9 Centrosomal protein of 135 kDa 16.75 133.40 6.21 
Q5TA50 Ceramide-1-phosphate transfer protein 50.47 24.30 7.21 
P23435 Cerebellin-1 30.05 21.10 7.28 
Q9BWS9 Chitinase domain-containing protein 1 16.79 44.90 8.63 
Q8NE62 Choline dehydrogenase, mitochondrial 7.58 65.30 8.28 
Q8NCS7 Choline transporter-like protein 5 3.34 81.60 8.16 
Q9Y259 Choline/ethanolamine kinase 7.09 45.20 5.49 
O75390 Citrate synthase, mitochondrial 13.09 51.70 8.32 
Q00610 Clathrin heavy chain 1 26.39 191.50 5.69 
P09496 Clathrin light chain A 17.74 27.10 4.51 
P10909 Clusterin 28.73 52.50 6.27 
Q96T59 CMT1A duplicated region transcript 15 protein 39.36 20.60 8.05 
Q96EY8 
Cob(I)yrinic acid a,c-diamide adenosyltransferase, 
mitochondrial 
12.40 27.40 8.60 
Q16568 Cocaine- and amphetamine-regulated transcript protein 18.10 12.80 8.25 
Q8IW40 Coiled-coil domain-containing protein 103 23.14 27.10 5.97 
Q8IYK2 Coiled-coil domain-containing protein 105 14.43 56.90 9.86 
Q6ZU64 Coiled-coil domain-containing protein 108 2.23 217.10 6.51 
Q96M91 Coiled-coil domain-containing protein 11 23.15 61.80 8.90 
Q9H0I3 Coiled-coil domain-containing protein 113 4.24 44.20 8.73 
Q96M63 Coiled-coil domain-containing protein 114 3.28 75.00 6.28 
Q8IYX3 Coiled-coil domain-containing protein 116 6.99 56.90 9.64 
Q8IYE0 Coiled-coil domain-containing protein 146 6.60 112.70 8.48 
Q5T655 Coiled-coil domain-containing protein 147 19.84 103.40 8.41 
A5D8V7 Coiled-coil domain-containing protein 151 4.71 69.10 9.07 
Q9UL16 Coiled-coil domain-containing protein 19, mitochondrial 31.40 65.70 8.90 
Q9UFE4 Coiled-coil domain-containing protein 39 10.95 109.80 6.44 
Q4G0X9 Coiled-coil domain-containing protein 40 11.47 130.00 5.29 
Q4VC31 Coiled-coil domain-containing protein 58 27.08 16.60 7.81 
Q6ZN84 Coiled-coil domain-containing protein 81 3.53 76.00 9.14 
Q9GZT6 
Coiled-coil domain-containing protein 90B, 
mitochondrial 
8.66 29.50 7.55 
Q2M329 Coiled-coil domain-containing protein 96 14.77 62.70 4.94 
Q8IY82 Coiled-coil domain-containing protein lobo homolog 9.15 103.40 5.67 
Q9NX63 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial 
59.03 26.10 8.28 
Q9BRQ6 
Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 6, mitochondrial 
46.81 26.40 8.85 
P38432 Coilin 6.42 62.60 9.07 
P39060 Collagen alpha-1(XVIII) chain 1.20 178.10 6.01 
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P08174 Complement decay-accelerating factor 13.12 41.40 7.59 
Q5U5X0 Complex III assembly factor LYRM7 38.46 11.90 9.66 
Q9BT78 COP9 signalosome complex subunit 4 9.61 46.20 5.83 
Q9NTM9 Copper homeostasis protein cutC homolog 48.35 29.30 8.18 
P12277 Creatine kinase B-type 19.16 42.60 5.59 
Q13618 Cullin-3 9.77 88.90 8.48 
Q86VP6 Cullin-associated NEDD8-dissociated protein 1 13.25 136.30 5.78 
P35663 Cylicin-1 4.92 74.20 9.67 
P01034 Cystatin-C 52.74 15.80 8.75 
Q9Y697 Cysteine desulfurase, mitochondrial 13.57 50.20 8.31 
P49589 Cysteine--tRNA ligase, cytoplasmic 6.15 85.40 6.76 
P54107 Cysteine-rich secretory protein 1 25.30 28.50 5.91 
P16562 Cysteine-rich secretory protein 2 20.58 27.20 6.49 
P31930 Cytochrome b-c1 complex subunit 1, mitochondrial 25.62 52.60 6.37 
P22695 Cytochrome b-c1 complex subunit 2, mitochondrial 25.17 48.40 8.63 
P07919 Cytochrome b-c1 complex subunit 6, mitochondrial 34.07 10.70 4.44 
P14927 Cytochrome b-c1 complex subunit 7 42.34 13.50 8.78 
O14949 Cytochrome b-c1 complex subunit 8 54.88 9.90 10.08 
P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial 21.53 29.60 8.32 
Q6P9G0 Cytochrome b5 domain-containing protein 1 32.02 26.70 5.60 
O43169 Cytochrome b5 type B 15.07 16.30 4.97 
Q5RI15 Cytochrome c oxidase protein 20 homolog 36.44 13.30 8.76 
P00403 Cytochrome c oxidase subunit 2 19.38 25.50 4.82 
P20674 Cytochrome c oxidase subunit 5A, mitochondrial 32.67 16.80 6.79 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial 75.19 13.70 8.81 
P14854 Cytochrome c oxidase subunit 6B1 43.02 10.20 7.05 
P09669 Cytochrome c oxidase subunit 6C 66.67 8.80 10.39 
P08574 Cytochrome c1, heme protein, mitochondrial 19.38 35.40 9.00 
P28838 Cytosol aminopeptidase 17.34 56.10 7.93 
Q96P26 Cytosolic 5'-nucleotidase 1B 12.46 68.80 8.82 
O00154 Cytosolic acyl coenzyme A thioester hydrolase 9.21 41.80 8.54 
P53384 Cytosolic Fe-S cluster assembly factor NUBP1 7.81 34.50 5.33 
Q9Y5Y2 Cytosolic Fe-S cluster assembly factor NUBP2 10.70 28.80 5.83 
O43175 D-3-phosphoglycerate dehydrogenase 6.75 56.60 6.71 
P30046 D-dopachrome decarboxylase 68.64 12.70 7.30 
Q96EP5 DAZ-associated protein 1 9.83 43.40 8.56 
Q96GG9 DCN1-like protein 1 10.04 30.10 5.34 
Q58WW2 DDB1- and CUL4-associated factor 6 2.21 96.20 5.27 
Q6UWP2 Dehydrogenase/reductase SDR family member 11 31.15 28.30 6.64 
P13716 Delta-aminolevulinic acid dehydratase 5.45 36.30 6.79 
Q13011 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
37.50 35.80 8.00 
Q16854 Deoxyguanosine kinase, mitochondrial 18.77 32.00 8.66 
P33316 
Deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial 
28.17 26.50 9.36 
P81605 Dermcidin 22.73 11.30 6.54 
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O43323 Desert hedgehog protein 4.80 43.50 9.28 
Q02413 Desmoglein-1 4.29 113.70 5.03 
P15924 Desmoplakin 1.71 331.60 6.81 
P60981 Destrin 20.00 18.50 7.85 
Q9NR28 Diablo homolog, mitochondrial 33.47 27.10 5.90 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial 22.00 54.10 7.85 
P10515 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 
5.56 69.00 7.84 
P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
7.73 48.70 8.95 
Q02127 
Dihydroorotate dehydrogenase (quinone), 
mitochondrial 
5.57 42.80 9.67 
Q9H4B8 Dipeptidase 3 12.91 53.70 7.96 
Q9UHL4 Dipeptidyl peptidase 2 25.41 54.30 6.32 
Q9NY33 Dipeptidyl peptidase 3 5.29 82.50 5.10 
P27487 Dipeptidyl peptidase 4 1.83 88.20 6.04 
O95989 Diphosphoinositol polyphosphate phosphohydrolase 1 22.09 19.50 6.34 
Q9UKF5 
Disintegrin and metalloproteinase domain-containing 
protein 29 
3.29 92.70 7.40 
Q9UKF2 
Disintegrin and metalloproteinase domain-containing 
protein 30 
7.97 88.90 7.61 
Q8TC27 
Disintegrin and metalloproteinase domain-containing 
protein 32 
19.06 87.90 5.55 
Q16531 DNA damage-binding protein 1 12.28 126.90 5.26 
Q9NRW3 DNA dC->dU-editing enzyme APOBEC-3C 12.63 22.80 7.59 
Q8WW22 DnaJ homolog subfamily A member 4 7.30 44.80 7.59 
P25685 DnaJ homolog subfamily B member 1 24.12 38.00 8.63 
Q9UBS4 DnaJ homolog subfamily B member 11 23.18 40.50 6.18 
P59910 DnaJ homolog subfamily B member 13 36.08 36.10 7.87 
Q9UDY4 DnaJ homolog subfamily B member 4 12.76 37.80 8.50 
O75190 DnaJ homolog subfamily B member 6 19.94 36.10 9.16 
Q8NHS0 DnaJ homolog subfamily B member 8 24.57 25.70 6.42 
Q9UBS3 DnaJ homolog subfamily B member 9 14.80 25.50 8.27 
Q9NVH1 DnaJ homolog subfamily C member 11 9.12 63.20 8.40 
Q13217 DnaJ homolog subfamily C member 3 7.34 57.50 6.15 
Q8WXX5 DnaJ homolog subfamily C member 9 22.69 29.90 5.73 
P04843 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 
7.91 68.50 6.38 
A8MYV0 Doublecortin domain-containing protein 2C 13.52 40.40 9.42 
Q8WWB3 DPY30 domain-containing protein 1 62.15 20.90 4.67 
P36507 
Dual specificity mitogen-activated protein kinase kinase 
2 
6.75 44.40 6.55 
Q14203 Dynactin subunit 1 16.74 141.60 5.81 
O75935 Dynactin subunit 3 27.42 21.10 5.47 
O60313 Dynamin-like 120 kDa protein, mitochondrial 5.42 111.60 7.87 
Q9P2D7 Dynein heavy chain 1, axonemal 2.12 493.60 5.94 
 128 
Q8IVF4 Dynein heavy chain 10, axonemal 2.12 514.50 5.88 
Q6ZR08 Dynein heavy chain 12, axonemal 1.75 356.70 6.19 
Q9UFH2 Dynein heavy chain 17, axonemal 7.27 511.50 5.77 
Q9P225 Dynein heavy chain 2, axonemal 0.77 507.40 6.37 
Q8TD57 Dynein heavy chain 3, axonemal 1.97 470.50 6.43 
Q9C0G6 Dynein heavy chain 6, axonemal 0.87 475.70 6.00 
Q8WXX0 Dynein heavy chain 7, axonemal 6.06 460.90 6.00 
Q96JB1 Dynein heavy chain 8, axonemal 6.12 514.30 6.32 
Q9UI46 Dynein intermediate chain 1, axonemal 10.73 79.20 6.87 
Q9GZS0 Dynein intermediate chain 2, axonemal 14.88 68.80 4.74 
Q8TF09 Dynein light chain roadblock-type 2 34.38 10.80 7.50 
O75928 E3 SUMO-protein ligase PIAS2 5.96 68.20 7.52 
P62877 E3 ubiquitin-protein ligase RBX1 38.89 12.30 6.96 
Q8WVD3 E3 ubiquitin-protein ligase RNF138 11.02 28.20 6.93 
Q13508 Ecto-ADP-ribosyltransferase 3 10.03 43.90 6.06 
Q9HAE3 EF-hand calcium-binding domain-containing protein 1 15.64 24.50 5.06 
Q5VUJ9 EF-hand calcium-binding domain-containing protein 2 13.75 29.70 8.79 
A4FU69 EF-hand calcium-binding domain-containing protein 5 1.06 173.30 5.82 
Q5THR3 EF-hand calcium-binding domain-containing protein 6 6.13 172.80 8.40 
Q8N7U6 EF-hand domain-containing family member B 16.33 93.70 7.58 
Q5JST6 EF-hand domain-containing family member C2 9.35 87.30 7.37 
Q5JVL4 EF-hand domain-containing protein 1 18.59 73.90 6.16 
P13804 
Electron transfer flavoprotein subunit alpha, 
mitochondrial 
15.02 35.10 8.38 
P38117 Electron transfer flavoprotein subunit beta 38.43 27.80 8.10 
P68104 Elongation factor 1-alpha 1 10.39 50.10 9.01 
P29692 Elongation factor 1-delta 24.56 31.10 5.01 
P26641 Elongation factor 1-gamma 24.03 50.10 6.67 
P13639 Elongation factor 2 25.06 95.30 6.83 
P49411 Elongation factor Tu, mitochondrial 19.03 49.50 7.61 
Q99963 Endophilin-A3 17.87 39.30 5.38 
Q9Y371 Endophilin-B1 19.73 40.80 6.04 
Q9BS26 Endoplasmic reticulum resident protein 44 25.12 46.90 5.26 
Q9Y282 
Endoplasmic reticulum-Golgi intermediate 
compartment protein 3 
23.50 43.20 6.06 
P14625 Endoplasmin 26.65 92.40 4.84 
P42126 Enoyl-CoA delta isomerase 1, mitochondrial 37.09 32.80 8.54 
O75521 Enoyl-CoA delta isomerase 2, mitochondrial 7.61 43.60 9.00 
P30084 Enoyl-CoA hydratase, mitochondrial 11.72 31.40 8.07 
Q14507 Epididymal secretory protein E3-alpha 38.10 17.60 8.35 
P56851 Epididymal secretory protein E3-beta 14.29 17.60 6.99 
Q96BH3 Epididymal sperm-binding protein 1 15.70 26.10 6.62 
Q9NRG7 Epimerase family protein SDR39U1 9.09 34.70 9.77 
O75477 Erlin-1 12.14 38.90 7.87 
Q86YB8 ERO1-like protein beta 7.92 53.50 7.99 
P30042 ES1 protein homolog, mitochondrial 14.55 28.20 8.27 
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Q92506 Estradiol 17-beta-dehydrogenase 8 16.48 27.00 6.54 
Q99447 Ethanolamine-phosphate cytidylyltransferase 30.33 43.80 6.92 
P60842 Eukaryotic initiation factor 4A-I 11.58 46.10 5.48 
Q14240 Eukaryotic initiation factor 4A-II 15.48 46.40 5.48 
O43324 Eukaryotic translation elongation factor 1 epsilon-1 24.14 19.80 8.54 
Q14152 Eukaryotic translation initiation factor 3 subunit A 1.30 166.50 6.79 
P55884 Eukaryotic translation initiation factor 3 subunit B 3.56 92.40 5.00 
Q99613 Eukaryotic translation initiation factor 3 subunit C 3.29 105.30 5.68 
Q13347 Eukaryotic translation initiation factor 3 subunit I 6.46 36.50 5.64 
P06730 Eukaryotic translation initiation factor 4E 11.98 25.10 6.15 
P56537 Eukaryotic translation initiation factor 6 13.88 26.60 4.68 
O14980 Exportin-1 5.98 123.30 6.06 
P55060 Exportin-2 4.12 110.30 5.77 
Q9UIA9 Exportin-7 20.70 123.80 6.32 
P52907 F-actin-capping protein subunit alpha-1 23.78 32.90 5.69 
Q96KX2 F-actin-capping protein subunit alpha-3 21.40 35.00 7.69 
P47756 F-actin-capping protein subunit beta 35.38 31.30 5.59 
P55789 FAD-linked sulfhydryl oxidase ALR 49.27 23.40 7.62 
Q9UNN5 FAS-associated factor 1 2.77 73.90 4.88 
Q9NQT6 Fascin-3 23.29 56.60 7.72 
P49327 Fatty acid synthase 1.43 273.30 6.44 
Q01469 Fatty acid-binding protein, epidermal 41.48 15.20 7.01 
O00519 Fatty-acid amide hydrolase 1 8.98 63.00 7.66 
P02794 Ferritin heavy chain 19.67 21.20 5.55 
Q8N4E7 Ferritin, mitochondrial 26.86 27.50 7.27 
P22830 Ferrochelatase, mitochondrial 4.02 47.80 8.73 
Q08830 Fibrinogen-like protein 1 5.77 36.40 5.87 
P02751 Fibronectin 5.99 262.50 5.71 
Q8TC99 Fibronectin type III domain-containing protein 8 7.10 35.90 5.08 
Q5CZC0 Fibrous sheath-interacting protein 2 2.30 780.10 6.71 
Q5D862 Filaggrin-2 1.92 247.90 8.31 
O75369 Filamin-B 1.77 278.00 5.73 
P30043 Flavin reductase (NADPH) 17.96 22.10 7.65 
O75955 Flotillin-1 3.75 47.30 7.49 
Q13642 Four and a half LIM domains protein 1 7.12 36.20 8.97 
Q8N0W7 Fragile X mental retardation 1 neighbor protein 27.06 29.20 8.94 
Q9NQ88 Fructose-2,6-bisphosphatase TIGAR 12.59 30.00 7.69 
P04075 Fructose-bisphosphate aldolase A 41.76 39.40 8.09 
P07954 Fumarate hydratase, mitochondrial 13.33 54.60 8.76 
Q9BWH2 FUN14 domain-containing protein 2 11.11 20.70 9.73 
Q92820 Gamma-glutamyl hydrolase 16.98 35.90 7.11 
Q9BVM4 Gamma-glutamylaminecyclotransferase 26.14 17.30 6.87 
P20142 Gastricsin 6.44 42.40 4.46 
Q6ZNW5 GDP-D-glucose phosphorylase 1 5.71 42.30 6.47 
P57678 Gem-associated protein 4 1.61 120.00 6.04 
O60763 General vesicular transport factor p115 3.22 107.80 4.91 
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Q2KHT4 Germ cell-specific gene 1 protein 6.30 39.20 7.99 
Q4G1C9 GLIPR1-like protein 2 6.98 40.20 4.91 
P11413 Glucose-6-phosphate 1-dehydrogenase 11.84 59.20 6.84 
P06744 Glucose-6-phosphate isomerase 26.52 63.10 8.32 
P14314 Glucosidase 2 subunit beta 13.26 59.40 4.41 
P15104 Glutamine synthetase 34.58 42.00 6.89 
Q06210 
Glutamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1 
6.58 78.80 7.11 
P47897 Glutamine--tRNA ligase 3.74 87.70 7.15 
Q9H0J4 Glutamine-rich protein 2 7.46 180.70 6.73 
P07203 Glutathione peroxidase 1 15.27 22.10 6.55 
P21266 Glutathione S-transferase Mu 3 46.22 26.50 5.54 
Q9H4Y5 Glutathione S-transferase omega-2 42.39 28.20 7.56 
P48637 Glutathione synthetase 6.75 52.40 5.92 
P04406 Glyceraldehyde-3-phosphate dehydrogenase 16.72 36.00 8.46 
O14556 
Glyceraldehyde-3-phosphate dehydrogenase, testis-
specific 
51.47 44.50 8.19 
Q14410 Glycerol kinase 2 25.14 60.60 5.77 
Q9NZC3 Glycerophosphodiester phosphodiesterase 1 14.20 37.70 6.71 
Q8N9F7 
Glycerophosphodiester phosphodiesterase domain-
containing protein 1 
15.61 36.10 8.47 
P41250 Glycine--tRNA ligase 10.28 83.10 7.03 
P11216 Glycogen phosphorylase, brain form 2.25 96.60 6.86 
P49841 Glycogen synthase kinase-3 beta 9.52 46.70 8.78 
Q9UBQ7 Glyoxylate reductase/hydroxypyruvate reductase 22.56 35.60 7.39 
Q8N158 Glypican-2 10.54 62.80 8.00 
Q92896 Golgi apparatus protein 1 1.61 134.50 6.90 
O95995 Growth arrest-specific protein 8 29.08 56.30 7.94 
P62826 GTP-binding nuclear protein Ran 40.74 24.40 7.49 
Q9NR31 GTP-binding protein SAR1a 20.71 22.40 6.68 
Q9Y6B6 GTP-binding protein SAR1b 15.66 22.40 6.11 
P63244 
Guanine nucleotide-binding protein subunit beta-2-like 
1 
15.14 35.10 7.69 
Q9H0R4 
Haloacid dehalogenase-like hydrolase domain-
containing protein 2 
35.14 28.50 6.24 
Q7Z4H3 HD domain-containing protein 2 58.82 23.40 5.49 
P34931 Heat shock 70 kDa protein 1-like 37.75 70.30 6.02 
P08107 Heat shock 70 kDa protein 1A/1B 35.10 70.00 5.66 
P34932 Heat shock 70 kDa protein 4 16.43 94.30 5.19 
O95757 Heat shock 70 kDa protein 4L 21.45 94.50 5.88 
P11142 Heat shock cognate 71 kDa protein 20.12 70.90 5.52 
Q92598 Heat shock protein 105 kDa 12.59 96.80 5.39 
Q12931 Heat shock protein 75 kDa, mitochondrial 5.54 80.10 8.21 
P04792 Heat shock protein beta-1 33.17 22.80 6.40 
P07900 Heat shock protein HSP 90-alpha 27.19 84.60 5.02 
P08238 Heat shock protein HSP 90-beta 15.75 83.20 5.03 
P54652 Heat shock-related 70 kDa protein 2 43.97 70.00 5.74 
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P30519 Heme oxygenase 2 42.72 36.00 5.41 
P19367 Hexokinase-1 41.55 102.40 6.80 
P49773 Histidine triad nucleotide-binding protein 1 29.37 13.80 6.95 
Q9BX68 
Histidine triad nucleotide-binding protein 2, 
mitochondrial 
26.99 17.20 9.16 
Q9NQE9 Histidine triad nucleotide-binding protein 3 25.82 20.30 6.60 
Q96DB2 Histone deacetylase 11 5.76 39.20 7.65 
Q96QV6 Histone H2A type 1-A 75.57 14.20 10.86 
Q6FI13 Histone H2A type 2-A 40.00 14.10 10.90 
Q16777 Histone H2A type 2-C 40.31 14.00 10.90 
P0C5Z0 Histone H2A-Bbd type 2/3 50.43 12.70 10.67 
Q96A08 Histone H2B type 1-A 40.16 14.20 10.32 
P84243 Histone H3.3 69.12 15.30 11.27 
P62805 Histone H4 57.28 11.40 11.36 
Q86YZ3 Hornerin 7.16 282.20 10.04 
P50502 Hsc70-interacting protein 14.09 41.30 5.27 
Q16543 Hsp90 co-chaperone Cdc37 18.52 44.40 5.25 
O00291 Huntingtin-interacting protein 1 12.05 116.10 5.30 
Q4G0P3 Hydrocephalus-inducing protein homolog 1.15 575.50 6.06 
Q16836 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 12.74 34.30 8.85 
Q16775 Hydroxyacylglutathione hydrolase, mitochondrial 14.29 33.80 8.12 
P35914 Hydroxymethylglutaryl-CoA lyase, mitochondrial 6.77 34.30 8.54 
P00492 Hypoxanthine-guanine phosphoribosyltransferase 52.75 24.60 6.68 
Q9Y4L1 Hypoxia up-regulated protein 1 15.42 111.30 5.22 
P52292 Importin subunit alpha-1 15.50 57.80 5.40 
O00629 Importin subunit alpha-3 9.21 57.90 4.96 
O00505 Importin subunit alpha-4 10.75 57.80 4.94 
O60684 Importin subunit alpha-7 11.19 60.00 4.98 
Q14974 Importin subunit beta-1 11.99 97.10 4.78 
Q8TEX9 Importin-4 17.02 118.60 4.96 
O00410 Importin-5 5.56 123.50 4.94 
Q8IV63 Inactive serine/threonine-protein kinase VRK3 9.07 52.80 9.04 
P29218 Inositol monophosphatase 1 12.27 30.20 5.26 
P49441 Inositol polyphosphate 1-phosphatase 6.27 44.00 5.26 
Q9Y287 Integral membrane protein 2B 9.40 30.30 5.14 
O75569 
Interferon-inducible double-stranded RNA-dependent 
protein kinase activator A 
13.10 34.40 8.41 
Q6NXR0 Interferon-inducible GTPase 5 16.85 50.30 5.35 
Q86XH1 IQ and AAA domain-containing protein 1 3.04 95.30 9.47 
A8MTL0 IQ domain-containing protein F5 29.05 18.00 10.01 
Q8N0W5 IQ domain-containing protein K 11.50 33.30 8.21 
Q86U28 Iron-sulfur cluster assembly 2 homolog, mitochondrial 20.78 16.50 5.25 
Q8IWL3 
Iron-sulfur cluster co-chaperone protein HscB, 
mitochondrial 
8.94 27.40 7.69 
Q7L266 Isoaspartyl peptidase/L-asparaginase 23.38 32.00 6.24 
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Q96AB3 
Isochorismatase domain-containing protein 2, 
mitochondrial 
37.07 22.30 7.77 
P50213 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 
20.49 39.60 6.92 
O43837 
Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial 
20.78 42.20 8.46 
P51553 
Isocitrate dehydrogenase [NAD] subunit gamma, 
mitochondrial 
24.17 42.80 8.50 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic 9.66 46.60 7.01 
P41252 Isoleucine--tRNA ligase, cytoplasmic 1.66 144.40 6.15 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial 15.61 113.70 7.20 
P26440 Isovaleryl-CoA dehydrogenase, mitochondrial 11.35 46.30 8.19 
Q6UXV1 Izumo sperm-egg fusion protein 2 23.08 24.80 8.79 
Q5VZ72 Izumo sperm-egg fusion protein 3 10.04 27.70 8.29 
P14923 Junction plakoglobin 6.04 81.70 6.14 
Q6JEL2 Kelch-like protein 10 9.38 68.90 5.68 
P13645 Keratin, type I cytoskeletal 10 68.15 58.80 5.21 
P19012 Keratin, type I cytoskeletal 15 16.67 49.20 4.77 
P08779 Keratin, type I cytoskeletal 16 40.80 51.20 5.05 
Q04695 Keratin, type I cytoskeletal 17 29.86 48.10 5.02 
P35527 Keratin, type I cytoskeletal 9 63.24 62.00 5.24 
P04264 Keratin, type II cytoskeletal 1 74.53 66.00 8.12 
Q7Z794 Keratin, type II cytoskeletal 1b 25.43 61.90 5.99 
P13647 Keratin, type II cytoskeletal 5 51.02 62.30 7.74 
P02538 Keratin, type II cytoskeletal 6A 53.37 60.00 8.00 
P04259 Keratin, type II cytoskeletal 6B 51.77 60.00 8.00 
Q8N1N4 Keratin, type II cytoskeletal 78 15.96 56.80 6.02 
P05787 Keratin, type II cytoskeletal 8 11.39 53.70 5.59 
Q5T749 Keratinocyte proline-rich protein 2.76 64.10 8.27 
Q9HAQ2 Kinesin-like protein KIF9 6.08 89.90 7.17 
Q5H943 Kita-kyushu lung cancer antigen 1 32.74 12.80 10.20 
P49223 Kunitz-type protease inhibitor 3 41.57 10.20 6.44 
Q96RQ9 L-amino-acid oxidase 32.45 62.80 8.68 
Q9NRN7 
L-aminoadipate-semialdehyde dehydrogenase-
phosphopantetheinyl transferase 
38.83 35.80 6.80 
P00338 L-lactate dehydrogenase A chain 10.54 36.70 8.27 
P07864 L-lactate dehydrogenase C chain 21.08 36.30 7.46 
Q7Z4W1 L-xylulose reductase 54.92 25.90 8.10 
Q08431 Lactadherin 7.24 43.10 8.15 
P02788 Lactotransferrin 34.37 78.10 8.12 
Q04760 Lactoylglutathione lyase 16.85 20.80 5.31 
O43813 LanC-like protein 1 7.77 45.30 7.75 
P46379 Large proline-rich protein BAG6 10.16 119.30 5.60 
O75610 Left-right determination factor 1 21.58 40.90 8.27 
O95202 
LETM1 and EF-hand domain-containing protein 1, 
mitochondrial 
4.74 83.30 6.70 
Q9UIC8 Leucine carboxyl methyltransferase 1 15.87 38.40 6.04 
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Q9NQ48 Leucine zipper transcription factor-like protein 1 16.39 34.60 5.36 
Q9C099 
Leucine-rich repeat and coiled-coil domain-containing 
protein 1 
15.21 119.50 5.88 
Q8N456 Leucine-rich repeat-containing protein 18 19.92 29.70 9.80 
Q53EV4 Leucine-rich repeat-containing protein 23 17.78 39.70 4.65 
A6NM11 Leucine-rich repeat-containing protein 37A2 6.53 188.30 5.50 
O60309 Leucine-rich repeat-containing protein 37A3 5.39 180.50 5.31 
Q96QE4 Leucine-rich repeat-containing protein 37B 11.30 105.50 4.91 
Q96E66 Leucine-rich repeat-containing protein 51 19.27 22.20 9.35 
Q6XZB0 Lipase member I 5.00 53.00 9.03 
P06858 Lipoprotein lipase 6.53 53.10 8.15 
P36776 Lon protease homolog, mitochondrial 7.82 106.40 6.39 
P33121 Long-chain-fatty-acid--CoA ligase 1 17.48 77.90 7.15 
Q9UKU0 Long-chain-fatty-acid--CoA ligase 6 8.32 77.70 7.43 
P24666 
Low molecular weight phosphotyrosine protein 
phosphatase 
50.00 18.00 6.74 
Q9P2M1 LRP2-binding protein 10.66 39.80 7.90 
Q9HD34 LYR motif-containing protein 4 28.57 10.80 10.73 
Q15046 Lysine--tRNA ligase 12.56 68.00 6.35 
P10253 Lysosomal alpha-glucosidase 11.45 105.30 6.00 
P42785 Lysosomal Pro-X carboxypeptidase 9.88 55.80 7.21 
Q6UWQ5 Lysozyme-like protein 1 40.54 16.60 8.05 
Q96KX0 Lysozyme-like protein 4 26.71 16.40 8.28 
O75951 Lysozyme-like protein 6 16.89 16.90 6.14 
Q8NDA8 
Maestro heat-like repeat-containing protein family 
member 1 
1.71 181.10 6.89 
Q7Z745 
Maestro heat-like repeat-containing protein family 
member 2B 
2.40 180.70 6.28 
Q68CQ1 
Maestro heat-like repeat-containing protein family 
member 7 
3.25 145.60 6.96 
P40925 Malate dehydrogenase, cytoplasmic 7.49 36.40 7.36 
P40926 Malate dehydrogenase, mitochondrial 12.72 35.50 8.68 
O43708 Maleylacetoacetate isomerase 23.15 24.20 8.54 
Q9NR99 Matrix-remodeling-associated protein 5 0.67 312.00 8.32 
P11310 
Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
30.17 46.60 8.37 
Q8NEH6 Meiosis-specific nuclear structural protein 1 13.74 60.50 7.12 
Q495T6 Membrane metallo-endopeptidase-like 1 6.42 89.30 5.87 
O00264 
Membrane-associated progesterone receptor 
component 1 
26.15 21.70 4.70 
O15173 
Membrane-associated progesterone receptor 
component 2 
18.39 23.80 4.88 
P55145 Mesencephalic astrocyte-derived neurotrophic factor 23.63 20.70 8.69 
Q13505 Metaxin-1 4.72 51.40 9.79 
P56192 Methionine--tRNA ligase, cytoplasmic 3.11 101.10 6.16 
Q13825 Methylglutaconyl-CoA hydratase, mitochondrial 8.85 35.60 9.48 
Q8IVH4 Methylmalonic aciduria type A protein, mitochondrial 6.46 46.50 9.29 
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Q9BQA1 Methylosome protein 50 5.85 36.70 5.17 
Q9H492 Microtubule-associated proteins 1A/1B light chain 3A 17.36 14.30 8.68 
Q8TC71 Mitochondria-eating protein 33.46 61.10 8.63 
Q02978 Mitochondrial 2-oxoglutarate/malate carrier protein 21.66 34.00 9.91 
Q96AQ8 Mitochondrial calcium uniporter regulator 1 8.08 39.70 9.63 
O43772 Mitochondrial carnitine/acylcarnitine carrier protein 12.96 32.90 9.41 
Q9Y6C9 Mitochondrial carrier homolog 2 33.00 33.30 7.97 
Q9UBX3 Mitochondrial dicarboxylate carrier 22.65 31.30 9.54 
Q9Y3D6 Mitochondrial fission 1 protein 31.58 16.90 8.79 
Q3ZCQ8 
Mitochondrial import inner membrane translocase 
subunit TIM50 
6.80 39.60 8.37 
Q9NS69 Mitochondrial import receptor subunit TOM22 homolog 21.13 15.50 4.34 
Q15785 Mitochondrial import receptor subunit TOM34 23.95 34.50 8.98 
O96008 Mitochondrial import receptor subunit TOM40 homolog 18.56 37.90 7.25 
Q96LU5 Mitochondrial inner membrane protease subunit 1 20.48 18.50 8.09 
Q96T52 Mitochondrial inner membrane protease subunit 2 16.00 19.70 9.36 
Q16891 Mitochondrial inner membrane protein 20.05 83.60 6.48 
Q9Y5U8 Mitochondrial pyruvate carrier 1 44.04 12.30 9.61 
O95563 Mitochondrial pyruvate carrier 2 27.56 14.30 10.43 
Q9HC21 Mitochondrial thiamine pyrophosphate carrier 12.81 35.50 9.55 
Q6PF18 MORN repeat-containing protein 3 20.00 27.60 8.44 
Q5VZ52 MORN repeat-containing protein 5 22.98 18.70 5.88 
O75425 Motile sperm domain-containing protein 3 19.57 25.50 9.20 
P78406 mRNA export factor 24.18 40.90 7.83 
P22234 Multifunctional protein ADE2 19.29 47.00 7.23 
Q9NUJ1 
Mycophenolic acid acyl-glucuronide esterase, 
mitochondrial 
17.65 33.90 8.57 
P58340 Myeloid leukemia factor 1 32.46 30.60 9.45 
Q96S97 Myeloid-associated differentiation marker 4.97 35.30 8.15 
P05164 Myeloperoxidase 15.97 83.80 8.97 
P14649 Myosin light chain 6B 16.35 22.70 5.73 
P19105 Myosin regulatory light chain 12A 28.07 19.80 4.81 
O14950 Myosin regulatory light chain 12B 27.91 19.80 4.84 
P13533 Myosin-6 0.62 223.60 5.73 
P12883 Myosin-7 0.88 223.00 5.80 
Q9UJ70 N-acetyl-D-glucosamine kinase 16.86 37.40 6.24 
P15586 N-acetylglucosamine-6-sulfatase 12.50 62.00 8.31 
Q8NFW8 N-acylneuraminate cytidylyltransferase 5.53 48.30 7.93 
O95777 N-alpha-acetyltransferase 38, NatC auxiliary subunit 43.75 10.40 4.48 
Q9BV86 N-terminal Xaa-Pro-Lys N-methyltransferase 1 12.11 25.40 5.52 
P20933 N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase 6.94 37.20 6.28 
O95865 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 8.42 29.60 6.01 
Q4G0N4 NAD kinase 2, mitochondrial 6.33 49.40 8.18 
P23368 NAD-dependent malic enzyme, mitochondrial 15.58 65.40 7.61 
Q9NXA8 
NAD-dependent protein deacylase sirtuin-5, 
mitochondrial 
8.06 33.90 8.47 
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Q9BU61 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 3 
17.39 20.30 8.22 
Q86Y39 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 11 
48.23 14.80 8.72 
Q9UI09 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 12 
26.90 17.10 9.63 
Q9P0J0 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 
24.31 16.70 8.43 
O43678 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 2 
74.75 10.90 9.57 
P56556 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 6 
22.73 17.90 10.14 
O95182 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 7 
19.47 12.50 10.18 
P51970 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 8 
13.37 20.10 7.65 
O96000 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 10 
23.26 20.80 8.48 
O95168 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 4 
31.01 15.20 9.85 
O43674 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 5, mitochondrial 
14.29 21.70 9.63 
P17568 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 7 
27.01 16.40 8.92 
O95169 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 8, mitochondrial 
23.12 21.80 6.80 
Q9Y6M9 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 9 
41.90 21.80 8.38 
P49821 
NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial 
5.60 50.80 8.21 
P19404 
NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial 
18.47 27.40 8.06 
O75489 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 
3, mitochondrial 
51.14 30.20 7.50 
O43920 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 23.58 12.50 9.14 
O75251 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 
7, mitochondrial 
11.74 23.50 9.99 
O00217 
NADH dehydrogenase [ubiquinone] iron-sulfur protein 
8, mitochondrial 
21.43 23.70 6.34 
Q6BCY4 NADH-cytochrome b5 reductase 2 27.17 31.40 8.50 
P00387 NADH-cytochrome b5 reductase 3 11.30 34.20 7.59 
P28331 
NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 
20.91 79.40 6.23 
P22570 NADPH:adrenodoxin oxidoreductase, mitochondrial 5.09 53.80 8.44 
O43847 Nardilysin 8.26 131.50 5.00 
Q13564 NEDD8-activating enzyme E1 regulatory subunit 4.87 60.20 5.40 
P56730 Neurotrypsin 9.03 97.00 8.03 
Q14697 Neutral alpha-glucosidase AB 27.22 106.80 6.14 
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Q86X76 Nitrilase homolog 1 35.17 35.90 7.74 
Q9UNZ2 NSFL1 cofactor p47 17.03 40.50 5.10 
O75694 Nuclear pore complex protein Nup155 25.95 155.10 6.16 
Q12769 Nuclear pore complex protein Nup160 3.48 162.00 5.50 
Q92621 Nuclear pore complex protein Nup205 12.52 227.80 6.19 
Q9BW27 Nuclear pore complex protein Nup85 3.66 75.00 5.55 
Q99567 Nuclear pore complex protein Nup88 13.50 83.50 5.69 
Q8N1F7 Nuclear pore complex protein Nup93 21.73 93.40 5.72 
P52948 Nuclear pore complex protein Nup98-Nup96 2.97 197.50 6.40 
P37198 Nuclear pore glycoprotein p62 10.73 53.20 5.31 
Q8TEM1 Nuclear pore membrane glycoprotein 210 5.41 205.00 6.81 
Q5VU65 Nuclear pore membrane glycoprotein 210-like 14.67 210.50 7.50 
Q8TAT6 Nuclear protein localization protein 4 homolog 3.13 68.10 6.38 
P80303 Nucleobindin-2 9.29 50.20 5.12 
Q5SRE5 Nucleoporin NUP188 homolog 10.86 195.90 6.73 
Q8NFH3 Nucleoporin Nup43 6.58 42.10 5.63 
Q8NFH5 Nucleoporin NUP53 25.15 34.80 9.09 
Q7Z3B4 Nucleoporin p54 9.47 55.40 7.02 
Q9BVL2 Nucleoporin p58/p45 7.68 60.90 9.33 
Q96EE3 Nucleoporin SEH1 7.78 39.60 8.09 
Q9Y5B8 Nucleoside diphosphate kinase 7 23.94 42.50 6.47 
P15531 Nucleoside diphosphate kinase A 35.53 17.10 6.19 
P22392 Nucleoside diphosphate kinase B 40.79 17.30 8.41 
P56597 Nucleoside diphosphate kinase homolog 5 27.83 24.20 6.29 
P55209 Nucleosome assembly protein 1-like 1 7.67 45.30 4.46 
Q8WVJ2 NudC domain-containing protein 2 24.84 17.70 5.07 
Q8IVD9 NudC domain-containing protein 3 6.37 40.80 5.25 
Q9Y3B8 Oligoribonuclease, mitochondrial 18.99 26.80 6.87 
Q9H6K4 Optic atrophy 3 protein 8.38 20.00 8.91 
Q7L8S5 OTU domain-containing protein 6A 7.64 33.30 6.74 
Q14990 Outer dense fiber protein 1 42.00 28.30 8.03 
Q5BJF6 Outer dense fiber protein 2 30.76 95.30 7.62 
Q96PU9 Outer dense fiber protein 3 31.10 27.70 9.89 
Q8IXM7 Outer dense fiber protein 3-like protein 1 13.87 31.00 9.54 
A8MYP8 Outer dense fiber protein 3B 46.25 27.30 10.42 
Q9BUP3 Oxidoreductase HTATIP2 17.77 27.00 8.38 
Q15645 Pachytene checkpoint protein 2 homolog 8.56 48.50 6.09 
Q96M98 Parkin coregulated gene protein 11.82 33.30 8.21 
P62937 Peptidyl-prolyl cis-trans isomerase A 40.61 18.00 7.81 
P23284 Peptidyl-prolyl cis-trans isomerase B 20.83 23.70 9.41 
P30405 Peptidyl-prolyl cis-trans isomerase F, mitochondrial 24.15 22.00 9.38 
P26885 Peptidyl-prolyl cis-trans isomerase FKBP2 15.49 15.60 9.13 
Q8IXY8 Peptidyl-prolyl cis-trans isomerase-like 6 9.65 35.20 7.02 
O60664 Perilipin-3 6.22 47.00 5.44 
Q06830 Peroxiredoxin-1 29.15 22.10 8.13 
P32119 Peroxiredoxin-2 32.83 21.90 5.97 
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Q13162 Peroxiredoxin-4 36.90 30.50 6.29 
P30044 Peroxiredoxin-5, mitochondrial 17.29 22.10 8.70 
P30041 Peroxiredoxin-6 36.61 25.00 6.38 
O96011 Peroxisomal membrane protein 11B 33.59 28.40 9.85 
Q96HA9 Peroxisomal membrane protein 11C 20.75 26.60 9.13 
P51659 Peroxisomal multifunctional enzyme type 2 3.94 79.60 8.84 
Q9Y285 Phenylalanine--tRNA ligase alpha subunit 10.04 57.50 7.80 
Q9NSD9 Phenylalanine--tRNA ligase beta subunit 19.02 66.10 6.84 
Q00325 Phosphate carrier protein, mitochondrial 10.77 40.10 9.38 
P30086 Phosphatidylethanolamine-binding protein 1 33.69 21.00 7.53 
Q96S96 Phosphatidylethanolamine-binding protein 4 16.74 25.70 6.54 
Q8WUK0 
Phosphatidylglycerophosphatase and protein-tyrosine 
phosphatase 1 
30.35 22.80 9.77 
Q8TBX8 
Phosphatidylinositol 5-phosphate 4-kinase type-2 
gamma 
4.51 47.30 6.84 
Q8TCT1 Phosphoethanolamine/phosphocholine phosphatase 13.86 29.70 7.71 
P00558 Phosphoglycerate kinase 1 13.67 44.60 8.10 
P07205 Phosphoglycerate kinase 2 12.47 44.80 8.54 
P18669 Phosphoglycerate mutase 1 59.45 28.80 7.18 
P15259 Phosphoglycerate mutase 2 62.06 28.70 8.88 
A6NDG6 Phosphoglycolate phosphatase 33.33 34.00 6.14 
P14555 Phospholipase A2, membrane associated 43.75 16.10 9.23 
P36969 
Phospholipid hydroperoxide glutathione peroxidase, 
mitochondrial 
30.46 22.20 8.37 
O15305 Phosphomannomutase 2 14.63 28.10 6.77 
Q15126 Phosphomevalonate kinase 16.15 22.00 5.73 
Q9GZP4 PITH domain-containing protein 1 8.06 24.20 5.74 
P23634 Plasma membrane calcium-transporting ATPase 4 8.86 137.80 6.60 
P13796 Plastin-2 2.55 70.20 5.43 
P43034 
Platelet-activating factor acetylhydrolase IB subunit 
alpha 
5.37 46.60 7.37 
P68402 Platelet-activating factor acetylhydrolase IB subunit beta 9.61 25.60 5.92 
Q15102 
Platelet-activating factor acetylhydrolase IB subunit 
gamma 
17.75 25.70 6.84 
Q8TC44 POC1 centriolar protein homolog B 7.32 53.60 7.24 
Q9NX46 Poly(ADP-ribose) glycohydrolase ARH3 16.25 38.90 5.07 
Q8TBY8 Polyamine-modulated factor 1-binding protein 1 18.40 119.00 6.29 
Q8TCS8 
Polyribonucleotide nucleotidyltransferase 1, 
mitochondrial 
9.20 85.90 7.77 
P0CG48 Polyubiquitin-C 59.12 77.00 7.66 
Q6ICG8 Postacrosomal sheath WW domain-binding protein 14.56 31.90 7.84 
Q9UI14 Prenylated Rab acceptor protein 1 10.27 20.60 7.34 
Q5JRX3 Presequence protease, mitochondrial 9.35 117.30 6.92 
Q6NUT2 Probable C-mannosyltransferase DPY19L2 4.22 87.30 9.10 
Q8NA82 Probable E3 ubiquitin-protein ligase MARCH10 4.70 90.50 6.71 
Q8N9V2 Probable E3 ubiquitin-protein ligase TRIML1 21.79 53.00 5.49 
Q9UKR5 Probable ergosterol biosynthetic protein 28 20.00 15.90 9.83 
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Q5GAN3 Probable inactive ribonuclease-like protein 13 22.44 17.80 8.59 
A4D1T9 Probable inactive serine protease 37 22.13 26.40 8.87 
P60673 Profilin-3 43.07 14.60 9.26 
Q8WUM4 Programmed cell death 6-interacting protein 3.80 96.00 6.52 
O75340 Programmed cell death protein 6 19.37 21.90 5.40 
P35232 Prohibitin 43.75 29.80 5.76 
Q99623 Prohibitin-2 64.88 33.30 9.83 
P12273 Prolactin-inducible protein 27.40 16.60 8.05 
Q9UQ80 Proliferation-associated protein 2G4 10.15 43.80 6.55 
Q15185 Prostaglandin E synthase 3 13.75 18.70 4.54 
Q8WXA2 Prostate and testis expressed protein 1 72.22 14.30 7.93 
B3GLJ2 Prostate and testis expressed protein 3 40.82 11.70 8.97 
P07288 Prostate-specific antigen 18.39 28.70 7.68 
P15309 Prostatic acid phosphatase 8.55 44.50 6.24 
Q16186 Proteasomal ubiquitin receptor ADRM1 16.46 42.10 5.07 
Q14997 Proteasome activator complex subunit 4 13.08 211.20 6.90 
Q969U7 Proteasome assembly chaperone 2 6.06 29.40 6.98 
Q92530 Proteasome inhibitor PI31 subunit 23.25 29.80 5.74 
P25786 Proteasome subunit alpha type-1 60.08 29.50 6.61 
P25787 Proteasome subunit alpha type-2 26.07 25.90 7.43 
P25788 Proteasome subunit alpha type-3 45.10 28.40 5.33 
P25789 Proteasome subunit alpha type-4 15.71 29.50 7.72 
P60900 Proteasome subunit alpha type-6 28.86 27.40 6.76 
O14818 Proteasome subunit alpha type-7 40.73 27.90 8.46 
Q8TAA3 Proteasome subunit alpha type-7-like 38.28 28.50 8.98 
P20618 Proteasome subunit beta type-1 45.23 26.50 8.13 
P49721 Proteasome subunit beta type-2 35.32 22.80 7.02 
P49720 Proteasome subunit beta type-3 43.41 22.90 6.55 
P28070 Proteasome subunit beta type-4 8.71 29.20 5.97 
P28074 Proteasome subunit beta type-5 40.68 28.50 6.92 
P28072 Proteasome subunit beta type-6 31.80 25.30 4.92 
Q5VYK3 Proteasome-associated protein ECM29 homolog 1.25 204.20 7.12 
O14744 Protein arginine N-methyltransferase 5 4.08 72.60 6.29 
O43822 Protein C21orf2 34.38 28.30 7.34 
Q9Y2B0 Protein canopy homolog 2 22.53 20.60 4.92 
Q6TDU7 Protein CASC1 3.07 83.10 5.29 
Q8WTU0 Protein DDI1 homolog 1 8.59 44.10 5.73 
P07237 Protein disulfide-isomerase 12.80 57.10 4.87 
P30101 Protein disulfide-isomerase A3 28.51 56.70 6.35 
P13667 Protein disulfide-isomerase A4 13.49 72.90 5.07 
Q15084 Protein disulfide-isomerase A6 23.86 48.10 5.08 
Q99497 Protein DJ-1 46.03 19.90 6.79 
Q9BVM2 Protein DPCD 20.20 23.20 9.03 
Q9BPY3 Protein FAM118B 5.41 39.50 5.99 
Q8IYX7 Protein FAM154A 37.34 54.60 8.37 
Q96A26 Protein FAM162A 16.88 17.30 9.77 
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Q6J272 Protein FAM166A 45.43 36.10 7.81 
A1A519 Protein FAM170A 18.48 37.10 5.03 
Q6ZVS7 Protein FAM183B 37.78 16.20 8.43 
Q6ZU69 Protein FAM205A 10.56 148.00 8.29 
Q5JX71 Protein FAM209A 45.03 19.60 9.42 
Q5JX69 Protein FAM209B 31.58 19.50 8.84 
Q8IYT1 Protein FAM71A 17.34 63.10 9.64 
Q8TC56 Protein FAM71B 16.20 64.70 9.48 
Q8NEG0 Protein FAM71C 29.88 27.50 6.98 
Q96LP2 Protein FAM81B 7.52 52.00 9.10 
Q9BUN1 Protein MENT 65.98 36.70 8.59 
Q9UFN0 Protein NipSnap homolog 3A 26.32 28.40 9.16 
Q7Z5V6 Protein phosphatase 1 regulatory subunit 32 12.71 47.30 8.54 
Q15435 Protein phosphatase 1 regulatory subunit 7 23.61 41.50 4.91 
P35813 Protein phosphatase 1A 16.49 42.40 5.36 
P41236 Protein phosphatase inhibitor 2 13.17 23.00 4.74 
Q9Y570 Protein phosphatase methylesterase 1 9.59 42.30 5.97 
P31151 Protein S100-A7 41.58 11.50 6.77 
P05109 Protein S100-A8 29.03 10.80 7.03 
P55735 Protein SEC13 homolog 9.63 35.50 5.48 
P49221 Protein-glutamine gamma-glutamyltransferase 4 5.56 77.10 6.76 
P22061 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase 
32.16 24.60 7.21 
P55786 Puromycin-sensitive aminopeptidase 21.11 103.20 5.72 
Q5VTE0 Putative elongation factor 1-alpha-like 3 10.39 50.20 9.07 
Q14409 Putative glycerol kinase 3 11.93 60.60 6.39 
Q9GZT8 Putative GTP cyclohydrolase 1 type 2 NIF3L1 6.37 41.90 6.65 
A6NK58 Putative lipoyltransferase 2, mitochondrial 22.08 25.20 8.27 
Q8NHP8 Putative phospholipase B-like 2 6.45 65.40 6.80 
Q7L7V1 
Putative pre-mRNA-splicing factor ATP-dependent RNA 
helicase DHX32 
2.29 84.40 4.97 
Q8N5Q1 Putative protein FAM71E2 5.86 99.90 9.39 
P0C874 Putative spermatogenesis-associated protein 31D3 4.91 102.40 8.07 
Q6ZUB0 Putative spermatogenesis-associated protein 31D4 4.91 102.30 8.00 
Q5T440 Putative transferase CAF17, mitochondrial 21.35 38.10 9.83 
O00764 Pyridoxal kinase 9.94 35.10 6.13 
Q53H96 Pyrroline-5-carboxylate reductase 3 9.49 28.60 7.50 
P08559 
Pyruvate dehydrogenase E1 component subunit alpha, 
somatic form, mitochondrial 
17.95 43.30 8.06 
P29803 
Pyruvate dehydrogenase E1 component subunit alpha, 
testis-specific form, mitochondrial 
41.75 42.90 8.46 
P11177 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial 
16.99 39.20 6.65 
O00330 
Pyruvate dehydrogenase protein X component, 
mitochondrial 
18.76 54.10 8.66 
P14618 Pyruvate kinase PKM 45.20 57.90 7.84 
P31150 Rab GDP dissociation inhibitor alpha 20.13 50.60 5.14 
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P50395 Rab GDP dissociation inhibitor beta 46.07 50.60 6.47 
Q5HYI8 Rab-like protein 3 27.12 26.40 7.11 
Q8WYR4 Radial spoke head 1 homolog 27.51 35.10 4.63 
Q86UC2 Radial spoke head protein 3 homolog 10.89 63.60 5.69 
Q9H0K4 Radial spoke head protein 6 homolog A 20.22 80.90 4.39 
Q9H1X1 Radial spoke head protein 9 homolog 30.43 31.30 5.43 
P35241 Radixin 4.46 68.50 6.37 
P43487 Ran-specific GTPase-activating protein 14.43 23.30 5.29 
P0DJD0 RANBP2-like and GRIP domain-containing protein 1 0.74 196.50 6.14 
Q7Z3J3 RanBP2-like and GRIP domain-containing protein 4 0.74 197.20 6.27 
Q99666 RANBP2-like and GRIP domain-containing protein 5/6 0.74 198.80 6.42 
O14715 RANBP2-like and GRIP domain-containing protein 8 0.74 198.90 6.49 
Q13576 Ras GTPase-activating-like protein IQGAP2 4.38 180.50 5.64 
P63000 Ras-related C3 botulinum toxin substrate 1 15.63 21.40 8.50 
P61026 Ras-related protein Rab-10 30.00 22.50 8.38 
P62491 Ras-related protein Rab-11A 60.65 24.40 6.57 
P61106 Ras-related protein Rab-14 36.74 23.90 6.21 
Q9NP72 Ras-related protein Rab-18 18.93 23.00 5.24 
P62820 Ras-related protein Rab-1A 24.39 22.70 6.21 
Q9H0U4 Ras-related protein Rab-1B 24.88 22.20 5.73 
P61019 Ras-related protein Rab-2A 47.64 23.50 6.54 
Q8WUD1 Ras-related protein Rab-2B 46.76 24.20 7.83 
P61018 Ras-related protein Rab-4B 16.43 23.60 6.06 
P61020 Ras-related protein Rab-5B 14.42 23.70 8.13 
P51148 Ras-related protein Rab-5C 19.91 23.50 8.41 
P20340 Ras-related protein Rab-6A 34.62 23.60 5.54 
P11233 Ras-related protein Ral-A 29.13 23.60 7.11 
Q96HR9 Receptor expression-enhancing protein 6 36.96 20.70 8.56 
P18754 Regulator of chromosome condensation 13.30 44.90 7.52 
O94788 Retinal dehydrogenase 2 5.02 56.70 6.05 
O43924 
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic 
phosphodiesterase subunit delta 
16.00 17.40 5.67 
P02753 Retinol-binding protein 4 11.44 23.00 6.07 
Q9UHP6 Rhabdoid tumor deletion region protein 1 20.11 38.60 6.90 
P52565 Rho GDP-dissociation inhibitor 1 36.76 23.20 5.11 
Q8N443 RIB43A-like with coiled-coils protein 1 12.40 44.00 8.76 
Q9H4K1 RIB43A-like with coiled-coils protein 2 20.39 37.00 9.54 
P13489 Ribonuclease inhibitor 41.00 49.90 4.82 
P60891 Ribose-phosphate pyrophosphokinase 1 6.92 34.80 6.98 
Q9Y3A5 Ribosome maturation protein SBDS 13.60 28.70 8.75 
P16083 Ribosyldihydronicotinamide dehydrogenase [quinone] 10.39 25.90 6.29 
Q96AT9 Ribulose-phosphate 3-epimerase 7.46 24.90 5.58 
Q96C74 Ropporin-1-like protein 35.22 26.10 7.72 
Q9HAT0 Ropporin-1A 74.53 23.90 5.66 
Q9BZX4 Ropporin-1B 75.47 23.90 5.15 
Q9Y265 RuvB-like 1 24.56 50.20 6.42 
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Q9Y230 RuvB-like 2 39.96 51.10 5.64 
P31153 S-adenosylmethionine synthase isoform type-2 5.82 43.60 6.48 
P10768 S-formylglutathione hydrolase 19.15 31.40 7.02 
P63208 S-phase kinase-associated protein 1 16.56 18.60 4.54 
Q8NBX0 Saccharopine dehydrogenase-like oxidoreductase 17.25 47.10 9.14 
Q499Z3 Schlafen-like protein 1 19.90 45.60 5.90 
O15127 Secretory carrier-associated membrane protein 2 4.26 36.60 6.10 
P04279 Semenogelin-1 52.38 52.10 9.29 
Q02383 Semenogelin-2 18.73 65.40 9.07 
Q9P0V9 Septin-10 6.61 52.60 6.80 
Q8IYM1 Septin-12 15.64 40.70 7.11 
O43236 Septin-4 12.97 55.10 6.11 
P34896 Serine hydroxymethyltransferase, cytosolic 16.98 53.00 7.71 
O43464 Serine protease HTRA2, mitochondrial 5.24 48.80 10.07 
P20155 Serine protease inhibitor Kazal-type 2 54.76 9.30 9.00 
Q07955 Serine/arginine-rich splicing factor 1 24.60 27.70 10.36 
P84103 Serine/arginine-rich splicing factor 3 14.02 19.30 11.65 
Q15172 
Serine/threonine-protein phosphatase 2A 56 kDa 
regulatory subunit alpha isoform 
4.73 56.20 6.71 
P30153 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
9.34 65.30 5.11 
Q15257 Serine/threonine-protein phosphatase 2A activator 22.63 40.60 5.94 
P67775 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform 
14.56 35.60 5.54 
P62714 
Serine/threonine-protein phosphatase 2A catalytic 
subunit beta isoform 
14.56 35.60 5.43 
P60510 
Serine/threonine-protein phosphatase 4 catalytic 
subunit 
15.31 35.10 5.06 
Q8TF05 
Serine/threonine-protein phosphatase 4 regulatory 
subunit 1 
3.58 106.90 4.77 
O00743 
Serine/threonine-protein phosphatase 6 catalytic 
subunit 
20.98 35.10 5.69 
O15084 
Serine/threonine-protein phosphatase 6 regulatory 
ankyrin repeat subunit A 
2.94 112.90 6.25 
Q96HS1 
Serine/threonine-protein phosphatase PGAM5, 
mitochondrial 
24.91 32.00 8.68 
P62140 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit 
35.78 37.20 6.19 
P36873 
Serine/threonine-protein phosphatase PP1-gamma 
catalytic subunit 
50.15 37.00 6.54 
Q96P63 Serpin B12 4.20 46.20 5.53 
P35237 Serpin B6 24.73 42.60 5.27 
P02768 Serum albumin 31.20 69.30 6.28 
P02743 Serum amyloid P-component 34.08 25.40 6.54 
P16219 
Short-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
22.33 44.30 7.99 
P67812 Signal peptidase complex catalytic subunit SEC11A 19.55 20.60 9.48 
Q15005 Signal peptidase complex subunit 2 20.35 25.00 8.47 
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Q04837 Single-stranded DNA-binding protein, mitochondrial 81.08 17.20 9.60 
O43805 Sjoegren syndrome nuclear autoantigen 1 52.94 13.60 5.38 
O60232 Sjoegren syndrome/scleroderma autoantigen 1 29.15 21.50 5.24 
O43765 
Small glutamine-rich tetratricopeptide repeat-
containing protein alpha 
8.63 34.00 4.87 
Q9UBC9 Small proline-rich protein 3 18.34 18.10 8.57 
Q8NHG7 Small VCP/p97-interacting protein 27.27 8.40 8.91 
P13637 Sodium/potassium-transporting ATPase subunit alpha-3 5.92 111.70 5.38 
Q13733 Sodium/potassium-transporting ATPase subunit alpha-4 6.51 114.10 6.64 
P54709 Sodium/potassium-transporting ATPase subunit beta-3 15.41 31.50 8.35 
Q8TDB8 
Solute carrier family 2, facilitated glucose transporter 
member 14 
16.92 56.30 7.83 
Q00796 Sorbitol dehydrogenase 34.17 38.30 7.97 
Q9Y512 
Sorting and assembly machinery component 50 
homolog 
7.68 51.90 6.90 
O60493 Sorting nexin-3 19.75 18.80 8.66 
Q9H3U7 SPARC-related modular calcium-binding protein 2 8.97 49.60 8.46 
Q76KD6 Speriolin 5.25 62.40 8.19 
Q9HBV2 Sperm acrosome membrane-associated protein 1 21.09 32.10 4.61 
Q8IXA5 Sperm acrosome membrane-associated protein 3 26.98 23.40 7.94 
Q8TDM5 Sperm acrosome membrane-associated protein 4 21.77 13.00 5.80 
Q96QH8 Sperm acrosome-associated protein 5 16.35 17.90 6.42 
Q6UW49 Sperm equatorial segment protein 1 18.00 38.90 5.73 
Q9C093 Sperm flagellar protein 2 3.73 209.70 5.54 
Q9NS25 
Sperm protein associated with the nucleus on the X 
chromosome B/F 
32.04 11.80 6.15 
Q9BXN6 
Sperm protein associated with the nucleus on the X 
chromosome D 
48.45 11.00 6.11 
Q8TAD1 
Sperm protein associated with the nucleus on the X 
chromosome E 
48.45 11.00 5.26 
Q15506 Sperm surface protein Sp17 34.44 17.40 4.78 
Q8N0X2 Sperm-associated antigen 16 protein 10.94 70.80 6.33 
Q9NPE6 Sperm-associated antigen 4 protein 10.30 48.10 7.14 
O75602 Sperm-associated antigen 6 14.54 55.40 6.83 
Q8NCR6 Spermatid-specific manchette-related protein 1 51.15 30.10 8.40 
Q7Z5L4 Spermatogenesis-associated protein 19, mitochondrial 58.68 19.20 6.96 
Q8NHX4 Spermatogenesis-associated protein 3 9.84 19.90 10.17 
Q6ZQQ2 Spermatogenesis-associated protein 31D1 4.89 175.50 8.85 
Q96N06 Spermatogenesis-associated protein 33 27.34 15.50 9.22 
Q9NWH7 Spermatogenesis-associated protein 6 4.10 56.00 8.48 
Q9NXE4 Sphingomyelin phosphodiesterase 4 5.80 93.30 7.97 
Q13838 Spliceosome RNA helicase DDX39B 8.41 49.00 5.67 
Q5W111 SPRY domain-containing protein 7 11.22 21.70 6.70 
P16949 Stathmin 18.12 17.30 5.97 
Q9P1V8 Sterile alpha motif domain-containing protein 15 3.41 77.10 4.45 
Q9UJZ1 Stomatin-like protein 2, mitochondrial 22.75 38.50 7.39 
P38646 Stress-70 protein, mitochondrial 9.87 73.60 6.16 
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P31948 Stress-induced-phosphoprotein 1 11.79 62.60 6.80 
Q9HCN8 Stromal cell-derived factor 2-like protein 1 17.65 23.60 7.03 
P31040 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
25.45 72.60 7.39 
P21912 
Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial 
20.36 31.60 8.76 
P51649 Succinate-semialdehyde dehydrogenase, mitochondrial 6.17 57.20 8.28 
Q9P2R7 
Succinyl-CoA ligase [ADP-forming] subunit beta, 
mitochondrial 
10.80 50.30 7.42 
P55809 
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, 
mitochondrial 
13.08 56.10 7.46 
Q9BYC2 
Succinyl-CoA:3-ketoacid coenzyme A transferase 2, 
mitochondrial 
4.84 56.10 7.14 
Q8TC36 SUN domain-containing protein 5 10.03 43.10 8.31 
P00441 Superoxide dismutase [Cu-Zn] 29.87 15.90 6.13 
O95473 Synaptogyrin-4 6.84 25.80 7.75 
P57105 Synaptojanin-2-binding protein 24.14 15.90 6.30 
Q86Y82 Syntaxin-12 14.49 31.60 5.59 
P17987 T-complex protein 1 subunit alpha 19.60 60.30 6.11 
P78371 T-complex protein 1 subunit beta 29.53 57.50 6.46 
P50991 T-complex protein 1 subunit delta 25.05 57.90 7.83 
P48643 T-complex protein 1 subunit epsilon 14.97 59.60 5.66 
Q99832 T-complex protein 1 subunit eta 25.05 59.30 7.65 
P49368 T-complex protein 1 subunit gamma 30.09 60.50 6.49 
P50990 T-complex protein 1 subunit theta 13.87 59.60 5.60 
P40227 T-complex protein 1 subunit zeta 9.60 58.00 6.68 
Q92526 T-complex protein 1 subunit zeta-2 12.45 57.80 7.24 
Q8IYX1 TBC1 domain family member 21 8.33 39.20 6.19 
Q8IZS6 Tctex1 domain-containing protein 3 18.69 23.20 9.33 
Q969V4 Tektin-1 34.93 48.30 6.37 
Q9UIF3 Tektin-2 47.91 49.60 5.55 
Q9BXF9 Tektin-3 44.69 56.60 7.34 
Q8WW24 Tektin-4 51.72 50.60 6.44 
Q96M29 Tektin-5 44.33 56.30 7.14 
Q9P2T0 Testicular haploid expressed gene protein 11.61 43.40 9.04 
Q9BY14 Testis-expressed sequence 101 protein 16.47 26.60 4.94 
O43247 Testis-expressed sequence 33 protein 8.21 30.70 7.99 
Q5T0J7 Testis-expressed sequence 35 protein 10.30 26.50 9.11 
Q96LM6 Testis-expressed sequence 37 protein 11.11 20.60 7.55 
Q9BZW7 Testis-specific gene 10 protein 40.97 81.40 5.97 
Q75WM6 Testis-specific H1 histone 25.49 28.10 11.78 
Q9BXA7 Testis-specific serine/threonine-protein kinase 1 7.36 41.60 7.71 
Q96PF2 Testis-specific serine/threonine-protein kinase 2 17.60 40.90 8.84 
Q9BXA6 Testis-specific serine/threonine-protein kinase 6 20.88 30.30 9.11 
Q6URK8 Testis, prostate and placenta-expressed protein 60.15 30.70 8.82 
Q8NDW8 Tetratricopeptide repeat protein 21A 1.82 150.80 7.24 
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Q96NG3 Tetratricopeptide repeat protein 25 12.50 76.60 5.60 
Q8N5M4 Tetratricopeptide repeat protein 9C 12.87 20.00 8.92 
Q9BU02 Thiamine-triphosphatase 31.30 25.60 4.82 
Q8N427 Thioredoxin domain-containing protein 3 4.59 67.20 4.97 
Q9NNW7 Thioredoxin reductase 2, mitochondrial 13.74 56.50 7.50 
Q9H1E5 Thioredoxin-related transmembrane protein 4 12.32 38.90 4.37 
O00142 Thymidine kinase 2, mitochondrial 7.17 31.00 8.46 
P23919 Thymidylate kinase 26.89 23.80 8.27 
O43617 Trafficking protein particle complex subunit 3 26.11 20.30 4.96 
Q9BV79 Trans-2-enoyl-CoA reductase, mitochondrial 7.24 40.40 8.76 
P37837 Transaldolase 9.79 37.50 6.81 
Q15369 Transcription elongation factor B polypeptide 1 43.75 12.50 4.78 
Q00059 Transcription factor A, mitochondrial 41.06 29.10 9.72 
Q00577 Transcriptional activator protein Pur-alpha 13.98 34.90 6.44 
Q96QR8 Transcriptional activator protein Pur-beta 6.73 33.20 5.43 
Q9Y4P3 Transducin beta-like protein 2 9.40 49.80 9.44 
P55072 Transitional endoplasmic reticulum ATPase 50.74 89.30 5.26 
Q14232 Translation initiation factor eIF-2B subunit alpha 6.23 33.70 7.33 
P13693 Translationally-controlled tumor protein 19.19 19.60 4.93 
Q15631 Translin 49.56 26.20 6.44 
Q99598 Translin-associated protein X 31.38 33.10 6.55 
P51571 Translocon-associated protein subunit delta 21.97 19.00 6.15 
Q8N6Q1 
Transmembrane and coiled-coil domain-containing 
protein 5A 
21.88 34.20 6.05 
P49755 Transmembrane emp24 domain-containing protein 10 24.66 25.00 7.44 
Q7Z7H5 Transmembrane emp24 domain-containing protein 4 17.18 25.90 8.28 
Q9BVK6 Transmembrane emp24 domain-containing protein 9 15.74 27.30 8.02 
P17152 Transmembrane protein 11, mitochondrial 17.19 21.50 7.36 
Q9H061 Transmembrane protein 126A 32.31 21.50 9.26 
Q8WZ59 Transmembrane protein 190 43.50 19.40 5.24 
Q6UW68 Transmembrane protein 205 37.04 21.20 8.62 
Q96SK2 Transmembrane protein 209 4.10 62.90 8.63 
A2RUT3 Transmembrane protein 89 64.15 17.60 10.01 
Q5BJF2 Transmembrane protein 97 10.23 20.80 9.38 
A6NFA0 Transmembrane protein ENSP00000340100 7.69 37.60 7.97 
P40939 Trifunctional enzyme subunit alpha, mitochondrial 22.28 82.90 9.04 
P55084 Trifunctional enzyme subunit beta, mitochondrial 19.20 51.30 9.41 
P60174 Triosephosphate isomerase 26.22 30.80 5.92 
P29144 Tripeptidyl-peptidase 2 9.21 138.30 6.32 
P06753 Tropomyosin alpha-3 chain 7.02 32.90 4.72 
P23381 Tryptophan--tRNA ligase, cytoplasmic 8.49 53.10 6.23 
Q71U36 Tubulin alpha-1A chain 49.67 50.10 5.06 
Q13748 Tubulin alpha-3C/D chain 58.89 49.90 5.10 
Q9BVA1 Tubulin beta-2B chain 33.93 49.90 4.89 
P68371 Tubulin beta-4B chain 38.43 49.80 4.89 
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P59282 
Tubulin polymerization-promoting protein family 
member 2 
26.47 18.50 9.00 
Q99426 Tubulin-folding cofactor B 22.95 27.30 5.15 
Q9BTW9 Tubulin-specific chaperone D 9.40 132.50 6.19 
O15042 U2 snRNP-associated SURP motif-containing protein 1.94 118.20 8.47 
Q9Y333 U6 snRNA-associated Sm-like protein LSm2 28.42 10.80 6.52 
Q9UK45 U6 snRNA-associated Sm-like protein LSm7 31.07 11.60 5.27 
Q96DE0 U8 snoRNA-decapping enzyme 18.97 21.30 6.89 
P54578 Ubiquitin carboxyl-terminal hydrolase 14 5.26 56.00 5.30 
P45974 Ubiquitin carboxyl-terminal hydrolase 5 5.01 95.70 5.03 
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 13.79 128.20 5.55 
P09936 Ubiquitin carboxyl-terminal hydrolase isozyme L1 26.46 24.80 5.48 
Q9Y5K5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 5.17 37.60 5.33 
Q14139 Ubiquitin conjugation factor E4 A 2.06 122.50 5.24 
Q8WUN7 Ubiquitin domain-containing protein 2 11.11 26.20 5.67 
Q92890 Ubiquitin fusion degradation protein 1 homolog 16.94 34.50 6.70 
Q96FW1 Ubiquitin thioesterase OTUB1 19.93 31.30 4.94 
Q96DC9 Ubiquitin thioesterase OTUB2 24.79 27.20 6.23 
P62979 Ubiquitin-40S ribosomal protein S27a 28.85 18.00 9.64 
P62987 Ubiquitin-60S ribosomal protein L40 35.16 14.70 9.83 
P61077 Ubiquitin-conjugating enzyme E2 D3 19.73 16.70 7.80 
P61086 Ubiquitin-conjugating enzyme E2 K 17.00 22.40 5.44 
P61088 Ubiquitin-conjugating enzyme E2 N 38.16 17.10 6.57 
Q13404 Ubiquitin-conjugating enzyme E2 variant 1 24.49 16.50 7.93 
Q15819 Ubiquitin-conjugating enzyme E2 variant 2 35.86 16.40 8.09 
Q9Y3C8 Ubiquitin-fold modifier-conjugating enzyme 1 23.95 19.40 7.40 
P22314 Ubiquitin-like modifier-activating enzyme 1 8.98 117.80 5.76 
A0AVT1 Ubiquitin-like modifier-activating enzyme 6 2.19 117.90 6.14 
Q9BZV1 UBX domain-containing protein 6 10.43 49.70 6.89 
Q14376 UDP-glucose 4-epimerase 6.32 38.30 6.73 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 2.32 177.10 5.63 
Q5T681 Uncharacterized protein C10orf62 13.90 25.10 7.59 
Q8WW14 Uncharacterized protein C10orf82 12.61 25.90 8.47 
Q6P656 Uncharacterized protein C15orf26 27.91 34.30 6.28 
H3BRN8 Uncharacterized protein C15orf65 22.31 13.80 8.31 
Q8NEP4 Uncharacterized protein C17orf47 8.42 63.10 9.20 
A8MV24 Uncharacterized protein C17orf98 42.86 17.60 9.79 
A6NCJ1 Uncharacterized protein C19orf71 86.12 24.20 8.95 
Q5SVJ3 Uncharacterized protein C1orf100 25.17 17.60 9.61 
Q8N1D5 Uncharacterized protein C1orf158 30.93 23.10 9.73 
Q5T5A4 Uncharacterized protein C1orf194 55.03 19.30 9.28 
Q9H1P6 Uncharacterized protein C20orf85 40.88 15.70 8.46 
Q8N801 Uncharacterized protein C2orf61 10.48 27.80 9.58 
Q96M34 Uncharacterized protein C3orf30 8.58 60.10 5.80 
Q6V702 Uncharacterized protein C4orf22 25.32 26.90 5.44 
Q6ZNM6 Uncharacterized protein C5orf48 46.27 15.40 9.16 
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A4QMS7 Uncharacterized protein C5orf49 58.50 17.00 7.59 
Q5TEZ5 Uncharacterized protein C6orf163 10.64 38.50 6.96 
Q8N865 Uncharacterized protein C7orf31 5.08 68.40 7.31 
Q8IZ16 Uncharacterized protein C7orf61 14.56 23.80 10.40 
A4D263 Uncharacterized protein C7orf72 24.89 49.60 8.48 
Q5VTT2 Uncharacterized protein C9orf135 13.10 26.40 7.21 
Q6ZQR2 Uncharacterized protein C9orf171 28.75 36.50 10.26 
Q96E40 Uncharacterized protein C9orf9 42.79 25.10 9.13 
Q9H0B3 Uncharacterized protein KIAA1683 17.80 127.60 10.23 
Q9HB07 UPF0160 protein MYG1, mitochondrial 25.27 42.40 6.67 
Q9H993 UPF0364 protein C6orf211 6.58 51.10 5.76 
Q9Y6A4 UPF0468 protein C16orf80 39.90 22.80 9.76 
A6NJV1 UPF0573 protein C2orf70 26.87 23.40 9.99 
Q9NWV4 UPF0587 protein C1orf123 15.63 18.00 5.01 
Q9H5F2 UPF0686 protein C11orf1 28.67 17.80 8.37 
Q5BN46 UPF0691 protein C9orf116 64.71 15.30 8.81 
Q537H7 UPF0732 protein C1orf227 45.92 11.30 10.07 
Q16851 UTP--glucose-1-phosphate uridylyltransferase 11.22 56.90 8.15 
P38606 V-type proton ATPase catalytic subunit A 9.56 68.30 5.52 
P21281 V-type proton ATPase subunit B, brain isoform 7.44 56.50 5.81 
Q96A05 V-type proton ATPase subunit E 2 31.42 26.10 8.76 
Q16864 V-type proton ATPase subunit F 41.18 13.40 5.52 
O75348 V-type proton ATPase subunit G 1 53.39 13.70 8.79 
Q9UK41 Vacuolar protein sorting-associated protein 28 homolog 20.36 25.40 5.54 
Q86WA6 Valacyclovir hydrolase 18.56 32.50 9.14 
P26640 Valine--tRNA ligase 20.57 140.40 7.59 
P49748 
Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
6.72 70.30 8.75 
Q96AJ9 
Vesicle transport through interaction with t-SNAREs 
homolog 1A 
22.58 25.20 6.40 
Q15836 Vesicle-associated membrane protein 3 55.00 11.30 8.79 
O75379 Vesicle-associated membrane protein 4 25.53 16.40 7.34 
Q9P0L0 
Vesicle-associated membrane protein-associated 
protein A 
23.29 27.90 8.62 
O95292 
Vesicle-associated membrane protein-associated 
protein B/C 
21.81 27.20 7.30 
P46459 Vesicle-fusing ATPase 15.46 82.50 6.95 
O75396 Vesicle-trafficking protein SEC22b 17.21 24.60 6.92 
Q8N0U8 
Vitamin K epoxide reductase complex subunit 1-like 
protein 1 
19.89 19.80 9.13 
P45880 Voltage-dependent anion-selective channel protein 2 7.14 31.50 7.56 
Q9NY47 
Voltage-dependent calcium channel subunit alpha-
2/delta-2 
2.17 129.70 5.80 
Q8IUA0 WAP four-disulfide core domain protein 8 38.59 27.80 8.02 
Q8N1V2 WD repeat-containing protein 16 20.32 68.30 6.95 
Q96MT7 WD repeat-containing protein 52 2.34 111.70 4.84 
Q96MR6 WD repeat-containing protein 65 13.52 144.90 5.80 
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Q9UHR6 Zinc finger HIT domain-containing protein 2 11.41 42.90 5.99 
Q9H0C1 Zinc finger MYND domain-containing protein 12 13.15 41.80 6.23 
Q9BS86 Zona pellucida-binding protein 1 33.90 40.10 9.28 
Q6X784 Zona pellucida-binding protein 2 14.20 38.60 7.78 
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Supplementary Table S3 – Quantification values (means ± standard deviation; Mean ± SD) of each 
differential protein detected in Asthenozoospermic (Astheno) vs Normozoospermic (Normo) samples 
experiment, and associated P value. 
All the proteins shown in this table were statistically different (p-value<0.05). 
UniprotKB/ 
Swiss-Prot 
accession 
number 
Protein name 
Astheno 
samples 
Normo 
samples P value 
Mean±SD Mean±SD 
Q9P2T0 
Testicular haploid expressed gene 
protein 
0.701±0.175 1.305±0.202 0.001 
Q13642 Four and a half LIM domains protein 1 0.648±0.244 1.129±0.243 0.014 
O95831 
Apoptosis-inducing factor 1, 
mitochondrial 
0.790±0.308 1.242±0.083 0.013 
Q6UWQ5 Lysozyme-like protein 1 0.792±0.210 1.207±0.315 0.040 
P55060 Exportin-2 0.764±0.196 1.140±0.300 0.047 
Q96M32 Adenylate kinase 7 0.852±0.353 1.267±0.085 0.034 
P10253 Lysosomal alpha-glucosidase 0.805±0.238 1.187±0.176 0.020 
Q92526 T-complex protein 1 subunit zeta-2 0.818±0.199 1.189±0.250 0.032 
P48047 ATP synthase subunit O, mitochondrial 0.843±0.258 1.213±0.206 0.036 
Q3ZCQ8 
Mitochondrial import inner membrane 
translocase subunit TIM50 
0.750±0.226 1.067±0.093 0.020 
Q96KX0 Lysozyme-like protein 4 0.793±0.256 1.125±0.071 0.042 
Q99798 Aconitate hydratase, mitochondrial  0.854±0.265 1.200±0.127 0.040 
P55786 Puromycin-sensitive aminopeptidase 0.829±0.201 1.153±0.115 0.014 
Q9H4K1 RIB43A-like with coiled-coils protein 2 0.856±0.251 1.180±0.179 0.047 
Q15172 
Serine/threonine-protein phosphatase 
2A 56 kDa regulatory subunit alpha 
isoform  
0.864±0.096 1.190±0.206 0.012 
Q9NR28 Diablo homolog, mitochondrial 0.781±0.132 1.069±0.183 0.021 
P13667 Protein disulfide-isomerase A4 0.826±0.121 1.116±0.159 0.012 
Q8N7U6 
EF-hand domain-containing family 
member B 
0.864±0.214 1.166±0.059 0.016 
P36776 Lon protease homolog, mitochondrial 0.872±0.242 1.173±0.136 0.041 
P06744 Glucose-6-phosphate isomerase 0.856±0.170 1.150±0.092 0.009 
P06576 
ATP synthase subunit beta, 
mitochondrial 
0.856±0.256 1.144±0.101 0.048 
Q96M91 
Coiled-coil domain-containing protein 
11 
0.856±0.112 1.143±0.137 0.007 
Q96MR6 WD repeat-containing protein 65 0.862±0.143 1.140±0.079 0.005 
P10515 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
0.875±0.211 1.154±0.114 0.032 
Q5T655 
Coiled-coil domain-containing protein 
147 
0.839±0.179 1.089±0.102 0.026 
P36957 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial  
0.896±0.192 1.151±0.091 0.027 
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O75190 DnaJ homolog subfamily B member 6 0.856±0.133 1.089±0.153 0.033 
Q5JVL4 EF-hand domain-containing protein 1 0.909±0.197 1.152±0.094 0.038 
P49841 Glycogen synthase kinase-3 beta 0.831±0.169 1.050±0.079 0.030 
Q86VP6 
Cullin-associated NEDD8-dissociated 
protein 1 
0.895±0.168 1.131±0.095 0.026 
Q4G0X9 
Coiled-coil domain-containing protein 
40 
0.900±0.210 1.137±0.064 0.042 
Q9BRQ6 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 6, 
mitochondrial 
0.883±0.153 1.115±0.160 0.047 
Q86Y39 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 11 
0.891±0.086 1.123±0.114 0.007 
P40939 
Trifunctional enzyme subunit alpha, 
mitochondrial  
0.893±0.144 1.122±0.147 0.038 
P41250 Glycine--tRNA ligase 0.978±0.171 1.227±0.089 0.020 
P14314 Glucosidase 2 subunit beta 0.854±0.111 1.068±0.066 0.006 
Q969V4 Tektin-1 0.986±0.166 1.215±0.089 0.026 
Q14697 Neutral alpha-glucosidase AB 0.908±0.123 1.105±0.140 0.046 
Q6BCY4 NADH-cytochrome b5 reductase 2 0.927±0.101 1.125±0.138 0.032 
P46459 Vesicle-fusing ATPase 0.912±0.107 1.089±0.091 0.022 
P11177 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
0.882±0.108 1.043±0.111 0.049 
Q14203 Dynactin subunit 1 0.934±0.036 1.104±0.097 0.014 
Q93009 
Ubiquitin carboxyl-terminal hydrolase 
7 
0.901±0.049 1.065±0.134 0.034 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial 0.907±0.080 1.071±0.089 0.016 
Q9Y371 Endophilin-B1 0.902±0.085 1.062±0.078 0.014 
O00330 
Pyruvate dehydrogenase protein X 
component, mitochondrial 
0.950±0.118 1.108±0.030 0.039 
Q8N1V2 WD repeat-containing protein 16 0.999±0.109 1.157±0.093 0.039 
P22234 Multifunctional protein ADE2 0.932±0.086 1.074±0.080 0.027 
Q15631 Translin 0.956±0.045 1.081±0.048 0.003 
Q96M29 Tektin-5 0.963±0.076 1.080±0.050 0.020 
P29218 Inositol monophosphatase 1 1.080±0.058 0.976±0.038 0.010 
Q9GZT6 
Coiled-coil domain-containing protein 
90B, mitochondrial 
1.074±0.117 0.932±0.055 0.040 
P67870 Casein kinase II subunit beta 1.131±0.161 0.943±0.082 0.048 
P10606 
Cytochrome c oxidase subunit 5B, 
mitochondrial 
1.134±0.154 0.942±0.095 0.045 
Q96DE0 U8 snoRNA-decapping enzyme 1.005±0.064 0.830±0.101 0.011 
P54652 Heat shock-related 70 kDa protein 2 1.091±0.162 0.895±0.079 0.041 
P80303 Nucleobindin-2 1.030±0.137 0.841±0.072 0.026 
P20933 
N(4)-(beta-N-acetylglucosaminyl)-L-
asparaginase 
1.134±0.161 0.907±0.112 0.033 
P57105 Synaptojanin-2-binding protein 1.118±0.100 0.875±0.093 0.004 
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P30041 Peroxiredoxin-6 1.114±0.252 0.838±0.070 0.046 
P60174 Triosephosphate isomerase 1.186±0.196 0.890±0.100 0.024 
Q8N0U8 
Vitamin K epoxide reductase complex 
subunit 1-like protein 1 
1.130±0.184 0.841±0.154 0.027 
Q8NA82 
Probable E3 ubiquitin-protein ligase 
MARCH10 
1.084±0.190 0.800±0.147 0.030 
Q8NBU5 
ATPase family AAA domain-containing 
protein 1 
1.216±0.179 0.875±0.146 0.011 
P28070 Proteasome subunit beta type-4 1.161±0.275 0.831±0.086 0.034 
Q96AJ9 
Vesicle transport through interaction 
with t-SNAREs homolog 1A 
1.217±0.222 0.859±0.226 0.035 
Q9H4Y5 Glutathione S-transferase omega-2 1.184±0.267 0.817±0.072 0.035 
Q8IZS6 Tctex1 domain-containing protein 3 1.037±0.282 0.700±0.145 0.045 
Q6UW68 
Transmembrane protein 205 
OS=Homo sapiens 
1.097±0.238 0.733±0.225 0.038 
P01034 Cystatin-C 1.263±0.365 0.844±0.059 0.035 
P60981 Destrin 1.127±0.321 0.751±0.167 0.049 
P24666 
Low molecular weight 
phosphotyrosine protein phosphatase 
1.330±0.178 0.882±0.216 0.007 
Q9P0L0 
Vesicle-associated membrane protein-
associated protein A 
1.213±0.215 0.801±0.068 0.010 
O43674 
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 5, 
mitochondrial 
1.200±0.350 0.766±0.116 0.048 
P26885 
Peptidyl-prolyl cis-trans isomerase 
FKBP2 
1.220±0.247 0.760±0.217 0.014 
Q8WY22 BRI3-binding protein 1.195±0.231 0.726±0.297 0.024 
P32119 Peroxiredoxin-2 1.325±0.550 0.706±0.138 0.041 
P02649 Apolipoprotein E 1.583±0.497 0.833±0.285 0.019 
P61088 Ubiquitin-conjugating enzyme E2 N 1.346±0.374 0.696±0.056 0.017 
P15309 Prostatic acid phosphatase 1.576±0.793 0.633±0.382 0.043 
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Supplementary Table S4 – Compiled list of proteins (185) differentially expressed in asthenozoospermic 
samples compared to normozoospermic samples.  
This list was obtained compiling our proteomic results with the results of other groups that perform comparative 
proteomics using asthenozoospermic vs normozoospermic samples (Zhao et al., 2007; Martínez-Heredia et al., 
2008; Chan et al., 2009; Siva et al., 2010; Parte et al., 2012) 
UniProtKB/ 
Swiss-Prot 
accession 
number 
Description Reference 
SPERMATOGENESIS/ SPERM MATURATION/ SEMINAL PLASMA/ SPERM-OOCYTE INTERACTION 
Q9P2T0 Testicular haploid expressed gene protein Present study 
Q6UWQ5 Lysozyme-like protein 1 Present study 
Q92526 T-complex protein 1 subunit zeta-2 Present study 
Q96KX0 Lysozyme-like protein 4 Present study 
Q8IZS6 Tctex1 domain-containing protein 3 Present study 
P54652 Heat shock-related 70 kDa protein 2 
Present study; Martínez-Heredia et al., 
2008; Siva et al., 2010; Parte et al., 
2012 
Q9Y4C1 Lysine-specific demethylase 3A Chan et al., 2009 
Q9Y265 RuvB-like 1 Chan et al., 2009 
Q9BXU0 Testis-expressed sequence 12 protein Martínez-Heredia et al., 2008 
Q6S8J3 POTE ankyrin domain family member E Parte et al., 2012 
P04279 Semenogelin-1 
Zhao et al., 2007; Martínez-Heredia et 
al., 2008 
P15309 Prostatic acid phosphatase Persent study; Parte et al., 2012 
P07288 Prostate specific antigen Parte et al., 2012 
Q9NS25 
Sperm protein associated with the nucleus on 
the X chromosome B F 
Parte et al., 2012 
P36969 
Phospholipid hydroperoxide glutathione 
peroxidase mitochondrial 
Parte et al., 2012 
Q5JQC9 A kinase anchor protein 4 Parte et al., 2012 
P26436 Acrosomal protein SP 10 Parte et al., 2012 
Q8NEB7 Acrosin binding protein Parte et al., 2012 
Q96BH3 Epididymal sperm binding protein 1 Chan et al., 2009; Parte et al., 2012 
P09622 Dihydrolipoyl dehydrogenase, mitochondrial Martínez-Heredia et al., 2008 
O75969 A kinase anchor protein 3 Parte et al., 2012 
SPERM TAIL STRUCTURE AND MOTILITY 
Q96M32 Adenylate kinase 7 Present study 
Q4G0X9 Coiled-coil domain-containing protein 40 Present study 
Q969V4 Tektin-1 Present study; Siva et al., 2010 
Q96M29 Tektin-5 Present study 
P60981 Destrin Present study 
Q9BZX4 Ropporin 1B Parte et al., 2012 
Q14990 Outer dense fiber protein 1 Parte et al., 2012 
P60709 Actin, cytoplasmic 1 
Martínez-Heredia et al., 2008; Parte et 
al., 2012 
Q562R1 Beta actin like protein 2 Parte et al., 2012 
P63267 Actin gamma enteric smooth muscle Parte et al., 2012 
P68133 Actin alpha skeletal muscle Parte et al., 2012 
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P68032 Actin alpha cardiac muscle 1 Parte et al., 2012 
P19105 Myosin regulatory light chain 12A Parte et al., 2012 
P63167 Dynein light chain 1 cytoplasmic Parte et al., 2012 
P13645 Keratin, type I cytoskeletal 10 Parte et al., 2012 
P35527 Keratin type I cytoskeletal 9 Parte et al., 2012 
P35908 Keratin, type II cytoskeletal 2 epidermal Chan et al., 2009 
P04264 Keratin type II cytoskeletal 1 Parte et al., 2012 
P04264 Keratin, type II cytoskeletal 1 Chan et al., 2009 
Q9BSJ2 Gamma-tubulin complex component 2 Chan et al., 2009 
P68371 Tubulin beta-4B chain Siva et al., 2010 
P04350 Tubulin beta 4 chain Parte et al., 2012 
Q6PEY2 Tubulin alpha 3E chain Parte et al., 2012 
A6NKZ8 Putative tubulin beta chain like protein Parte et al., 2012 
Q3ZCM7 Tubulin beta 8 chain Parte et al., 2012 
Q13509 Tubulin beta 3 chain Parte et al., 2012 
P07437 Tubulin beta chain Parte et al., 2012 
P68366 Tubulin alpha 4A Parte et al., 2012 
Q9BUF5 Tubulin beta 6 chain Parte et al., 2012 
Q9NY65 Tubulin alpha 8 chain Parte et al., 2012 
Q13748 Tubulin alpha 3C D chain TUBA3C Parte et al., 2012 
P68363 Tubulin alpha 1B chain Parte et al., 2012 
P68371 Tubulin beta 2C chain TUBB2C Parte et al., 2012 
INTRACELLULAR TRAFFICKING 
P55060 Exportin-2 Present study 
P46459 Vesicle-fusing ATPase Present study 
Q14203 Dynactin subunit 1 Present study 
Q96AJ9 
Vesicle transport through interaction with t-
SNAREs homolog 1A 
Present study 
Q9P0L0 
Vesicle-associated membrane protein-
associated protein A 
Present study 
METABOLISM AND ENERGY PRODUCTION 
P10253 Lysosomal alpha-glucosidase Present study 
P48047 ATP synthase subunit O, mitochondrial Present study 
Q99798 Aconitate hydratase, mitochondrial Present study 
P06744 Glucose-6-phosphate isomerase Present study 
P06576 ATP synthase subunit beta, mitochondrial Present study 
P10515 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase 
complex, mitochondrial 
Present study 
P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial 
Present study 
Q86Y39 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 11 
Present study 
P40939 
Trifunctional enzyme subunit alpha, 
mitochondrial 
Present study 
P14314 Glucosidase 2 subunit beta Present study 
Q6BCY4 NADH-cytochrome b5 reductase 2 Present study 
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P11177 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial 
Present study 
O00330 
Pyruvate dehydrogenase protein X component, 
mitochondrial 
Present study 
P22234 Multifunctional protein ADE2 Present study 
P10606 Cytochrome c oxidase subunit 5B, mitochondrial Present study 
P30041 Peroxiredoxin-6 Present study 
P60174 Triosephosphate isomerase 
Present study; Zhao et al., 2007; Siva 
et al., 2010; Parte et al., 2012 
Q9H4Y5 Glutathione S-transferase omega-2 Present study 
O43674 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 5, mitochondrial 
Present study 
P32119 Peroxiredoxin-2 Present study 
P02649 Apolipoprotein E Present study 
P17174 Aspartate aminotransferase, cytoplasmic Zhao et al., 2007 
P15104 Glutamine synthetase Zhao et al., 2007 
P01275 Glucagon Chan et al., 2009 
P21266 Glutathione S transferase Mu 3 Parte et al., 2012 
P21266 Glutathione S-transferase Mu 3 Chan et al., 2009 
Q14410 Glycerol kinase 2 Siva et al., 2010 
Q13011 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
Martínez-Heredia et al., 2008 
P55809 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1, mitochondrial 
Siva et al., 2010 
P15259 Phosphoglycerate mutase 2 Zhao et al., 2007 
Q00796 Sorbitol dehydrogenase Parte et al., 2012 
O14556 
Glyceraldehyde 3 phosphate dehydrogenase 
testis specific 
Parte et al., 2012 
P04075 Fructose bisphosphate aldolase A Parte et al., 2012 
P50213 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial 
Zhao et al., 2007 
P07954 Fumarate hydratase, mitochondrial Martínez-Heredia et al., 2008 
Q7L1R4 Cytochrome c oxidase subunit 6B2 Martínez-Heredia et al., 2008 
P06576 ATP synthase subunit beta mitochondrial Parte et al., 2012 
P12277 Creatine kinase B type Parte et al., 2012 
Q8N8V2 Guanylate-binding protein7 Chan et al., 2009 
P14555 Phospholipase A2 membrane associated Parte et al., 2012 
P25325 3-mercaptopyruvate sulfurtransferase Martínez-Heredia et al., 2008 
MITOCHONDRIAL MAINTENANCE 
Q3ZCQ8 
Mitochondrial import inner membrane 
translocase subunit TIM50 
Present study 
P36776 Lon protease homolog, mitochondrial Present study 
Q9BRQ6 
Coiled-coil-helix-coiled-coil-helix domain-
containing protein 6, mitochondrial 
Present study 
Q9NSE4 Isoleucine--tRNA ligase, mitochondrial Present study 
PROTEIN METABOLISM 
P55786 Puromycin-sensitive aminopeptidase Present study 
P13667 Protein disulfide-isomerase A4 Present study 
O75190 DnaJ homolog subfamily B member 6 Present study 
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Q86VP6 Cullin-associated NEDD8-dissociated protein 1 Present study 
P41250 Glycine--tRNA ligase Present study 
Q14697 Neutral alpha-glucosidase AB Present study 
P20933 
N(4)-(beta-N-acetylglucosaminyl)-L-
asparaginase 
Present study 
Q8NA82 Probable E3 ubiquitin-protein ligase MARCH10 Present study 
P28070 Proteasome subunit beta type-4 Present study 
P24666 
Low molecular weight phosphotyrosine protein 
phosphatase 
Present study 
P26885 Peptidyl-prolyl cis-trans isomerase FKBP2 Present study 
P61088 Ubiquitin-conjugating enzyme E2 N Present study 
P10909 Clusterin 
Martínez-Heredia et al., 2008; Parte et 
al., 2012 
P34931 Heat shock 70 kDa protein 1 like Parte et al., 2012 
P62988 Ubiquitin Parte et al., 2012 
P50502 Hsc70 interacting protein Parte et al., 2012 
P17066 Heat shock 70 kDa protein 6 Parte et al., 2012 
P08107 Heat shock 70 kDa protein 1A Parte et al., 2012 
Q58FF7 Putative heat shock protein HSP 90 beta 3 Parte et al., 2012 
Q58FF6 Putative heat shock protein HSP 90 beta 4 Parte et al., 2012 
P14625 Endoplasmin Parte et al., 2012 
Q14568 Putative heat shock protein HSP 90 alpha A2 Parte et al., 2012 
Q58FF8 Putative heat shock protein HSP 90 beta 2 Parte et al., 2012 
P04792 Heat shock protein beta 1 Parte et al., 2012 
P07900 Heat shock protein HSP 90 alpha Parte et al., 2012 
P08238 Heat shock protein HSP 90 beta Parte et al., 2012 
P11021 78 kDa glucose regulated protein Parte et al., 2012 
Q8TAT6 Nuclear protein localization protein 4 homolog Chan et al., 2009 
P35998 26S protease regulatory subunit 7 Zhao et al., 2007 
P49720 Proteasome subunit beta type-3 Martínez-Heredia et al., 2008 
P25788 Proteasome subunit alpha type-3 Siva et al., 2010 
P05387 60S acidic ribosomal protein P2 Parte et al., 2012 
P68104 Elongation factor 1 alpha 1 Parte et al., 2012 
Q5VTE0 Putative elongation factor 1 alpha like 3 Parte et al., 2012 
Q05639 Elongation factor 1 alpha 2 Parte et al., 2012 
P26641 Elongation factor 1 gamma Parte et al., 2012 
Q8WUD1 Ras related protein Rab 2B Parte et al., 2012 
P61019 Ras related protein Rab 2A Parte et al., 2012 
SIGNALLING 
Q15172 
Serine/threonine-protein phosphatase 2A 56 
kDa regulatory subunit alpha isoform 
Present study 
Q5JVL4 EF-hand domain-containing protein 1 Present study 
P49841 Glycogen synthase kinase-3 beta Present study 
P29218 Inositol monophosphatase 1 
Present study; Martínez-Heredia et al., 
2008 
P67870 Casein kinase II subunit beta Present study 
P57105 Synaptojanin-2-binding protein Present study 
P63104 14 3 3 protein zeta delta Parte et al., 2012 
P52565 Rho GDP dissociation inhibitor 1 Parte et al., 2012 
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OTHER / UNKNOWN 
Q13642 Four and a half LIM domains protein 1 Present study 
O95831 Apoptosis-inducing factor 1, mitochondrial Present study 
Q9H4K1 RIB43A-like with coiled-coils protein 2 Present study 
Q9NR28 Diablo homolog, mitochondrial Present study 
Q8N7U6 EF-hand domain-containing family member B Present study 
Q96M91 Coiled-coil domain-containing protein 11 Present study 
Q96MR6 WD repeat-containing protein 65 Present study 
Q5T655 Coiled-coil domain-containing protein 147 Present study 
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 Present study 
Q9Y371 Endophilin-B1 Present study 
Q8N1V2 WD repeat-containing protein 16 Present study 
Q15631 Translin Present study 
Q9GZT6 
Coiled-coil domain-containing protein 90B, 
mitochondrial 
Present study 
Q96DE0 U8 snoRNA-decapping enzyme Present study 
P80303 Nucleobindin-2 Present study 
Q8N0U8 
Vitamin K epoxide reductase complex subunit 1-
like protein 1 
Present study 
Q8NBU5 ATPase family AAA domain-containing protein 1 Present study 
Q6UW68 Transmembrane protein 205 OS=Homo sapiens Present study 
P01034 Cystatin-C Present study 
Q8WY22 BRI3-binding protein Present study 
P51398 28S ribosomal protein S29, mitochondrial Chan et al., 2009 
P00918 Carbonic anhydrase 2 Zhao et al., 2007 
P58304 Visual system homeobox 2 Chan et al., 2009 
P06702 Protein S100-A9 Martínez-Heredia et al., 2008 
P49913 Cathelicidin antimicrobial peptide Parte et al., 2012 
P02788 Lactotransferrin Parte et al., 2012 
P59665 Neutrophil defensin 1 Parte et al., 2012 
P11142 Heat shock cognate 71 kDa protein Parte et al., 2012 
P08758 Annexin A5 Martínez-Heredia et al., 2008 
P61769 Beta 2 microglobulin Parte et al., 2012 
Q93077 Histone H2A type 1-C Martínez-Heredia et al., 2008 
Q96A08 Histone H2B type 1 A Parte et al., 2012 
Q96QV6 Histone H2A type 1 A Parte et al., 2012 
P12273 Prolactin-inducible protein 
Martínez-Heredia et al., 2008; Parte et 
al., 2012 
A5A3E0 POTE ankyrin domain family member F Parte et al., 2012 
 
 
 
 

